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PREFACE: CONTEXT AND STRUCTURE OF THE THESIS 
The starting point of the work presented here was the identification of ANKRD55 as a 
genetic risk factor of multiple sclerosis by the Neurogenomiks research group in 2012 and 
its consequent characterization of expression in the immune and nervous systems.  
This thesis is organized in three parts. The first chapter includes a general introduction 
about multiple sclerosis, highlighting the role of the immune system and genetics, and 
characteristics of ANKRD55, a member of the ankyrin repeat domain family, associated 
with several autoimmune and other type of diseases. Then the aim and objectives of the 
thesis are specified. The second chapter contains the results and studies carried out in 
the context of DNA variants of ANKRD55. The third chapter includes the results and the 
analysis based on the ANKRD55 protein. More detailed introductions about functional 
genomics and proteomics are included in the corresponding chapters. Finally, the general 
conclusions derived from both chapters are presented. 
Part of this work was included in the publication in the appendix. Furthermore, a 



































1. DEFINITION AND HISTORY OF MULTIPLE SCLEROSIS 
Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous 
system (CNS) that results in chronic progressive disability for the majority of people with 
the disorder1. This condition has a heterogeneous presentation that can involve motor, 
sensory, visual and autonomic systems2. The variation in clinical manifestations correlates 
with the spatiotemporal dissemination of lesional sites of pathology within CNS3, 
affecting both white matter tracts and cortical and deep gray matter4. These lesions are 
a hallmark of MS and are caused by immune cell infiltration across the blood–brain 
barrier (BBB) that promotes inflammation, demyelination, gliosis and neuroaxonal 
degeneration, leading to disruption of neuronal signaling5.  
Tracing the historical roots of MS has proven to be difficult, given the lack of knowledge 
of clinical-anatomic localization in neurology prior to the late 19th century. Two cases 
from the late 13th century described women afflicted with chronic, multifocal, and 
partially remitting neurologic illnesses that conceivably might have been MS6–8. The idea 
that MS is a disseminated plaque-like sclerosis was established approximately 150 years 
ago9 when the features of MS were first well defined by Jean-Martin Charcot neurologist 
in 1868, as 'la sclérose en plaques'10,11.  
The discovery of the myelin sheath by Rudolf-Carl Virchow in 1854, the discovery of 
Ranvier nodes, Schwann cells and the characterization of the nerve-fiber by Louis-Antoine 
Ranvier, as well as the discovery of oligodendrocytes in the late 1920s, shed light on the 
pathophysiology of MS and provided an explanation for the wide range of clinical 
symptoms12. 
In 1916, James Dawson reported about MS neuropathology when he described 
microscopic myelin damage and blood vessel inflammation occurring in the brain thanks 
to the perfected new chemicals to enhance the visibility of nerve cells under the 
microscope by Dr. Camillo Golgi and Dr. Santiago Ramon y Cajal13,14.  
In the early 1930s, Thomas Rivers and colleagues showed that healthy monkeys injected 




and demyelinating lesions15 and established what is now the most well-studied model of 
MS and autoimmunity, the experimental autoimmune encephalomyelitis (EAE)12.  
In 1981, magnetic resonance imaging (MRI) was first used to examine patients with MS16. 
The use of MRI in MS has since revolutionized how patients are diagnosed and further 
enlightened researchers on the pathophysiology of the illness17.  
In 1993, interferon β (IFNβ) was the first Food and Drug Administration (FDA) approved 
immunomodulatory drug shown to alter the clinical course of MS by reducing both 
disability and MRI lesion burden18. A total of 15 FDA-approved treatments for relapsing-
remitting MS are now available as disease modifiers to control inflammatory lesions and 
clinical relapsing activity9,19. 
The completion of the human genome sequence in 2003 clearly marked the beginning of 
a new era for biomedical research. Moreover, it has revealed millions of genetic variants 
in the human genome. This has generated an unprecedented explosion of innovative 
analysis techniques that can take full advantage of the full sequence data and the 
corresponding functionality of the genome20. From 2005, the development of new, next-
generation sequencing technologies greatly facilitated the fast sequencing of DNA. As a 
result, genome-wide association studies (GWAS) have revolutionized the search for 
genetic risk variants underlying complex diseases20, such as MS. Currently, the greatest 
challenge in the ‘post GWAS’ era is to understand the functional consequences of these 
DNA variants and to accurately elucidate the biological mechanism by which these genes 
and variants act21. 
2. CLINICAL FEATURES AND COURSE OF MULTIPLE SCLEROSIS 
There is much variability in the clinical features of MS, in the onset as well as in the 
progression of the disease22. Clinical symptoms of MS often correlate with the functional 
localization of impaired conduction in MS lesion23 (Table 1). Few of the clinical features 
are disease-specific2. The most common features of MS are paralysis, sensory 




Classification of MS clinical forms is not straightforward due to the heterogeneity of the 
disease course and symptomatology. Therefore, these concepts are revised based on 
new evidence and increased understanding of MS and its pathology. The standardized 
definitions of the clinical courses of MS were proposed in 1996. The updated classification 
of MS clinical forms distinguishes three clinical patterns.  
The majority of patients who develop MS begin with a single episode, termed as clinically 
isolated syndrome (CIS)25, with clinical symptoms typical for a demyelinating event26. Not 
all patients have subsequent disease activity after a single CIS, but risk of another episode 
is increased if white matter lesions are detected by MRI27 and so fulfilling the diagnostic 
criteria for relapsing-remitting multiple sclerosis (RRMS)2.  
 




Table 1. Symptoms and signs of multiple sclerosis by site 





Hemisensory and motor 
Affective (mainly depression) 
Epilepsy (rare) 
Focal cortical deficits (rare) 
Deficits in attention, reasoning, and executive 
function (early); dementia (late) 
Upper motor neuron signs 
Optic nerve Unilateral painful loss of vision Scotoma, reduced visual acuity, colour vision, and 




Clumsiness and poor balance 
Postural and action tremor, dysarthria 
Limb incoordination and gait ataxia 




Impaired speech and emotional lability 
Paroxysmal symptoms 





Spinal cord Weakness 
















RRMS is the most common form, affecting approximately 85% of patients. It is 
characterized by recurring bouts of relapse (discrete episode of acute worsening of a 
given neurological function) and remission (complete or partial recovery period) (Figure 
1; black line). Relapses coincide with focal CNS inflammation and demyelination that are 
typically discernible as white matter lesions28. Eventually, improvement during each 
remission wanes as disability accumulates, and between 15 and 30% of patients go on to 
develop secondary progressive multiple sclerosis (SPMS) over a long-term follow up25.  
In SPMS inflammatory lesions are no longer characteristic, and progressive neurological 
decline is instead accompanied by CNS atrophy; that is, decreased brain volume and 








Primary progressive multiple sclerosis (PPMS) affects about 10-15% of patients with MS, 
which features progressive decline from the outset and an absence of relapses (Figure 1; 
blue line)28.  
Moreover, MRI findings that are consistent with MS have been observed in healthy 
people who underwent scanning for other purposes, and clinical MS develops in up to 
50% of people with this so-called radiologically isolated syndrome, sometimes with a 
primary progressive course29,30.  




The diagnosis of MS is based on the integration of clinical, imaging, and laboratory 
findings25. Since 2000, MRI has been the key diagnostic test when patients present with 
a clinical syndrome that is suggestive of MS, and the most recent criteria, McDonald 
criteria31. 
3. EPIDEMIOLOGY 
MS is one of the world's most common neurologic disorders, and in many countries it is 
the leading cause of nontraumatic neurologic disability in young adults32. It is usually 
diagnosed between 20 and 40 years old, with a later onset of disease for PPMS than for 
RRMS33.  
According to the Atlas of MS, the most extensive worldwide study of the epidemiology of 
MS, completed by MS International Federation (MSIF) in 2013, the estimated number of 
people with MS had increased from 2.1 million in 2008 to 2.3 million in 201332. The 
disease has a heterogeneous prevalence worldwide: it is highest in North America 
(140/100,000 population) and Europe (108/100,000), and lowest in East Asia 
(2.2/100,000 population) and sub-Saharan Africa (2.1/100,000)34. Nevertheless, 
notwithstanding difficulties in surveillance, MS is almost nonexistent in black Africans35 
(Figure 2).  
MS occurs more frequently in women than men (3:1 ratio)19. Remarkably, the prevalence 
of MS appears to have steadily increased over the past century, primarily in women 
leading to higher female to male sex ratios of MS36,37 and in regions previously considered 
low incidence38,39 . There is evidence that women generally have an earlier onset of 
disease, they have a slightly lower prevalence of PPMS and show in general less 










4. PATHOGENESIS OF MULTIPLE SCLEROSIS 
Although some suggest that MS is primarily a neurodegenerative process with secondary 
immune involvement41, overwhelming evidence points to immune-mediated disease 
mechanisms because of the following findings: T and B lymphocytes are present in 
demyelinating lesions42; CNS antigen-specific immune responses are detected in the 
peripheral blood of patients with MS43; the disease can be suppressed by 
immunomodulatory therapeutics44,45; and genetic studies point towards the adaptive 
immune system25, particularly its CD4+ T cell component. 
Both the innate and adaptive immune systems are known to influence the pathogenesis 
of MS25. Being the earliest defense against pathogens, the innate immune system fights 
against infections and protects against self or innocuous antigens46. Monocytes, 
macrophages, microglia, dendritic cells (DCs) and natural killer (NK) cells, among others, 
compose the innate immune system which do not have immunological memory46. While 
the innate immune system delivers an early and rapid response, the adaptive immune 
system develops a response that is highly specific to the encountered infectious agents 
and enhanced with subsequent pathogen exposures. B and T lymphocytes mediate the 
adaptive immune responses and provide long-term protection. T and B cells have specific 
antigen receptors and clonally expand after contact with antigen. B cells differentiate into 
plasma cells that secrete immunoglobulins43. The main T cell subsets are CD4+ T 
lymphocytes, also called helper T cells that coordinate numerous immune responses, and 




CD8+ T lymphocytes, also known as cytotoxic T cells that play key roles in controlling 
intracellular pathogens but also neoplastic cells. Antigen specificity is determined by the 
human leukocyte antigen (HLA), which refers in particular to the major histocompatibility 
complex (MHC) in humans, a group of cell surface proteins that is essential for the 
recognition of self-cells and non-self-cells and activation of the acquired immune system 
to eliminate the non-self-components47,48. Via T cell receptor (TCR) complex, CD4+ T 
lymphocytes recognize antigens that are presented by the MHC class II molecules, 
whereas CD8+ T lymphocytes recognize antigens presented by MHC class I molecules49.  
Without a known predominant exogenous risk factor, it is an open question whether MS 
is triggered in the periphery or in the CNS. In the CNS-extrinsic model, autoreactive T cells 
that are activated at peripheral sites, potentially through molecular mimicry50–52, 
bystander activation or the co-expression of TCRs with different specificities53, traffic to 
the CNS along with activated B cells and monocytes. Once in the CNS, autoreactive T cells 
are locally reactivated by antigen-presenting cells (APCs) and recruit additional T cells and 
macrophages to establish the inflammatory lesion25. MS lesions contain CD8+ T cells, 
which are mostly found at the edges of lesions, and CD4+ T cells, which are found deep in 
the lesions54,55. These cells cause myelin loss, oligodendrocyte destruction, and axonal 
damage, leading to neurologic dysfunction. In parallel, immune-modulatory networks are 
triggered to limit inflammation and to initiate repair, which results in at least partial 
remyelination and is associated with clinical remission56. The extrinsic model is consistent 
with the method used to induce EAE in animals: emulsified CNS antigen is administered 
along with immune stimulants, resulting in the generation of pathogenic CD4+ T helper 1 
(Th1) cells and Th17 cells in the draining lymph nodes. These cells then enter the 
circulation and ultimately exert their effector functions within the CNS, having crossed 
the BBB or the blood–cerebrospinal fluid (CSF) barrier at the choroid plexus28.  
Alternatively, CNS-intrinsic events may trigger disease development, with the infiltration 
of autoreactive lymphocytes occurring as a secondary phenomenon. It is unclear what 
these CNS-intrinsic events might be, although postulated mechanisms include 
inflammatory responses to an as yet unknown CNS viral infection, a hypothesis based 




leading to primary neurodegeneration, similar to those that have been implicated in 
Alzheimer disease or Parkinson disease59.  
4.1. THE MAJOR IMMUNE PLAYERS 
4.1.1. Effector T cells in MS 
The presence of T cells within CNS lesions is detectable in the early stages of MS60, and 
the long-appreciated HLA associations with the disease are thought to reflect the 
presentation of specific CNS autoantigens to autoreactive T cells. As demyelination is a 
key feature of MS neuropathology, myelin protein-derived antigens have been hypoth-
esized to be the main autoreactive targets28. Most autoreactive T cells are deleted by the 
negative selection in the thymus, resulting in central tolerance. This is further supported 
by regulatory mechanisms outside of primary lymphoid tissues, which are collectively 
known as peripheral tolerance. Breakdown of mechanisms that maintain immune 
tolerance to self tissues can lead to autoimmunity61.  
CD4+ Th1 and Th17 cells are believed to be the pathogenic initiators of MS. In the late 
1980s, CD4+ T cells were first separated into the functionally distinct IFNγ producing Th1 
cells, which clear extracellular pathogens, and the IL-4 producing Th2 cells, which mediate 
allergic responses62. Subsequent studies then identified CD4+ Th17 cells, which play a 
central role in autoimmunity63. A pathogenic role for IFNγ in MS is supported by a trial in 
1987 in which the administration of IFNγ to MS patients exacerbated their disease64. A 
role for IL-17 is supported by a double blind trial in which the administration of an anti-
IL-17 compound to MS patients reduced lesion formation, as assessed by MRI65. Thus, 
both IL-17 and IFNγ appear to play a role in the human disease, which is consistent with 
adoptive transfer EAE experiments that have shown that both Th1 and Th17 cells can 
independently induce CNS autoimmunity with distinct patterns of EAE histology56,66,67. 
Consequently, skewing of T cell differentiation away from these cells subsets and towards 
a Th2 cell phenotype has been a prominent therapeutic concept and is considered to be 
a mechanism of action of the first-line, disease-modifying therapies IFNβ68, glatiramer 




Although much research has focused on the encephalitogenic role of CD4+ T cells in MS, 
it appears that CD8+ T cells also play a significant role in human MS56. CD8+ T cells are 
found in higher frequency than CD4+ T cells in the white matter and in grey matter cortical 
demyelinating lesions, and their numbers closely correlate with axonal damage5.  
CD8+ T cells recognize peptides of endogenous intracelular proteins presented in the 
context of MHC class I molecules and kill cells via a cell-contact-mediated process 
involving the activities of granzyme A and granzyme B71. Microglial cells have the capacity 
to cross present exogenous antigens, potentially leading to the high frequency of myelin-
reactive CD8+ T cells that has been reported in patients with MS72. These myelin-reactive 
CD8+ T cells secrete IFNγ and kill cells that endogenously produced myelin. The cytotoxic 
function of CD8+ T cells might play a central role in axonal damage, as their intracellular 
lytic granules are directionally positioned toward nearby axons in immunohistochemical 
analysis. Axonal injury has been correlated with the presence of lesional CD8+ T cells in 
close apposition to neurons73. Pathogenic CD8+ T cells might also contribute to pathology 
by secreting IFNγ and IL-1774. These IFNγ-, IL-17-, and granzyme B-producing CD8+ T cells 
also potentially undergo enhanced endothelial transmigration in a BBB model with 
human cells and in mouse models75,76. Thus, CD8+ T cells may not only cause 
oligodendrocyte death and neuronal damage, but they may also potentiate IFNγ- and IL-
17-mediated pathology once inside the CNS.  
4.1.2. Effector B cells in MS 
Although MS is considered to be a T-cell-mediated disease, the dramatic effects produced 
by anti-CD20 therapy (rituximab and ocrelizumab) in MS demonstrate a central role for B 
cells in its pathogenesis77. Compared with T cells, infiltrating B cell numbers in the CNS 
vary more throughout disease progression. One of the classic findings in MS is the 
presence of oligoclonal bands in the CSF, which arise from the intrathecal synthesis of 
clonal IgG and are present in more than 95% of patients with MS77. 
Clonally expanded B cells are found in the brain parenchyma, meninges, and CSF of MS 
patients78 and are present in the CNS at greater frequency earlier in the disease79. 




Numbers of antibody-secreting plasma cells are increased with age in patients with 
primary or secondary progressive MS5. Beyond their potential ability to produce 
autoantibodies, B cells in the CNS could act in MS by secreting chemokines/cytokines and 
by presenting antigen to T cells56.  
B cell depleting anti-CD20 antibodies (rituximab) have become a powerful therapy of 
early MS substantially reducing relapse frequency, radiologically determined lesional load 
and improving neurological deficiencies81. This transmembrane protein is expressed in 
different stages of B-cell differentiation, from pre-B cells to naive and memory B cells, but 
is absent in earlier stages (pro-B) and plasma cells82,83. Therefore, the role of B cells as 
APCs and secretors of cytokines and chemokines is very likely more important than their 
capacity to produce antibodies in the pathogenesis of MS. 
4.1.3. Regulatory T cells in MS 
Subsets of T cells that modulate immune activation and control the development of 
autoimmunity have been identified84. Two important subsets of CD4+ regulatory T cells 
have been studied in the context of MS. Pathogenesis of the disease may be due to 
defects in their functions. These are (i) FOXP3 expressing CD4+ regulatory T (TReg) cells85 
that contribute to their capacity to suppress T cell proliferation in vitro via a cell-contact-
mediated mechanism86 and (ii) IL-10 producing T regulatory type 1 (TR1) cells87 that 
inhibit cell proliferation primarily via the secretion of IL-1088.  
TRegs, which make up less than 4% of circulating CD4+ T cells, are referred to as 
‘professional’ suppressor cells89,90, selected to recognize self-antigens91,92 and activated 
by self-antigens. Several studies have demonstrated that inflammation can adversely 
affect TReg suppression93, as high numbers of non-suppressing TRegs have been found 
to co-exist with proinflammatory T cells in autoimmune target tissues at peak disease in 
EAE in the CNS94.  
TRegs from MS patients have a reduced suppressive capacity as measured by the co-
culture of MS-derived TRegs and effector T cells95–97. Although increased TRegs function 




TReg defect observed in MS is related to the resistance of effector T cells to TRegs 
suppression or to an inherent defect in the TRegs themselves. Recent studies of TRegs 
and effector T cells isolated from patients with a number of autoimmune diseases, 
including MS, have demonstrated that patient-derived effector T cells are, in fact, 
resistant to TReg-mediated suppression98,99. Thus, published studies suggest that in MS 
there exists both a defect in TRegs and a resistance to TRegs suppression by effector T 
cells56.  
Inflammatory molecules expressed in autoimmune diseases can negatively affect TRegs 
suppression. The pro-inflammatory cytokine IL-6, which exacerbates EAE, can alter CD4+ 
T cell differentiation and promote the generation of Th17 cells at the expense of 
TRegs100,101.  
TR1 cells were first described in the mouse model of colitis and were shown to produce 
IL-10102. These TR1 cells secreted high amounts of IL-10 and killed myeloid APCs via a 
granzyme B-mediated mechanism. Although not as extensively studied as TRegs, TR1 cells 
from patients with MS have also been found to be dysfunctional. By stimulating CD4+ T 
cells through CD46, which strongly induces IL-10, it was found that MS CD4+ T cells 
express less IL-10 than those from healthy individuals103. Numerous studies have 
demonstrated the importance of IL-10 in ameliorating murine EAE104. In MS, the capacity 
of CD4+ T cells to secrete IL-10 is associated with decreased disease activity as the 
expression of IL-10 and CD46 is enhanced in patients who respond to IFNβ therapy 
compared to cells from patients who did not respond105.  
4.1.4. Dendritic cells in MS 
DCs are APCs that play an important role in promoting the activation and differentiation 
of T cells106. Human dendritic cells can be divided into myeloid and plasmacytoid cell 
types107. Dendritic cells can also be derived from monocytes under inflammatory 
conditions108. The interaction of DCs with CD4+ T cells is crucial in determining T cell 
differentiation into either effector (Th1, Th2, Th9, and Th17) or regulatory (TRegs and 
TR1) T cells thus shaping the adaptive response109–111. DCs are also important for the 




were also shown to be the most effective APC in the CNS in mediating epitope spreading 
in different EAE models113,114. Moreover, manipulating DC function alters the T-cell 
repertoire, thus affecting the disease course. In MS patients, DCs are found in MS 
lesions113,115 and DCs isolated from the peripheral blood of MS patients exhibit an altered 
phenotype with decreased or delayed expression of the activation markers in addition to 
their altered functionality in terms of T-cell proliferation and generation of regulatory T 
cells116. Moreover, changes in the cytokine profile and expression of costimulatory and 
inhibitory molecules were reported in SPMS versus RRMS117–120.  
4.1.5. Monocytes, macrophages and microglia in MS 
The mononuclear phagocyte system comprises a population of cells derived from 
progenitor cells in the bone marrow, which differentiate to form blood circulating 
monocytes and then upon activation enter tissues to become resident tissue 
macrophages121. Microglial cells are considered resident macrophages of the CNS, which 
regulate local innate and adaptive immune responses in the CNS tissue106.  
Under basal conditions, microglia are highly dynamic and constantly patrol the CNS 
microenvironment122. Microglial activation is a hallmark of demyelinating lesions in 
EAE123,124. Microglial cells are rapidly activated in response to injury, neurodegeneration, 
infection, tumors and inflammation46, which leads to an increase in their size, 
upregulated expression of several molecules, and initiation of effector functions, 
including antigen presentation, chemoattraction, and phagocytosis of debris or toxic 
factors108. Activated microglia can be injurious to the CNS, damaging oligodendrocytes 
and neurons by producing free radicals and proinflammatory cytokines, such as TNF125, 
or provide benefits such as neuroprotection, mobilization of neural precursors, 
remyelination and axonal regeneration126–129. During inflammatory disorders, such as MS, 
monocytes are repeatedly recruited from the periphery, thereby reinforcing the local 
inflammatory reaction within the CNS. In MS, macrophages act as APCs perpetuating 





4.1.6. Natural killer cells in MS 
NK cells contribute to both effector and regulatory functions of innate immunity106. NK 
cells are innate immune cells involved in early host defense against infection and tumor 
transformation. NK cells also have regulatory properties and suppress immune responses 
via their capacity to kill activated, and potentially pathogenic, CD4+ T cells56. They can also 
directly lyse oligodendrocytes, astrocytes, and microglIa131. NK cells secrete both pro-
inflammatory (IFNγ, TNFα) and anti-inflammatory (IL-4, IL-10) cytokines and have been 
suggested to play dual roles in disease132. It is unclear whether the specific two types of 
NK cells, which are commonly defined as CD56dimCD16hi, representing 90% of NK cells in 
peripheral blood, highest cytotoxic activity and much lower frequency in tissue, and 
CD56bright, which primarily secrete cytokines and acquire cytotoxic activity over time, 
predominate in tissues, play unique roles in autoimmunity133,134.  
Most lines of evidence suggest that NK cells play an immunoregulatory role in MS even 
though NK cells have been found in the demyelinating lesions of MS patients135. CD56bright 
NK cells are increased by immunomodulatory and immunosuppressant therapies, 
increases in NK frequency correlate with treatment response136, reduced NK frequency 
has been associated with relapse137, and in vitro NK functional activity increases at times 
of remission138. Daclizumab, which reduces MS relapses, is a humanized antibody against 
the IL-2 receptor that expands CD56bright NK cells136. A similar increase in CD56bright NK cell 
frequency has also been described in MS patients treated with IFNβ139. 
5. CAUSES OF MULTIPLE SCLEROSIS 
Despite major research efforts in the past few decades, the exact cause of MS, and 
whether this varies from one patient to the next, still remains elusive28. MS is believed to 
have autoimmune etiology. Its pathogenesis is best explained by a multifactorial model 
that incorporates interactions between genetic, epigenetic, and infectious, nutritional, 
climatic, or other environmental influences35. All these factors can influence adaptive 
and/or innate immunity, which is thought to be the main pathway modulated by MS 




5.1. LIFESTYLE AND ENVIRONMENTAL RISK FACTORS 
It is recognized that environmental and lifestyle factors interact with genetics to influence 
both MS susceptibility and the course of the disease56.  
5.1.1. Latitude gradient and migration 
The earliest clues to environmental influences came from studies into the effect of 
latitude and migration.  It has long been recognized that there is a latitudinal gradient in 
MS56; a gradual decrease in incidence and prevalence of MS from north to south in the 
northern hemisphere, and in the opposite direction in the southern hemisphere140.  
Migration studies show that the risk of MS depends on the age at which an individual 
migrates: the risk of MS for those who migrate from a low-risk country to a high-risk 
country before adolescence is similar to that of those who are born and reside in the 
high-risk country141,142.  
5.1.2. Vitamin D and sunlight exposure 
Vitamin D levels and exposure to ultraviolet radiation (UVR) are two environmental 
factors known to be negatively associated with MS susceptibility that might also help to 
explain the latitude effect56.  
Conversion of vitamin D to its active metabolite is dependent on URV making it very 
difficult to distinguish between the effects of UVR and vitamin D. UVR also protects 
against MS, probably both through its effects on vitamin D and through independent 
effects on the immune system143.  
Increased vitamin D levels, especially before the age of 20, are associated with a reduced 
risk of MS in later life 144, and later data on supplementation and sun exposure have 
supported the role of vitamin D in reducing the risk of MS145,146. In addition, a diet rich in 
fatty fish that contains vitamin D also reduces MS risk in individuals with low sunlight 
exposure147. Recently, high vitamin D levels were shown to correlate with decreased 




with a lower MRI activity149.  Vitamin D has broad effects on the immune system, including 
the suppression of both B cell and T cell proliferation, skewing T cells away from 
inflammatory responses and toward regulatory T cell responses, and promoting 
tolerogenic monocyte and dendritic cell phenotypes150. Vitamin D levels do not only 
influence risk for MS, but also that for other autoimmune diseases, including rheumatoid 
arthritis (RA), type 1 diabetes mellitus (T1DM) and systemic lupus erythematosus (SLE)56. 
5.1.3. Epstein-Barr virus infection 
Many infectious agents have been proposed to have a role in MS, but one of the most 
interesting candidate is EBV140. Nearly all individuals with MS (>99%) have been found to 
have been infected with EBV compared with approximately 94% of age-matched 
controls151. There is an increased risk of MS in individuals who have infectious 
mononucleosis during adolescence and adulthood, especially so in individuals with 
elevated antibody titers against EBV nuclear antigen 1 (EBNA1)56. It is not clear how EBV 
infection could contribute to MS. It could have a specific effect, either through a 
mechanism such as molecular mimicry, or through general immune effects on B cells or 
other immune regulatory elements56. 
5.1.4. Smoking and use of oral tobacco 
Cigarette smoking is a well-recognized environmental factor that is linked to both MS risk 
and disease activity152. The risk increases with duration and intensity, and is stronger in 
men than in women25. Besides the risk of developing MS, history of smoking is associated 
with a worse prognosis in MS153, and aggravated disease course153,154. In addition, 
continued smoking is also associated with the increased risk of developing neutralizing 
antibodies against biologics used in treatment of MS155,156. Cigarette smoking increases 
the risk of autoimmune diseases, including RA157 and SLE158. Smoking provokes lung 
inflammation and promotes pro-inflammatory pathways159. If CNS auto-antigenic cells 
are present in the lung, such cells might be activated to attack the CNS160. Smoking 
displays a considerable interaction with MS-associated HLA risk alleles140. In the 
Scandinavian population, having the class II HLA-DRB1*15:01 MS risk allele confers an 




OR of ~5 among non-smokers; however, in smokers, the combined OR is much higher, at 
~14161. 
5.1.5. Obesity 
Growing evidence strongly supports a role for obesity in the risk of MS. Obesity in early 
life is associated with a two-fold increase in risk in men and women25. For adult-onset MS 
the critical period regarding obesity seems to be during adolescence162,163. Obesity later 
in life is not associated with increased MS risk. The molecular pathways behind the 
association between adolescent obesity and MS may involve fat-related chronic 
inflammation. By promoting Th1 responses and decreasing the number of TReg, obesity 
may increase the risk of recruitment of autoreactive CD4+ T cells that target CNS 
autoantigens164. Furthermore, obesity also leads to decreased bioavailability of vitamin 
D165. Also in the case of obesity, there is an interaction with MS risk HLA genes in that 
HLA-DRB1*15 positive and HLA-A*02 negative individuals with adolescent obesity display 
an OR of ~14140,166. 
5.2. THE GENETICS OF MULTIPLE SCLEROSIS 
5.2.1. Evidence for a genetic component 
The earliest evidence supporting a genetic influence on MS susceptibility was derived 
from observations of familial aggregation and differences in MS risk among ethnic groups 
residing in the same geographical regions167. People with an affected first-degree relative 
have a 2-4% risk of MS (as compared with approximately 0.1% risk in the general 
population)9. Equally important, siblings of an affected individual are at least seven times 
more likely to develop MS than the general population168,169. Studies that were carried 
out in Canada on adoptees, half-siblings and spouses seem to confirm that genetics is 
primarily responsible for the co-incidence of MS within families167. Twin studies from 
several populations have shown that monozygotic twins have a higher concordance rate 
(20–30%) compared with dizygotic twins (2–5%), providing strong support for a 




recurrence and twin concordance rates for MS do not support the presence of a 
Mendelian trait172, but underscore a polygenic context of genetic risk. 
5.2.2. The Human Leukocyte Antigen Locus in Multiple Sclerosis 
The recognition during the early 1970s of the influence of specific HLA variants within the 
MHC gene complex (chromosome 6p21) in MS susceptibility represented the first 
empirical demonstration linking disease risk with common genetic variation35. This 4-
megabase region contains approximately 165 closely linked genes. About half of these 
genes have important roles in the regulation of the immune system, and include the six 
classical transplantation HLA genes (the class I genes HLA-A, HLA-B, and HLA-C, and the 
class II genes HLA-DPB1, HLA-DQB1, and HLA-DRB1)173. The extreme polymorphism, with 
more than 14,000 alleles identified to date, and extensive linkage disequilibrium (LD) 
characterize this gene-dense region174. Carriers of the HLA DRB1*15:01 allele are about 
three times more likely to develop MS than non-carriers175. The class I variants HLA-A*02 
(OR~0.6) and HLA-B*44 are associated with protection from disease1. The presence of 
DRB1*15:01 and absence of HLA-A*02 has a combined OR~5. Since individuals not 
carrying the HLA risk alleles also can develop MS, it was early on recognized that genes 
outside the MHC complex may contribute partially to the genetic risk. Despite decades of 
candidate-gene-based efforts to find such genes, little progress was made in the 
identification of relevant, genuinely associated risk alleles outside the MHC before the 
advent of GWAS1. Although largely negative, these studies strongly supported the notion 
that MS is not caused by a small amount of mutations of large effect but is likely to be 
due to many small risk effects spread across the genome176.  
5.2.3. Genome-Wide Association Studies  
In the early 2000s, the introduction of chip-based technologies with the capacity to 
genotype simultaneously hundreds of thousands of single-nucleotides polymorphism 
(SNP) allowed the development of a new analytical methodology known as GWAS, a 
hypothesis-free method in which SNP spaced across the entire genome are screened for 
association with a particular trait in case–control datasets composed of genetically 




families, the possibility to test unrelated individuals allows collecting much larger 
datasets, substantially increasing the statistical power of gene-discovery studies. These 
studies have demonstrated that the common disease–common variant hypothesis of 
human diseases178 is broadly true, where disease risk is driven by many common variants 
(those with minor allele frequency >5%), each of which explains a small fraction of the 
risk in a population176. 
Several GWAS and large-scale targeted studies followed in the ensuing 10 years showed 
unequivocal statistical evidence for the association of 200 autosomal susceptibility 
variants outside the MHC, one chromosome X variant, and 32 independent associations 
within the extended MHC179 (Figure 3). This data supports a polygenic model of 
heritability for MS in which risk is determined by a single moderate-effect allele (OR 
roughly 3) and many much-smaller-effect alleles (OR <1.5)1. 
Altogether, the observed heritability explained by all associations does not amount to 
more than 20–30%, of which a substantial proportion can be assigned to the MHC 
region35. The remaining fraction of the risk commonly known as ‘missing heritability’ is 
likely due to either still unknown common variants characterized by much smaller effects, 
below the detection limits of the GWAS conducted so far, as yet undiscovered very rare 
variants with large ORs, or epistatic interactions between gene loci19. Also, likewise gene 
by environment interactions, cis/trans-regulators of allelic expression,  population and/or 
disease heterogeneity, and hidden epigenetic effects may all contribute to the missing 
heritability19. 
Nearly all the identified associations map to noncoding regions of the genome, either in 
intragenic or intergenic regions. Naturally, those mapping to intragenic regions were 
explored first (IL7RA, TNFSF10, etc.) as their relationship to function is thought to relate 
to splicing, mRNA stability, or promoter activity of the gene in question. However, most 
associations lie in genomic regions distant from any known gene. In those cases, the most 
likely explanation is that they modify regulatory sites (open chromatin, histone 




In the most recent MS GWAS, careful pathway, transcriptomic and epigenetic enrichment 
analyses suggest T-cell biology is a major feature of the disease, but also highlight the 
involvement of many other components of both adaptive and innate immunity in 
pathogenesis176, a finding consistent with the notion that autoimmune mechanisms are 
paramount in the development of clinical MS9.  
5.2.4. Sharing with other autoimmune diseases 
One salient characteristic of the MS susceptibility map is the large proportion of the 
associations (either the exact same variant, or within the same gene or locus) that are 
shared with other autoimmune diseases, such as Crohn disease (CD), T1DM, RA, and SLE, 
among others35. Interestingly, some of these shared associations confer risk for one 
disease but protection for another. One example is rs744166 located in an intron of the 
STAT3 gene is associated with increased risk in MS180 and decreased risk in CD181. Allelic 
heterogeneity was also reported in the IL2RA locus, where rs11594656 was shown to be 
associated with susceptibility to MS and protection against T1DM. Furthermore, 
rs41295061 only conferred susceptibility to T1DM but not MS182. A few genetic 







































5.2.5. From Gene to Function 
One of the most difficult steps in any GWAS is to infer the biologically relevant 
consequences of each statistical association35. First reason for this shortcoming consists 
in the pervasive LD along the human genome, which hinders the identification of true 
causative variants. LD refers to the tendency of genetic loci in physical proximity to 
segregate together during meiosis, leading DNA to be inherited in large blocks through 
generations. This peculiarity of genome architecture substantially impairs GWAS 
resolution since SNPs in the same LD block are inherited together as well. Thus, 
statistically significant GWAS risk variants are usually proxy for the real causative variants, 
which can be located up to several megabases away within the same LD block19. The 
second challenge is that the majority of MS risk variants appear to localise to gene 
regulatory regions, rather than coding sequence183, and specifically to enhancer elements 
active in stimulated immune cell subsets184. Furthermore, a subset of associated SNPs 
have been shown to be expression quantitative trait loci (eQTL) in different cells of the 
immune system, supporting the idea that much risk is due to changes in gene 
regulation176. For example, associated variants that are eQTLs for genes such as IFITM3, 
CD37, and CD6 in CD4+ T cells strongly suggest that they have an effect in modulating 
adaptive immune responses. Additionally, eQTL variants in or near CLECL1, RGS1, and 
MERTK in CD14+ monocytes suggest that the innate immune system is also involved35. 
Notably, variants in genes expressed in the CNS are less common in these studies, thus 
supporting a model in which genetic susceptibility to MS is mediated primarily by 
sustained dysregulation of immune responses over several decades before clinical 
symptoms appear35. 
A variety of experimental systems have been employed to study the biological functions 
associated with MS risk variants, ranging from patients-derived primary blood cells to 
animal models of disease. The first such demonstration in MS was the discovery that 
rs6897932, located within the exon 6, influenced the function of the gene interleukin 7 
receptor alpha chain (IL7R)35. Specifically, the risk allele disrupts a splicing acceptor site 
and results in transcriptional skipping of exon 6 of the gene, thus altering the relative 




shown that the RNA helicase DEAD box polypeptide 39B (DDX39B) is also a potent 
activator of IL7R exon 6 and consequently a repressor of soluble IL7R. Moreover, the 
rs2523506 located in 5’UTR of DDX39B reduces translation of DDX39B mRNA and 
increases MS risk186. This example provides functional evidence that two associated loci 
can work together to confer susceptibility to MS35.  
A similar effect was described for the intronic rs2104286 in the gene interleukin 2 
receptor alpha (IL2RA)19. This risk variant was also found to alter the soluble/membrane-
bound ratio of IL2RA protein by driving the expression of higher levels of its soluble 
form182. 
Another well-characterized example is the intronic rs1800693 in the gene encoding 
tumor necrosis factor receptor super family 1A (TNFRSF1A)35. In this case, the risk allele 
promotes the skipping of exon 6 with the production of a novel soluble form of the TNF 
receptor which is able to inhibit TNF signaling inside the cells, mirroring somehow, the 
exacerbating effects of TNF-blocking drugs on MS course187. 
Regarding the MS-associated tyrosine kinase 2 (TYK2) rs34536443 located in the exon 21, 
protective allele infers decreased tyrosine kinase 2 activity, and this reduction of activity 
is associated with a shift in the cytokine profile favouring the secretion of Th2 cytokines. 
These findings suggest that the rs34536443 variant effect on MS susceptibility might be 
mediated by deviating T lymphocyte differentiation toward a Th2 phenotype188.  
More recently, it was reported that the exonic rs11808092 in the ecotropic viral 
integration site 5 (EVI5) gene induces changes in superficial hydrophobicity patterns of 
the coiled-coil domain of EVI5 protein, which, in turn, affects the EVI5 interactome35. In 
particular, this work showed that the EVI5 protein bearing the risk allele selectively 
interacts with sphingosine 1-phosphate lyase (SGPL1), an enzyme important for the 
creation of the S1P gradient, which is relevant to the adaptive immune response and the 







An intronic variant in ANKRD55, rs6859219, was identified as a genetic risk factor for 
MS190, and subsequently this association was validated with genome-wide significance191. 
A proxy of rs6859219 (r2 = 0.9, D’= 1), rs71624119, also was associated with MS in a 
comprehensive fine-mapping of autoinmune disease related genomic regions192. 
rs6859219 in ANKRD55 emerged originally from a meta-analysis of GWAS on RA193. Other 
studies have linked ANKRD55 to several autoimmune diseases, including RA194,195, 
CD196,197, T1DM198, juvenile idiopathic arthritis199, celiac disease200 and inflammatory 
myopathies (polymyositis and dermatomyositis)201,202,  as well as post-traumatic stress 
disorder203, Alzheimer's disease (cognitive decline)204, and type 2 diabetes205,206. 
Recently, ANKRD55 was associated with IgA levels207. Moreover, another variant near this 
gene was also linked with changes in N-glycosylation of IgG208, which is altered in RA. 
Interestingly, defective N-glycosylation was also implicated in MS209.  
ANKRD55 locus, located on chromosome 5q11.2, codes for Ankyrin Repeat Domain 
Protein-55. The Ensembl Release 75 (http://www.ensembl.org)210 of February 2014 
includes six alternatively spliced transcript variants: four are protein coding (001, 002, 
005 and 006), and the remaining two processed transcripts (007 and 008) without protein 
products (Figure 4). However, only Ensembl protein coding transcripts 001 
(corresponding to the full-length form) and 005 are included in UniProt databases. 
Information about cells and tissues that express ANKRD55 protein, its subcellular 
localization, and its function is relatively scarce. Some gene expression databases, such 
as BioGPS (http://biogps.gnf.org)211, GTEx (https://gtexportal.org)212 and Gene 
Expression Atlas (http://www.ebi.ac.uk/gxa)213 shows expression in appendix, testis, 
superior cervical ganglion, spinal cord, brain, megakaryocytes, eosinophils and CD4+ T 
cells. The Human Protein Atlas (http://www.proteinatlas.org)214 documents ANKRD55 




The ankyrin repeat (AR), a 30-34 residue sequence motif, is one of the most common, 
modular, protein–protein interaction motifs in nature215. AR has been found in proteins 
with diverse functions, such as transcription, cell cycle regulation, cytoskeletal integrity, 
inflammatory response, development, cell–cell signaling, and various transport 
phenomena216,217. The AR is found in several biologically important proteins. The family 
of INK4 tumor suppressors, p15, p16, p18, and p19, as well as 53BP2, a regulator of the 
tumor suppressor p53, all contain ARs. The signaling protein Notch, which is involved in 
many cell-fate decisions during development, has seven ARs. NF-κB, a transcription factor 
that regulates inflammatory response is inhibited by IκB, which contains seven ARs216. 
Each AR motif exhibits a canonical helix-turn-helix conformation, in which two α-helices 
are arranged in an antiparallel fashion and the loop projects outward at an approximately 
90° angle to facilitate the formation of hairpinlike β-sheets with neighboring loops218–220. 
Usually, a hairpinlike β-sheet structure consists of the last three residues of the preceding 
AR and the first four residues of the next AR. Overall, the topology of an AR motif 
resembles the letter L with the helices as the vertical arm and the N- and C-terminal 
stretches as the base220–222. The AR proteins that have been characterized closely 
resemble one another despite their different cellular functions, supporting the role of the 
AR as a versatile scaffold for protein–protein interactions215.  It appears that the AR motif 
Figure 4. Representation of ANKRD55 transcript variants. The six transcript variants described in Ensembl are shown. 
Gold and maroon colors depicts protein-coding transcripts, and blue color processed non protein-coding transcripts. 
Exons are repesented with boxes, and introns with lines. Filled boxes represent coding exons, and empty boxes UTRs. 




is defined by its fold rather than by its function, as there is no specific sequence or 
structural motif that is universally recognized by AR proteins215. To retain this 
characteristic topology, some residues are well-conserved in most AR sequences while 
residues at other positions vary220. Figure 5 shows the comparison between AR consensus 
sequences derived from statistical analyses of AR sequences by Mosavi et al.215 and the 
AR from ANKRD55 isoform 001 and 005.  
Figure 5. Comparison between ankyrin repeat sequences of ANKRD55 isoform 001 and 005 and consensus sequence of 
the ankyrin repeat proteins. ARs from isoform 001 contains nine repeats (position of each repeat defined by Uniprot is 
indicated in parentheses and 005 shares ANK9 repeat (9-38). The conservation degree of each aminoacid in AR is 
marked in different colours and is shown in consensus sequence. The structural integrity of AR motif is kept by specific 
residues, most of them highly conserved: 1) T-P-L-H motif (4-7 position) initiates the first α-helix, 2) V/I-V-hydrophilic-
L/V-L-L motif (17-22 position) is the central piece of the second α-helix and 3) glycines (13 and 25 position) terminate 






























































The aim of this study is to gain insight into the biological functions of ANKRD55 associated 
with MS and RA and increase our understanding of its role in autoimmune diseases. To 
address the aim of the project, we pursued the following specific objectives: 
1. Identification of the main cellular source of ANKRD55 in PBMC.  
2. Determination of MS and RA-associated ANKRD55 intronic variant as eQTL for 
three transcripts of ANKRD55 in five PBMCs immune subsets.  
3. Study of MS and RA-associated ANKRD55 intronic variants, localized to a putative 
enhancer element, for their possible capacity to regulate the expression of 
ANKRD55 transcripts and its interacting genes, IL6ST and IL31RA. 
4. Analysis of endogenous and recombinant ANKRD55 subcellular localization in 
immune and non-immune cells.  









































































GWAS have identified thousands of genetic variants that are associated with diseases and 
traits of medical importance in humans223. As previously mentioned, genetic variants that 
are associated with diseases are primarily noncoding: ‘lead’ GWAS SNPs are more likely 
to be associated with the expression levels of neighboring genes (eQTLs) than is expected 
by chance224,225 and the same lead SNPs are enriched in regulatory regions marked by 
chromatin accessibility and modification183,226. Of all the genetic risk variants discovered 
to date, the number that impact enhancer function is estimated to far exceed the number 
that affect protein-coding genes or disrupt promoter function. These enhancer variants 
probably play an important part in common disease susceptibility by influencing 
transcriptional output227. Fine-mapping has revealed enrichment of autoimmune and 
inflammatory diseases associated variants in enhancer elements active in stimulated T-
cell subpopulations184. All this suggest that the majority of disease risk is mediated by 
changes to gene regulation in specific cell subpopulations228.  
Gene enhancer elements are noncoding segments of DNA that play a central role in 
regulating transcriptional programs that control development, cell identity, and 
evolutionary processes227. The locations of enhancer elements coincide with DNase I 
hypersensitive regions of open chromatin flanked by nucleosomes marked with 
H3K4me1/2229,230. Enhancers can be active or repressed, and each state generally 
correlates with the presence of additional histone marks, such as H3K27ac and H4K16ac 
associated with active chromatin, or H3K27me3 and H3K9me3 associated with repressed 
chromatin227,231–234 (Figure 6235).  
eQTL enable the identification of genetic variants that influence gene expression and they 
can be used to quantify the impact of a possible enhancer variants within a specific cell 
type. These studies involve stratifying a panel of individuals based on their particular SNP 
genotypes and then determining whether transcript levels differ between individuals 





CRISPR-based genome editing systems have offered a host of strategies to study non-
coding genomes and evaluate the effect of DNA variants. In particular, enhancers have 
been a large focus of study via genome editing236. CRISPR (clustered regularly interspaced 
short palindromic repeats)/Cas9 (CRISPR-associated protein) is an RNA-mediated 
adaptive immune system found in bacteria and archaea, in which it protects host cells 
from invasion by foreign DNA elements237. The CRISPR/Cas9 platform requires an RNA 
molecule to guide the Cas9 nuclease for site specific cleavage upstream of a genomic 
protospacer adjacent motif (PAM) sequence238,239. The natural dual trans-activating 
CRISPR RNA (tracrRNA) – CRISPR RNA (crRNA) structure has been simplified by a synthetic 
single-guide RNA (sgRNA) to facilitate genome editing experiments236,240. 
In addition to using the nuclease Cas9 for editing genomic sequences, the CRISPR/Cas9 
technology can be used as a sequence-specific, non-mutagenic gene regulation tool236. 
This repurposing was first demonstrated by introducing mutations into the S. pyogenes 
Cas9 in its two nuclease domains241,242. The resulting nuclease-deactivated Cas9 (dCas9) 
is unable to cleave DNA but retains the ability to specifically bind to DNA when guided by 
a sgRNA. dCas9 allows for direct manipulation of the transcription process without 
genetically altering the DNA sequence243. dCas9 can be fused to epigenome-modifying 
Figure 6. Transcriptional regulatory elements. The promoter is typically comprised of proximal, core and downstream 
elements. Transcription of a gene can be regulated by multiple enhancers that are located distantly and interspersed 
with silencer and insulator elements. which are bound by regulatory proteins such as CCCTC-binding factor (CTCF). 
Many enhancers can be defined by unique chromatin features and the binding of cyclic AMP-responsive element-
binding (CREB) protein (CBP). Abbreviations: H3K4me1/2, histone H3 mono- or dimethylation at lysine 4; H3K4me3, 
histone H3 trimethylation at lysine 4; H3K27me3, histone H3 trimethylation at lysine 27; H3.3/H2A.Z, histone variants 
H3.3 and H2A.Z; LCR, locus control region; TATA, 5′-TATAAAA-3′ core DNA sequences; TSS, transcription start site. 






protein domains to precisely modulate gene expression from gene promoters and 
enhancer regions244–249. Fusion of the KRAB (Krüppel-associated box) domain to dCas9 
and subsequent targeting to a promoter or enhancer causes highly specific gene 
repression through the recruitment of a host of factors that deposit H3K9me3, which 
ultimately results in heterochromatin formation242,248. Conversely, fusion of the histone 
acetyltransferase p300 core domain to dCas9 and targeting to either promoters or 
enhancers induces target gene activation concomitant with the deposition of 
H3K27ac249,250. 
Following the identification of a functional enhancer variant, the next major challenge is 
to identify its target and to test the effect of the SNP on target transcript levels. Many 
enhancer elements are located within 100 kb of the genes that they regulate but can also 
be located more than a megabase away, or even on separate chromosomes. Enhancers 
can regulate genes or long noncoding RNAs. Most genes are regulated by more than one 
enhancer, and many enhancers regulate more than one target gene227,251,252.  
It is well-established that enhancers regulate gene transcription by physical 
interactions253. Higher-order three-dimensional organization of chromatin facilitates 
physical interactions between enhancers and their target promoters. Interactions 
between enhancers and their targets may occur on the same chromosome (in cis) or on 
different chromosomes (in trans)227. Chromosome conformation capture technology 
(Capture Hi-C) has been used for the detection of patterns of interactions between 
chromosomal regions254–258. In 2015, Capture Hi-C was used to study the chromatin 
interactions between associated variants for four autoimmune diseases (RA, T1DM, JIA 
and psoriatic arthritis) and their functional targets in human B (GM12878) and T (Jurkat) 
cell lines with the aim of linking disease-associated SNPs with disease-causing genes. The 
interactions were tested in two complementary experiments: (i) region capture targeting 
regions associated with disease and (ii) promoter capture obtaining promoters within 
500kb of lead disease-associated SNP254. Both region capture and promoter capture 
analysis revealed that ANKRD55 showed potential interactions with  IL6ST and IL31RA 




As previously mentioned, ANKRD55 has been linked to several autoimmune diseases. A 
non-coding variant in ANKRD55, rs6859219, was identified as a genetic risk factor for 
MS190, which emerged originally from a meta-analysis of GWAS on RA193. A proxy of 
rs6859219, rs71624119, was also associated with MS192 and RA195. Other three DNA 
variants (rs10213692260, rs11377254260 (indel) and rs7731626194) within ANKRD55 were 
also associated with RA. In addition, preliminary chromatin immunoprecipitation (ChIP) 
data was suggestive of a greater enrichment for the histone mark of enhancer activity, 
H3K4me1, with carriage of the risk allele at both rs10065637 and rs6859219261. 
In the present work, we characterize five ANKRD55 non-coding variants associated with 
several autoimmune diseases as possible enhancer variants. For this purpose, first we 
identified the main cellular source of ANKRD55 expression in PBMCs and we correlated 
the expression of the three ANKRD55 transcripts with rs6859219 in the five isolated 
immune cell subtypes. Subsequently, we analyze five ANKRD55 predicted enhancer 
variants for their possible capacity to modulate the expression of ANKRD55 transcripts 
and its interacting genes, IL6ST and IL31RA, using CRISPR/dCas9-based epigenome 







Figure 7. Long-range interactions in the 5q11 locus. (A) Refseq gene annotations. (B-E) Identified interactions in the Region and Promoter capture experiments in GM12878 (B, C) and Jurkat (D, E) 





MATERIALS AND METHODS 
1. Primary human cell and cell lines 
 Human peripheral blood samples were collected after obtaining written informed 
consent from donors and approval by local ethics committee (Comité Ético de 
Investigación Clínica de Euskadi). Peripheral blood mononuclear cells (PBMC) of 23 
healthy donors were provided by the Basque BioBank for Research-OEHUN 
(http://www.biobancovasco.org). Demographical and genotype data of controls samples 
are included in Table 2.  
      
 
Human embryonic kidney 293 that expresses SV40 large T antigen (HEK293-T) and 
HEK293-T clone selected for high-titer lentivirus production (Lenti-X HEK293-T) (Cat. No. 
632180; ClonTech) cell lines were maintained in Dulbecco's Modified Eagle's medium 
(DMEM) supplemented with 10% inactivated fetal bovine serum (FBSi), and 1% 
penicillin/streptomycin (all from Sigma-Aldrich).  All cultures were maintained at 37°C and 
5% CO2 in a humidified atmosphere. 
2. Single guide RNAs design and cloning procedure 
Five ANKRD55 DNA variants were analyzed in 3 separated regions, as follow: region 1 
(rs6859219 and rs10065637), region 2 (rs71624119) and region 3 (rs11377254 and 
rs7731626) (Table 3). Two sgRNAs spanning less than 250bp from the SNPs included in 
each region (except one sgRNA) and positive and negative controls for ANKRD55 
transcripts 001 and 005 and IL6ST (Table 3) were designed using Chop Chop  tool 
(http://chopchop.cbu.uib.no/)262 and Benchling software (https://benchling.com). 
Individual group Number (Female/Male) Age (mean ± SD) rs6859219 (AA/AC/CC) 
Controls 23 (11/12) 43 ± 10,12 (6/7/10) 




sgRNAs were ordered as pair of primers including specific restriction site from Sigma-
Aldrich. 
Each pair of oligos annealed and cloned directly into pLKO5.sgRNA.EFS.GFP vector (Cat. 
No. 57822; Addgene)263. Briefly, the vector was digested and dephosphorylated using 
FastDigest BsmBI (Thermo Fisher), verified by agarose gel electrophoresis and purified 
using QIAquick Gel extraction Kit (Qiagen) following manufacturer’s protocol. Oligos were 
annealed and phosphorylated mixing in equimolar concentrations with T4 polynucleotide 
kinase (New England Biolabs), and ligated with purified and digested vector with T4 DNA 
ligase (New England Biolabs). Stbl3 competent cells were transformed with ligation 
reaction. 2-3 selected colonies from each construct were purified using Qiaprep spin 





Table 3. List of designed and cloned sgRNAs for CRISPR/dCas9 study    






















2A  rs685+rs100 F CACCGAGTATGTAGGAGGGTGCTAT GGG 
rs685+rs100 R AAACATAGCACCCTCCTACATACTC  
3A rs685 F CACCGCCAACAGAAATCAACTGTGG GGG 











 4B rs716 F1 CACCGAAAGCTAGGAGACAACACCT TGG 
rs716 R1 AAACAGGTGTTGTCTCCTAGCTTTC  
6B rs716 F  CACCGAATGAAGATGCCTGATAAAG GGG 




















 7B rs113 F CACCGTTGTTCCCCGTCTTGGTTGG CGG 
rs113 R AAACCCAACCAAGACGGGGAACAAC  
9A rs113 F CACCGCCACCACAATTTCAGTTAA AGG 
rs113 R  AAACTTAACTGAAATTGTGGTGGC  




 B1 ANKp F CACCGTTTCAAGGCTCGAGTGTCTG               TGG 




 C12A ANK005p F CACCGTAAGTGTTAAATGAGCCCGA AGG 
ANK005p R AAACTCGGGCTCATTTAACACTTAC           
ANKRD55 negative control  I1 ANKneg F CACCGTTTGAGTTAGAGAGATCTAG CGG 
ANKneg R AAACCTAGATCTCTCTAACTCAAAC  
IL6ST positive control  6FA IL6STp F CACCGGGCAAAGTGGGCCTGCTAA            CGG 




3. Lentivirus production  
Lentivirus was produced using third-generation system with the vectors pRSV-REV, 
pMDLg/pRRE and pMD2.G (Cat. No: 12253, 12251 and 12259, respectively; Addgene)264 
and polyethyenimine (PEI) transfection protocol.  
For this purpose, 10x106 Lenti-X HEK293-T cells in DMEM/10% FBSi w/o antibiotics were 
plated in 15cm dish the day before transfection. Transfection day, a mixture of lentiviral 
transfer plasmid including specific sgRNA or dCas9p300 (pLKO5.sgRNA.EFS.GFP or pLV-
dCas9-p300-P2A-PuroR (Cat. No. 83889; Addgene)249, respectively) and lentiviral 
envelope and packaging plasmids (pRSV-REV, pMDLg/pRRE and pMD2.G) at 4:2:1:2 DNA 
ratio were mixed with serum-free DMEM w/o phenol red and FBSi. PEI (1µg/µl) was 
added to diluted DNA at 6:1 ratio of PEI (µg): total DNA (µg), vortex and incubated for 15 
min at room temperature (RT). Lenti-X HEK293-T cells were transfected with the mixture. 
72 h after transfection, the virus containing supernatant was harvested and concentrated 
using Vivaspin 20 columns (Sartorious). Transfection of empty pLKO5.sgRNA.EFS.GFP 
vector was carried out as negative control.  
4. Stable cell line generation 
First, HEK293-T cells were transduced with concentrated dCas9p300 lentivirus and selected 
with puromycin (Sigma-Aldrich) to obtain a polyclonal cell line that stably expressed the 
transgene. Briefly, 500x103 HEK293T cells/well in DMEM/10% FBSi w/o antibiotics were 
plated in a six-well plate. The following day, cells were transduced with 8µl/ml polybrene 
(1mg/ml) and 50 µl of previously thawed dCas9p300 concentrated lentivirus. 72 h after 
transduction, the cells were collected and plated in DMEM/10% FBSi containing 
puromycin. The cell media was changed every 2-3 days to maintain the dose of antibiotic. 
Once the polyclonal cell populations grew well and expanded sufficiently, cell stocks were 
prepared.  
Next, we transduced HEK293T-dCas9p300 with ten individual sgRNAs (Table 3) and 
negative control lentivirus as described earlier. 72 h later, GFP level of a small amount of 




determine the percent transduction. Then the expanded cell populations expressing GFP 
were sorted using BD FACS Aria Fusion cell sorter (BD Biosciences) in flow cytometry core 
facility within the Faculty of Biology, Medicine and Health at the University of 
Manchester. HEK293T-dCas9p300-B1 and C12A (ANKRD55 transcripts positive controls) 
stable cell lines could not be sorted (+ GFP% 92.2 and 95.4%, respectively). 
5. Isolation of immune cell subsets 
PBMC samples were removed from liquid nitrogen storage, thawed, washed with 
phosphate-buffered saline (PBS) (Gibco) and centrifuged at 300 g for 10 min. PBMC 
number and viability were determined using Neubauer chamber and trypan blue staining. 
20x106 PBMC were divided in two tubes, resuspended in PBS and centrifuged at 300 g for 
10 min. Positive selection of immune cell subsets was performed by suspending 10x106 
PBMC in 80 μl of ice-cold separation buffer (PBS, 0.5% bovine serum albumin (BSA) and 
2 mM EDTA) (all from Sigma-Aldrich) and 20 μl antibody-labelled microbeads (Miltenyi 
Biotec) for 15 min at 4°C. PBMC were washed with 2 ml of ice-cold separation buffer and 
centrifugated at 300 g for 10 min at 4 °C. Magnetic separation of microbead-labelled cells 
was done using MS Columns (Miltenyi Biotec) following manufacturer’s protocol. CD8+ (T 
cytotoxic cells; Cat. No. 130-045-201) were purified from first tube and CD56+ (natural 
killer (NK) cells; Cat. No. 130-050-401) were retrieved from the resulting CD8- fraction. 
CD19+ (B cells; Cat. No. 130-050-301) were recovered from the second tube, CD14+ 
(monocytes; Cat. No. 130-050-201) were obtained from the CD19- fraction and CD4+ 
(helper T cells; Cat. No. 130-045-101) were subsequently obtained from the CD14- 
fraction.  
Subset purity was determined using flow cytometric analysis using PE mouse anti-human 
CD4+ (Cat. No. 130-098-167), PE-Vio 770 mouse anti-human CD8+ (Cat. No. 130-098-060), 
FITC mouse anti-human CD14+ (Cat. No. 130-080-701), VioBlue mouse anti-human CD19+ 
(Cat. No. 130-098-606) and PE-Vio 770 mouse anti-human CD56+ (Cat. No. 130-098-132) 
antibodies, as well as PE mouse IgG2a (Cat. No. 130-098-849), PE-Vio 770 mouse IgG2a 
(Cat. No. 130-098-564), FITC mouse IgG2a (Cat. No. 130-098-877), VioBlue mouse IgG1 
(Cat. No. 130-099-756) and PE-Vio 770 mouse IgG1 (Cat. No. 130-098-563) isotype 




6. Gene expression analysis 
Total RNA from human immune subsets was obtained with TRI Reagent® (Sigma-Aldrich), 
following the manufacturer’s protocol and treated with DNase I (Sigma-Aldrich) for 
genomic DNA removal. Total RNA extraction and DNAse I treatment from stable 
HEK293T-dCas9p300-sgRNA expressing cell lines was done with RNeasy Micro Kit and 
QIAshredder (Qiagen) following the manufacturer’s protocol. RNA concentration was 
determined using a NanoDrop spectrophotometer. RNA was reverse transcribed with 
High-capacity cDNA reverse transcription kit (Applied BioSystems) and qPCR was 
performed using Fast SYBR Green Master Mix or Power SYBR Green PCR Master Mix 
(Applied BioSystems) and primers for different ANKRD55 transcripts265, IL6ST266, IL31RA, 
GAPDH purchased from Integrated DNA Technologies (IDT) or Sigma-Aldrich and ACTB 
(predesigned from QIAGEN or Sigma-Aldrich) (Table 4). Expression of ANKRD55 
transcripts, IL6ST and IL31RA was normalized to internal controls (GAPDH and ACTB) and 
analyzed using the 2-ΔCt method267. Reactions were run in triplicate and no-template and 
no reverse transcription controls were included. 
 
 
Table 4. List of primers used for gene expression analysis in eQTL and CRISPR/dCas9 studies    
Analysis Gene symbol - Transcript variant Primer Sequence 5'-3' 
CRISPR/dCas9 
eQTL 
ANKRD55-001 001qF CAGCCTCAACACACACAAATGC 
001qR TAGTTGATTATGGACGGCCCCTG 
ANKRD55-005 005qF CGGGCTCATTTAACACTTACTATTTC 
005qR CTTAGCCAGCAACAGCTCCTG 
ANKRD55-007 007qF TCCACTATGCTCGGCTGC 
007qR CTCGCTGATGTTCGACTGTTG 
CRISPR/dCas9 IL6ST IL6STF CCGCCACATAATTTATCAGT 
IL6STR AAGGTCTTGGACAGTGAATG 




GAPDH GAPDHF GCAACAATATCCACTTTACCAGAG 
GAPDHR CACATCGCTCAGACACCAT 





7. Statistical analysis 
Analysis of the gene expression data was performed with GraphPad v.6 (GraphPad 
Software, San Diego, CA, USA). Paired t test for comparison of CD4+ and the other 
immune subsets, Kruskal–Wallis test for comparison of three groups and Pearson 
correlation coefficient for correlation analysis between the three transcripts.  
8. Bioinformatic analysis 
Several MS and RA ANKRD55 variants and their proxies were subjected to in silico analysis 
to evaluate their regulatory potential using the following bioinformatic tools: Ensembl 
Variant Effect Predictor (VEP)268, RegulomeDB269 and HaploReg270.  
HaploReg v4.1 (https://pubs.broadinstitute.org/mammals/haploreg/haploreg.php)270 
was used to search for proxy SNPs (r2>0.8) associated with the rs6859219, rs11377254 
and rs7731626 in the ANKRD55 intronic region. HaploReg uses LD information from the 
1000 Genomes Phase 1271. Evidences from ENCODE272 about regulatory protein binding, 
chromatin structure, chromatin state of the region, and putative transcription factor 
binding motifs that are altered by the variant are also included.  
For all input variants, the VEP contains detailed annotation for effects on transcripts, 
proteins and regulatory regions268. The Ensembl Regulatory Build273, which uses data 
from ENCODE272, BLUEPRINT274, and the NIH Epigenomics Roadmap275, is the primary 
regulatory annotation268. 
RegulomeDB (http://www.regulomedb.org/) expounds SNPs with known and predicted 
regulatory elements in the intergenic regions using data included in public datasets from 
GEO276, ENCODE project272, and published literature as well as computational predictions 
and manual annotations to identify putative regulatory potential and identify functional 
variants. Known and predicted regulatory DNA elements include regions of DNAase 
hypersensitivity, binding sites of transcription factors, and promoter regions that have 
been biochemically characterized to regulation transcription. Each variant includes a 
score (1-6) based on functional evidence, lower scores indicate increasing evidence for a 





Several bioinformatic tools such as, RegulomeDB269, HaploReg270 and VEP268, are useful 
to determine the effect of the variant and identify candidate regulatory SNPs for 
prioritizing SNPs for functional analyses.  
HaploReg showed that four SNPs (rs6873385, rs10065637, rs71624119 and rs10213692) 
are in strong LD (r2>0.9) with rs6859219. However, rs11377254 and rs7731626 did not 
have any proxy in strong LD (r2>0.8) (Table 5). Haploreg v4.1 also showed that three SNPs 
(rs6859219, rs11377254 and rs7731626) overlap with a ChromHMM-predicted promoter 
region in diverse primary T helper cells, monocytes-CD14+ RO01746 primary cells and 
GM12878 lymphoblastoid cell line. Moreover, analysis of chromatin state showed that 
five SNPs (rs6873385, rs6859219, rs71624119, rs11377254 and rs7731626) mapped to 
enhancer regions in several tissues, including numerous cell lines and primary monocytes, 
neutrophils, and T cell subtypes, among others. ChIP-Seq experiments also detected that 
rs6859219, rs10065637, rs11377254 and rs7731626 bound to different proteins and six 
out seven SNPs affected diverse protein-binding motifs (Table 5).  
According to the VEP, rs6859219 and rs10065637, overlap with a transcription enhancer 
region in lymphoblastoid cell lines (GM12878). Moreover, rs71624119, rs11377254 and 
rs7731626 are located in regulatory regions in neutrophil, CD14+CD16- monocyte, M0 
macrophage, GM12878 and monocytes-CD14+ (Table 5).  
In RegulomeDB analysis, two (rs11377254 and rs7731626) out of seven DNA variants 
achieved the highest regulatory score (i.e., 2a) likely to affect binding. Rs6859219 scored 
2b likely to affect binding. rs10065637 and rs71624119 showed lower regulatory score, 
3a and 5, respectively. However, two SNPs in LD with rs6859219 (rs10213692 and 




Table 5. In silico analysis for regulatory potential evaluation of rs6859219, rs11377254 and rs7731626 and their proxies. Proxies for three DNA variants were found using HaploReg, according to 
European ancestral super-population from 1000 Genomes Project Phase 1 release. SNP with r2>0.8 were included. The predicted regulatory effects from each SNP were studied using HaploReg, 
VEP and RegulomeDB and summarized in the table. Abbreviations: TF: transcription factor 






















5 56141024 0.99 1 rs6873385   4 tissues       No data Trancript 001: intron variant; trancript 
002: intron variant; trancript 007: 
intron variant, non-coding transcript 
variant   






ERalpha-a 2b (TF binding + 
any motif + DNase 
Footprint + DNase 
peak) 
Regulatory region variant (GM12878, 
TF binding site); trancript 001: intron 
variant; trancript 002: intron variant; 
trancript 006: downstream gene 
variant; trancript 007: intron variant, 
non-coding transcript variant   
5 56143024 0.99 1 rs10065637 
  
4 tissues EBF1, NFKB, 
PU1 
Maf, Pou5f1 3a (TF binding + 
any motif + DNase 
peak) 
Regulatory region variant (GM12878, 
TF binding site); trancript 001: intron 
variant; trancript 002: intron variant; 
trancript 006: downstream gene 
variant; trancript 007: intron variant, 
non-coding transcript variant   






5 (TF binding or 
DNase peak) 
Regulatory region variant (neutrophil 
(VB), CD14+CD16- monocyte (VB), M0 
macrophage (VB), GM12878, 
Monocytes-CD14+, promoter flanking 
region); trancript 001: intron variant; 
trancript 002: intron variant; trancript 
006: intron variant; trancript 007: 
intron variant, non-coding transcript 
variant   





No data Trancript 001: intron variant; trancript 
002: intron variant; trancript 006: 
intron variant; trancript 007: intron 


























2a (TF binding + 
matched TF motif 
+ matched DNase 
Footprint + DNase 
peak) 
Regulatory region variant (neutrophil 
(VB), CD14+CD16- monocyte (VB), M0 
macrophage (VB), GM12878, 
Monocytes-CD14+, promoter flanking 
region); trancript 001: intron variant; 
trancript 002: intron variant; trancript 
006: intron variant; trancript 007: 
intron variant, non-coding transcript 




























2a (TF binding + 
matched TF motif 
+ matched DNase 
Footprint + DNase 
peak) 
Regulatory region variant (neutrophil 
(VB), CD14+CD16- monocyte (VB), M0 
macrophage (VB), GM12878, 
Monocytes-CD14+, promoter flanking 
region); trancript 001: intron variant; 
trancript 002: intron variant; trancript 
006: intron variant; trancript 007: 
intron variant, non-coding transcript 






The risk (C) allele of rs6859219 is associated with higher expression of 
ANKRD55 001, 005, and 007 in CD4+ T cells 
Considering that ANKRD55 is a genetic risk factor for diverse autoimmune diseases, it is 
likely to have a role in the immune system. In a previous work from our research group, 
Lopez de Lapuente et al.265 characterized ANKRD55 expression in immune and non-
immune cells by conventional RT-PCR and concluded that 001, 005 and 007 transcript 
variants were expressed in PBMC. Moreover, we analyzed the association of rs6859219 
with ANKRD55 expression by qPCR in MS patients and healthy controls. When individuals 
were grouped by genotype, homozygotes for the risk allele (CC) showed significantly 
higher expression of the three ANKRD55 transcripts than carriers of the protective allele 
(AA). No significant differences were found between MS patients and controls.  
PBMC are composed of lymphocytes (T cells, B cells and NK cells), monocytes and 
dendritic cells. In humans, the frequencies of these populations vary across individuals, 
but typically, lymphocytes are in the range of 70–90 %, monocytes range from 10 to 20 
%, while dendritic cells are rare, accounting for 1–2 %. The frequencies of cell types within 
the lymphocyte population include 70–85 % CD3+ T cells, 5–10 % B cells and 5–20 % NK 
cells. The CD3+ lymphocytes are composed of CD4+ and CD8+ T cells, roughly in a 2:1 
ratio277.  
We set out to identify the main cellular source of ANKRD55 expression in this 
heterogeneous mixture of cell types. For this purpose, CD4+, CD8+, CD14+, CD19+ and 
CD56+ immune subsets were isolated from PBMC of 23 healthy controls, subsets purity 
was determined using flow cytometric analysis showing a mean of 92.26%, 91.36%, 
89.53%, 51.53% and 61.88% for CD4+, CD8+, CD14+, CD19+ and CD56+, respectively, and 
ANKRD55 transcripts were analyzed by qPCR using specific primers. The results showed 
that the three ANKRD55 transcripts were uniquely and highly expressed in CD4+ T cells 
but were undetectable or minimally expressed in the other subsets (Figure 8, A-C). 
Individual transcript levels were highly correlated (Figure 8, G-I) and the homozygotes for 




T cells (Figure 8, D-F). Consequently, we found that rs6859219 regulated the expression 
of ANKRD55 in PBMC and CD4+ T cells, qualifying rs6859219 as a novel eQTL for ANKRD55.  
 
 
Figure 8. qPCR analysis of ANKRD55 transcripts 001, 005, and 007 in CD4+, CD8+, CD14+, CD19+ and CD56+ immune subsets 
of PBMC from healthy controls. (A-C) The expression of three ANKRD55 transcripts was analyzed by qPCR in five purified 
immune subsets of PBMC from 23 healthy controls. Expression differences between CD4+ T cells and the other subsets 
was analyzed by paired t-test. The highest p-values from the comparisons are shown. (D–F) CD4+ ANKRD55 transcripts 
were grouped according to genotype and compared using the Kruskal–Wallis test. (G–I) Correlation analysis among 
three ANKRD55 transcripts in CD4+ T cells was determined using the Pearson correlation coefficient. Expression of each 
transcript was normalized to internal controls (GAPDH and ACTB) and for each individual 2-ΔCt value is represented with 




ANKRD55 transcript 001 is regulated by rs71624119 in HEK293-T-Cas9p300 
cells 
In this study dCas9-p300 activator expression vector was used because of the low 
expression levels of ANKRD55 transcripts in HEK293-T cells, and this was done with the 
aim to assess any potential increase in ANKRD55, IL6ST and IL31RA expression due to the 
presence of predicted enhancer variants. Preliminary data from two independent 
experiments showed that expression of ANKRD55 transcript 001 was increased in 
engineered HEK293-T-Cas9p300 cells which stably expressed 4B sgRNA construct that 
targets the region 2 including rs71624119 (Figure 9). ANKRD55 transcript 005 expression 
levels were highly increased in HEK293-T-Cas9p300-C12A cells (Figure 9). This sgRNA was 
designed in the promoter region as the positive control for transcript 005. IL6ST 
expression in experiment 1 was highly increased in HEK293-T-Cas9p300 transduced with 
9A (region 3 including rs11377154 and rs7731626) as well as 6FA (positive control, IL6ST 
promoter region) compared to the control (CT) (Figure 9). Moreover, in both experiments 
HEK293-T-Cas9p300-7B cell line targeting also region 3 showed more modest expression 
increased compared to the IL6ST positive control. For IL31RA expression, HEK293-T-


































































































































Figure 9. Expression analysis of ANKRD55 transcripts 001 and 005, IL6ST and IL31RA in HEK293T-Cas9p300-specific sgRNA cells. The expression of ANKRD55, IL6ST and IL31RA was analyzed in two 
independent experiments (Exp 1 and 2) by qPCR in HEK293T stably expressing Cas9p300 and individual sgRNA, as negative control empty sgRNA delivery vector stably expressing cells were used 





Much progress has been made to increase understanding of the role of the immune 
system in MS278. All genetic studies point to the immune system as being the primary 
cause of MS pathology, with a complex interaction occurring between genes and 
environment56. Genetic susceptibility and environmental factors prime the immune 
response in MS that targets the CNS. Genetic predisposition accounts for about only 25% 
of the life-time risk of patients developing MS. To define this risk at the molecular level, 
the associated gene for every SNP needs to be identified and its biological effect needs 
to be characterized278. 
The first identified MS-associated SNP in ANKRD55, rs6859219190,191, is located in a 
genomic region with a high recombination rate265; it has only four proxies with r2 > 0.8 
(Table 5). It is interesting to note that four SNPs at this locus that are reported to be 
associated with MS and other autoimmune diseases, such as RA193,195, CD196, JIA199 and 
T1D198, correspond to rs6859219 itself or its closest proxies. rs6859219 in ANKRD55 
emerged originally from a meta-analysis of GWAS on RA193. However, other DNA variants 
in moderate (rs7731626194; r2<0.5) or non-LD (rs11377254260) with rs6859219 in 
ANKRD55 locus have also been associated with RA. The most strongly associated SNP at 
the ANKRD55 locus of the latest comprehensive association studies of MS179,192 appears 
to be a perfect proxy of rs6859219.  
The qPCR results from this study indicate that 001 is the most highly expressed protein-
coding transcript in human CD4+ T cells, whereas the noncoding transcript variant 007 is 
by far the most abundant transcript overall. ANKRD55 007 is 853 bp long and contains 
seven exons, some of which partially or completely overlap with the exons of the protein-
coding transcripts, whereas others are made up of intronic sequences. According to these 
features, it can be categorized as a long noncoding RNA (lncRNA)279. LncRNAs are RNAs > 
200 nt that do not contain an open reading frame; although their biological meaning and 
function still need to be elucidated, ample evidence, including specific subcellular 
localization, tissue specificity, and association with disease, indicates that they may be 




by some studies showing that various SNPs associated with MS in GWAS are located in 
genomic regions that code for lncRNAs282 or regulate lncRNA expression in cis in human 
monocytes283. Abundant expression of ANKRD55 007 in CD4+ T cells may be an indication 
of the unique cell-specific functional role for this noncoding RNA265. 
Most autoimmune-disease-risk effects identified by GWAS localize to open chromatin 
with gene-regulatory activity. GWAS loci are also enriched in eQTLs, thus suggesting that 
most risk variants alter gene expression183,284. Importantly, we found that the risk (C) allele 
of rs6859219 is associated with higher expression of ANKRD55 mRNA in PBMC and CD4+ 
T cells, qualifying this SNP as a novel eQTL for ANKRD55. The genotype seems to increase 
the overall expression of the gene but not the splicing or differential expression of 
transcripts, because the effect was observed for all three transcripts assessed by qPCR 
(005, 007, and 001)265. Given that higher levels of ANKRD55 were observed in healthy 
carriers of the risk allele, and not only in patients, it is conceivable that the high level of 
ANKRD55 increases susceptibility to pathologic inflammation, rather than being a 
consequence of it265.  
Recently, Chun et al. (2017) identified in ANKRD55 an eQTL effect driven by rs71624119, 
a perfect proxy of rs6859219, in CD4+ T cells that exhibited shared associations with MS, 
CD and RA228. Moreover, James et al. (2018) also showed that rs71624119 was 
significantly associated with ANKRD55 expression and was found to be located in an 
active regulatory region (H3K4me1) with potential binding for STAT1 transcription 
factors, known to be involved in immunity285. Trynka et al. (2013) showed, based on 
chromatin mark datasets from the ENCODE and NIH Roadmap Epigenomics Mapping 
Consortium, that rs10065637, the perfect proxy of rs6859219 (separated by 271 bp), was 
found to occur very close to a H3K4me3 chromatin mark (distance of only 5 bp) that is 
specific to primary CD4+ TReg cells and CD4+ memory T cells226. In a study on RA, 
rs7731626, which is located in another ANKRD55 intron 6.1 kb from rs6859219, was 
found to regulate the expression of ANKRD55 in CD4+ T cells but not in CD14+CD16- 
cells194 (no ANKRD55 transcript-specific information). Westra et al. (2018) in a fine-
mapping and functional study including ANKRD55 T1DM and RA associated DNA variants 




rs11377254 overlaps with such sites in 101 experiments performed on distinct cell lines, 
and rs7731626 overlaps with 55 such, many of which are involved in the immune system. 
Similarly, rs11377254 and rs7731626 overlap with different transcription factor binding 
site peaks in lymphoblastoid cell lines and H3K4me3 sites in T-helper cells and monocytes, 
while rs10213692 does not. rs11377254 did overlap with a peak in their time course of 
Assay for Transposase Accessible Chromatin with high-throughput sequencing (ATAC-
seq), a method for mapping chromatin accessibility genome-wide. Only rs10213692 
showed differential binding in Jurkat T cells in the gel electrophoresis mobility shift assay 
(EMSA) used to detect protein complexes with nucleic acids260.The prediction of MS and 
RA-associated ANKRD55 DNA variants to be localized to  putative enhancer elements 
encouraged us to perform a study aiming to validate this data through their possible 
capacity to regulate the expression of ANKRD55 and its potential interacting genes, IL6ST 
and IL31RA259, using CRISPR/dCas9-based epigenome editing. The preliminary analysis of 
five ANKRD55 predicted enhancer variants showed that expression of ANKRD55 
transcript 001 was increased in engineered HEK293-T-Cas9p300 cells targeting the region 
including rs71624119. For IL31RA expression, only one experiment from HEK293-T-
Cas9p300 modifying the region containing rs71624119 showed upregulation compared to 
the control. IL6ST expression in a unique experiment was highly increased in HEK293-T-
Cas9p300 with modified region 3 including rs11377154 and rs7731626. Moreover, another 
HEK293-T-Cas9p300 stable cell line targeting also region 3 showed more modest 
expression increased compared to the IL6ST positive control.  
In summary, this study contributes toward understanding ANKRD55 in the context of MS 
and the immune system. Correlation of rs6859219 with expression of ANKRD55 in CD4+ 
T cells implies a functional link between the protein and ncRNA expression products of 
the ANKRD55 gene with MS, and higher expression of the gene in carriers of the risk allele 
points to a potential proinflammatory role for ANKRD555. While confirmation in 
additional experiments is needed, our data suggest that rs71624119 is located in an 
enhancer region and regulates ANKRD55 transcript 001 expression in HEK293‐T‐
Cas9p300 cells. Moreover, further functional analysis, using CRISPR/dCas9-based 




enhancer elements and to study their possible capacity to regulate the expression of 






















































Spatial partitioning of biological functions is a phenomenon fundamental to life. In 
humans, this spatial partitioning constitutes a hierarchy of specialized systems ranging 
across scales, from organs to specialized cells, to subcellular structures, down to macro-
molecular complexes286. At the cellular level, proteins function at specific times and 
locations. These subcellular locations such as organelles provide a specific chemical 
environment and set of interaction partners that are necessary to fulfill the protein’s 
function286. Using high-throughput protein labeling and imaging techniques, several 
proteome-wide studies have found that protein localization and function are strongly 
correlated to each other287–291. In 2017, the first analysis of how proteins are organized 
in a cell using two different high throughput approaches, high content imaging and spatial 
proteomic, revealed that approximately half of the proteins can be found in more than 
one compartment286. Mislocalization of proteins can be associated with cellular 
dysfunction and disease292,293. Thus, knowledge of the spatial distribution of proteins at 
a subcellular level is essential for understanding protein function, interactions, and 
cellular mechanisms286.  
Moreover, cellular functions are mediated by complex ‘interactome’ networks of physical 
and functional interactions between biological macromolecules, including DNA, RNA, 
proteins, and lipids, as well as smaller molecules such as metabolites294,295. Many proteins 
exert their functions within cells in the context of protein complexes. Therefore, 
identifying protein–protein interactions (PPIs), defined as a direct physical contact 
between two proteins, is pivotal to gaining insight into the biological function of 
proteins296. If an uncharacterized protein binds to a protein whose role in the cell is 
understood, its function is likely to be related297. 
These interactions may occur on their own in a binary manner or may require additional 
interaction partners. Proteins can form multimeric complexes in which there are many 
direct interactions as well as indirect protein–protein associations between the different 
proteins of the complex294. Binary mapping approaches interrogate pairs of proteins for 




approaches, by contrast, aim to identify the set of proteins that belong to a multimeric 
protein complex, where in pairs of proteins form either direct contacts or are linked by 
indirect associations294. Pioneering interactomic techniques, such as yeast two-hybrid 
(Y2H), were important initial tools for dissecting PPIs in cells298. In this system, two 
recombinant fusion proteins are generated: the bait is fused with a DNA-binding domain 
and the prey with a transcription activation domain. These two elements are expressed 
in yeast along with a reporter gene whose regulation is under a promoter recognised by 
the recombinant transcription activation domain. If these two proteins interact with each 
other, the transcription activation domain becomes functional leading to expression of 
the reporter gene299. 
During the past decades, mass spectrometry-based proteomics has become the method 
of choice to comprehensively identify PPIs296, for a single or a few proteins of interest and 
also in large-scale studies300–302. The first step in MS-based interaction proteomics is the 
purification nowadays mostly done via immunoprecipitation of the protein of interest 
with the aim to copurify and identify its interactors. Commonly used workflows are based 
on affinity-purification mass spectrometry of the protein of interest using specific 
antibodies or antibodies against epitope tags303,304, such as FLAG303,305, TAP304,306,307, and 
GFP tags308,309. This approach has been the most commonly used purification strategy for 
large-scale interactomes in, for example, human cell lines300,301 and yeast cultures306,307. 
After immunoprecipitation of the protein of interest, specific interactions must be 
identified. Target immunoprecipitations are compared to matched control samples, and 
specific interactors are identified by their significant enrichment in the target 
immunoprecipitations, whereas background binding proteins are equally present in 
target immunoprecipitations and controls.  
As mentioned previously, ANKRD55 belongs to a family containing AR, which exclusively 
functions to mediate PPIs. ANKRD55 isoform 001 and 005 includes nine and one ANK 
repeats, respectively, consequently should take part in diverse PPI as has been previously 
confirmed for other members of the ANK family. 
Therefore, the present study was conducted to provide clues about the biological 




For this purpose, in first instance we analyzed the subcellular localization of endogenous 
and recombinant ANKRD55 isoforms in several immune and non-immune cells. Then, we 







MATERIAL AND METHODS  
1. Cell culture 
Human embryonic kidney 293 (HEK293) and cervical cancer (HeLa) cell lines were 
maintained in DMEM supplemented with 10% FBSi and 2mM L-glutamine (all from Sigma-
Aldrich).  Human T-lymphocyte (Jurkat) and monocyte (U937) cell lines were kindly 
provided by Prof. Carlos Matute (University of the Basque Country, Leioa, Spain) and 
maintained in RPMI 1640 medium supplemented with 10% FBSi and 2mML-glutamine (all 
from Sigma-Aldrich). Neuroblastoma (SH-SY5Y) cell line was kindly provided by Prof. Pablo 
Villoslada (Institute of Biomedical Research August Pi Sunyer, Barcelona, Spain) and 
maintained in DMEM/F12 GlutaMAX supplement medium (Thermo Fisher Scientific) 
complemented with 10% FBSi (Sigma-Aldrich). All cultures were maintained at 37°C and 
5% CO2 in a humidified atmosphere. 
2. DNA constructs and cloning procedures 
pCMV6 containing TrueORF Gold Expression validated cDNA clone including C-terminal 
FLAG/myc tagged ORF of human ANKRD55 transcript 001 (NM_024669; Cat. No. 
RC221211) was purchased from OriGene. 
Human ANKRD55 transcript 005 coding sequence was amplified by PCR from pCR-BluntII-
TOPO clone IRCMp5012E115D (Source Bioscience) with specific primers including 
restriction sites (Supplementary Table 1) from IDT using Pfu DNA Polymerase (Agilent 
Technologies) following manufacturer’s protocol. The cycling conditions were set to 
initial denaturation at 94°C 45 sec, followed by 30 cycles of denaturation at 94°C 45 sec, 
annealing at 50°C 45 sec and extension at 72°C 1 min 30 sec and a final extension at 72°C 
for 10 min.  The PCR product size was verified by agarose gel electrophoresis, and the 
products were purified using GeneJET Gel Extraction and DNA Cleanup Micro Kit (Thermo 
Fisher Scientific) following manufacturer’s protocol. Amplified product was digested 
using SgfI and MluI restriction enzymes (New England Biolabs) and verified by agarose gel 




enzymes using T4 ligase (New England Biolabs). Individual colonies were screened by 
colony PCR and double digestion to identify those that contain the insert and confirmed 
by Sanger sequencing.  
pCMV6 vectors including ANKRD55 transcripts were modified by annealed oligo cloning 
to exchange myc for his-tag. Specific overlapping primers containing his-tag sequence 
(Supplementary Table 1) were designed, annealed and cloned directly into pCMV6 
vector. Briefly, oligos were resuspended in annealing buffer (10mM Tris, pH7.5, 50mM 
NaCl, 1mM EDTA), mixing in equimolar concentrations and incubate in the hot block at 
94°C for 5 min, which was removed from the heat source allowing for slow cooling to RT. 
Annealed oligos were ligated with purified and digested pCMV6 vector with EcoRV and 
XhoI using T4 ligase (all from New England Biolabs). The insert was confirmed by Sanger 
sequencing.  
3. ANKRD55 expression analysis and immunoprecipitation  
3.1. ANKRD55 isoform overexpression 
HEK293 and HeLa cells were cultured in T75 flasks (Sigma-Aldrich) and transfected with 
FLAG/myc or his-tagged ANKRD55 001 or 005 using MACsfectin Reagent (Miltenyi Biotec) 
according to manufacturer’s protocol and incubated for 48h.  
Jurkat cells were transfected with FLAG/myc-tagged ANKRD55 001 and pmaxGFP™ 
(positive control) using Amaxa 4D-Nucleofector device (Lonza). Jurkat cells were 
suspended in fresh complete RPMI 1640 medium and seeded into a six-well plate one 
day before transfection. The following day, 1x106 cells/reaction were transfected with 
6µg of specified plasmids using the SE Cell Line 4D-Nucleofector Kit (Cat. No. V4XC-1012, 
Lonza), according to the manufacturer’s protocol and incubated for 48h. 
3.2. Cross-linking 
Cells were cross-linked using the membrane-permeable thiol-cleavable homobifunctional 
cross-linker dithiobis[succinimidyl propionate] (DSP;Thermo Fisher) dissolved in dimethyl 




min, with gentle vortexing every 5 min. Reactions were quenched by adding 1 M Tris-HCl 
pH 7.5 to final concentration of 50 mM 15 min at RT. 
3.3. Obtaining cellular extracts 
For analysis of endogenous and recombinant ANKRD55 isoform expression, Jurkat, SH-
SY5Y, HeLa and HEK293 were fractionated into different subcellular compartments 
following the protocol from Horton and Holden310. Nuclei from human CD4+ T cells and 
Jurkat, SH-SY5Y, U937 and HEK293 cell lines were isolated by sucrose gradient 
centrifugation311. 
For silver staining analysis, FLAG-ANKRD55 immunoprecipitation (IP) was carried out from 
nuclear extracts obtained by sucrose gradient centrifugation; membranous organelles 
from subcellular fractionation and total protein extracts using lysis buffer (50mM 
NaH2PO4, 300mM NaCl, 1% triton X-100 and 1% cOmplete EDTA-free protease inhibitor 
cocktail pH adjusted to 8.0) or RIPA buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% NP-
40, 0.5% sodium deoxycholate and 0.1% SDS, 1U/ml Benzonase and 1% cOmplete EDTA-
free protease inhibitor cocktail). His-tagged ANKRD55 isoform-overexpressing cells were 
lysed with lysis buffer for IP under non-denaturing conditions and lysis buffer containing 
urea (50mM NaH2PO4, 300mM NaCl, 15mM Imidazole, 8M Urea, 1% cOmplete EDTA-free 
protease inhibitor cocktail at pH 8) for IP under denaturing conditions. Part of the lysates 
were kept as input controls. 
For interactome analysis, ANKRD55 IP was done from nuclear extracts lysed with RIPA 
buffer and total protein extracts using lysis buffer. Both buffers included phosphatase 
inhibitors (1mM sodium pervanadate, 5 mM beta-glycerophosphate and 5 mM NaF). Part 
of the lysates were kept as input controls. 






3.4. Subcellular fractionation  
Cells were fractionated into different subcellular compartments, sequentially generating 
fractions enriched for cytosolic, membrane bound organellar and nuclear proteins. Cells 
were washed three times with PBS from Gibco. Cell pellet was resuspended by gentle 
pipetting in ice cold buffer 1 (150mM NaCl, 50mM HEPES pH 7.4, 25 μl/ml digitonin 
(Sigma-Aldrich) and 1% cOmplete EDTA-free protease inhibitor cocktail (Roche)), 
incubated on ice for 10 min and centrifuged at 4°C, 2000 g for 3 min. This supernatant 
was the cytosol enriched fraction. The pellet was washed with ice cold PBS and centrifuge 
at 4°C, 100 g for 3 min to remove any remaining digitonin and resuspended by vortexing 
in ice cold buffer 2 (150mM NaCl, 50mM HEPES pH 7.4, 1% NP40 and 1% cOmplete EDTA-
free protease inhibitor cocktail), incubated on ice for 30 min and centrifuged at 4°C, 7000 
g for 5 min. This supernatant included membrane bound organelles such as the 
endoplasmic reticulum, golgi, mitochondria and some nuclear lumenal proteins. The 
pellet was washed with ice cold PBS and centrifuge at 4°C, 100 g for 3 min to remove any 
remaining NP40 extract and resuspended by vortexing in ice cold buffer 3 (150mM NaCl, 
50mM HEPES pH 7.4, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 
1U/ml Benzonase (Sigma-Aldrich) and 1% cOmplete EDTA-free protease inhibitor 
cocktail), incubated on ice for 1h and centrifuged at 4°C, 7000 g for 10 min to pellet 
insoluble proteins. This supernatant included nuclear membranes and nuclear proteins. 
3.5. Nuclear enrichment by sucrose gradient centrifugation 
Cells were washed three times with PBS and resuspended on ice-cold sucrose buffer I 
(0.32 M sucrose, 3 mM CaCl2, 2 mM magnesium acetate, 0.1 mM EDTA, 10 mM Tris-HCl 
pH 8.0, 1 mM DTT, 0.5% NP-40) in a 50ml tube. A small aliquot of cell was examined with 
a phase-contrast microscope to ensure that they were uniformly lysed. Sucrose buffer II 
(2 M sucrose, 5 mM magnesium acetate, 0.1 mM EDTA, 10 mM Tris-HCl pH 8.0, 1 mM 
DTT) was added and mixed by gentle pipetting and inversion. Sucrose buffer II was added 
to 50 ml polypropylene centrifuge tubes for JA-20 rotor (sucrose cushion). Nuclei mixture 
were carefully layered onto the sucrose cushion, the gradient was completed with 




in Beckman Coulter J2-MC High Speed Centrifuge. The supernatant was carefully 
removed, and nuclei were lysed with RIPA buffer. 
3.6. Immunoprecipitation  
For the IP of ANKRD55 isoforms together with their binding partners, ANKRD55 and 
control samples were incubated with Anti-FLAG G1 mouse monoclonal antibody 
coupled to the resin (cat.no. L00432; Genscript) at 4°C overnight (o/n), on rotating wheel. 
After incubation, resin was washed six times with washing buffer containing 50 mM Tris-
HCl and 150 mM NaCl, pH adjusted to 7.4 (phosphatase inhibitors were included for 
interactome analysis). Elution of ANKRD55 001 complexes was subjected to an 
optimization process in which different elution methods were tested: (A) 0.1M glycine-
HCl pH 2, neutralized with 1M Tris-HCl pH 10; (B) 0.1M glycine HCl pH 3.5 neutralized 
with 0.5M Tris, 1.5M NaCl pH 7.4; (C) 0.1M glycine, 0.15M NaCl and 0.5% SDS pH 2, 
neutralized with 1M Tris-HCl pH 10 (D) 0.1M glycine-NaOH pH 10 and neutralized with 
1M glycine-HCl, pH 2 and (E) 100µg/ml FLAG peptide (Cat. No. F3290; Sigma-Aldrich). 
For his-tagged ANKRD55 isoform IP, ANKRD55 and control samples were incubated with 
Ni2+-NTA agarose (Qiagen) at 4°C o/n, on rotating wheel. After incubation, resin was 
washed three times with washing buffer 1 (50mM NaH2PO4, 300mM NaCl, 20mM 
Imidazole with or w/o 8M urea at pH 6.3) and another three times with washing buffer 2 
(50mM NaH2PO4, 300mM NaCl, 20mM Imidazole at pH 5.5). ANKRD55 001 complexes 
were eluted using elution buffer (50mM NaH2PO4, 300mM NaCl, 10mM Imidazole, 
100mM EDTA, with or w/o 8M urea at pH 8). 
4. Western blot analysis 
Protein of each subcellular fraction, input controls and elution samples were separated 
by SDS-PAGE on 10% gels, transferred onto polyvinylidene difluoride membrane (Merck 
Millipore) and blocked with 2% casein in Tris-buffered saline for 1h at RT. The blots from 
endogenous ANKRD55 intracellular localization study were incubated with anti-ANKRD55 
Ab (Cat. No. ARP68892_P50; 1:1000) from Aviva Systems Biology at 4°C o/n, in the 




AAP68892; 2 mg/ml), whose sequence is part of both Ensembl isoforms 001 and 005 and 
is the original immunogen used to generate the polyclonal Ab, and then with horseradish 
peroxidase (HRP)-conjugated anti-rabbit (Cat.No.711-035-152; 1:3000) from Jackson 
Immunoresearch for 1 h at RT. Anti-GAPDH (Cat. No. MAB374; 1:1000) from Merck 
Millipore, anti-histone H3 (Cat. No. 9715; 1:1000) from Cell Signaling Technology, and 
anti-GRP94 (Cat. No. ADI-SPA-850-D; 1:1000) from Enzo Life Sciences Abs were used to 
validate fraction purity. The blots from recombinant ANKRD55 isoform overexpression 
analysis and interactome validation were incubated with anti-ANKRD55 (Cat. No. 
HPA051049; 1:500) from Sigma-Aldrich or anti-ANKRD55 (1:1000) from Aviva Systems 
Biology, anti-FLAG (Cat. No. 20543-1-AP; 1:1000), anti-RPS3 (Cat. No. 66046-1-Ig; 
1:2000), anti-CLTC (Cat. No. 66487-1-Ig; 1:1000), anti-VIM (Cat. No. 60330-1-Ig; 1:1000), 
anti-TUBB (Cat. No. 66240-1-Ig; 1:5000) and anti-SMC1A (Cat. No. 21695-1-AP; 1:500) 
from Proteintech; anti-SMC3 (Cat. No. 5696; 1:2000), anti-14-3-3 pan (Cat. No. 8312; 
1:1000) from Cell Signaling Technology; anti-PRKDC (Cat. No. NBP2-22128SS; 1:1000) and 
anti-HIF1AN (Cat. No. NB100-428; 1:1000) from Novus Biologicals and then with HRP-
conjugated anti-rabbit, anti-mouse (Cat. No. 715-035-150; 1:3000) from Jackson 
Immunoresearch and anti-rat (Cat. No. 7077; 1:3000) from Cell Signaling Technology 
secondary antibodies for 1h at RT. The membranes were incubated with clarity Western 
ECL Substrate (Bio-Rad) for chemiluminescent signal detection using ChemiDoc camera 
(Bio-Rad).  
5. Interactome analysis 
5.1. In-gel tryptic digestion 
Immunoprecipitated samples were separated by SDS-PAGE on 6% or 10% gels and 
stained with Pierce Silver Staining kit or SYPRO Ruby Protein Gel Stain (both from Thermo 
Fisher) according to manufacturer’s protocol. Either selected protein bands from silver 
stained gels were excised, or entire lanes from SYPRO Ruby-stained gels were cut into ten 
contiguous pieces (done for both the ANKRD55 001 and control lanes). These gel slabs 
were then cut into small pieces and washed in Milli-Q water. Reduction and alkylation 
was achieved by incubation with dithiothreitol (DTT, 10 mM in 50 mM ammonium 




in 50 mM ammonium bicarbonate) for another 20 min, in the dark. Gel pieces were dried 
and incubated with trypsin (12.5 µg/mL, in 50 mM ammonium bicarbonate) for 20 min 
on ice. After rehydration, the trypsin supernatant was discarded; gel bands were covered 
with 50 mM ammonium bicarbonate and incubated o/n at 37 ºC. After digestion, acidic 
peptides were further extracted with TFA 0.1% and dried in a RVC2 25 SpeedVac 
concentrator (Christ). The peptides were resuspended in 0.1% FA and sonicated for 5 min 
prior to their analysis. 
5.2. NanoLC-MS/MS and Data Analysis 
Identification of ANKRD55 interacting partners by nano-flow liquid chromatography 
coupled to tandem mass spectrometry (nLC-MS/MS) analysis was carried out by the 
Proteomics Platform from CICbioGUNE under the supervision of Dr. Felix Elortza. The 
functional analysis of the obtained results was also done in collaboration with Proteomics 
Platform.   
Peptide mixtures obtained from trypsin digestion were separated by online nanoLC and 
analyzed by electrospray tandem mass spectrometry. Peptide separation was performed 
on a nanoAcquity UPLC system (Waters) connected to an LTQ Orbitrap XL mass 
spectrometer (Thermo Electron). Approximately 40% of each sample was loaded onto a 
Symmetry 300 C18 UPLC Trap column, 180 µm x 20 mm, 5 µm (Waters). The precolumn 
was connected to a BEH130 C18 column, 75 μm x 200 mm, 1.7 μm (Waters) equilibrated 
in 3% acetonitrile and 0.1% FA, and peptides were eluted at 300 nl/min using a 60 min 
linear gradient of 3–50% acetonitrile directly onto the nanoelectrospray ion source 
(Proxeon Biosystems). The mass spectrometer automatically switched between MS and 
MS/MS acquisition in DDA mode. Survey full scan MS spectra (m/z 400–2000) were 
acquired in the orbitrap with a resolution of 30,000 at m/z 400. The 6 most intense ions 
were sequentially subjected to collision-induced dissociation (CID) fragmentation in the 
linear ion trap. Precursors with charge states of 2 and 3 were specifically selected for CID. 
Collision-energy applied to each peptide was automatically normalized as a function of 
the m/z and charge state. Analyzed peptides were excluded for further analysis during 30 
s using dynamic exclusion lists. Searches were performed using Mascot Search engine 




Carbamidomethylation of cysteines as fixed modification, oxidation of methionines as 
variable modification, 10 ppm of peptide mass tolerance, and 0.5 Da fragment mass 
tolerance were adopted as search parameters. 2 missed cleavages were allowed. Spectra 
were searched against a UNIPROT/Swissprot database restricted to Homo sapiens. A false 
discovery rate estimation procedure was applied for peptide identification (FDR <1%). 
Proteins identified with at least two peptides passing that cutoff were considered for 
further discussion. 
For interactome analysis, three replicates were run for each sample type, and a spectral 
counting approach was carried out in order to select specifically enriched proteins. This 
approach relies on the counting of the MS/MS spectra matching to a certain protein312. 
The comparison of this value for a certain protein in two different samples provides an 
idea of its putative differential abundance. In our case, proteins with an ANKRD55 
IP/Negative Ctrl IP spectral count ratio >5 in 3/3 replicates were selected for further 
analysis and discussion. In order to determine the relative abundance of each protein in 
each of the samples, a Normalized Spectral Abundance Factor (NSAF) approach was 
carried out313. The spectral counts for a protein were normalized to its length and further 
expressed as a % of the total of normalized spectral counts present in that particular 
sample. 
5.3. Phosphopeptide enrichment 
To  enrich  for  phosphorylated  peptides,  titanium  dioxide  chromatography  was  
performed  essentially  as described by Rigbolt and colleagues (2011)314 with some 
modifications. Briefly, an equal volume of Titansphere material (GL Sciences) was mixed 
with a buffer containing 80% ACN / 1% TFA / 0.6M glycolic acid. The slurry was incubated 
for 20 min at RT with end-over-end rotation. Sample buffer was adjusted to a final 
concentration of 60% ACN / 1% TFA before incubation with the beads. Titansphere beads 
were added to the sample in a 0.6 mg TiO2 / 100 peptide ug proportion and mixed 20 min 
at RT with end-over-end rotation. Finally, Titansphere material with bound 
phosphopeptides was washed three times with 150 μl 60% ACN / 1% TFA and transferred 
on top of a C8 disc (Empore) placed in 200 μL pipette-tip. Phopshopeptide samples were 




ACN/10% NH4OH, dried in a RVC2 25 SpeedVac concentrator (Christ), and resuspended 
in 2% ACN/0.3% TFA before mass spectrometry analysis. 
5.4. Functional and pathway analysis 
The DAVID tool from the NIH (https://david.ncifcrf.gov/)315 was used for Gene Ontology 
(GO) enrichment analysis. Results from the functional annotation clustering were used to 
select the interesting GO terms, and only results with p<0.05 for the modified Fisher’s 
test were considered. 
Ingenuity Pathway Analysis was used for more detailed characterization of the molecular 
events lying behind the differential protein patterns under analysis. The calculated p-
values determine the probability that the association between proteins in the dataset 
and a given canonical pathway is explained by chance alone, based on a Fisher’s exact 
test (p-value<0.05 being considered significant). 
5.5. Validation of ANKRD55 partners 
5.5.1. Validation by immunocytochemistry  
For endogenous ANKRD55 subcelullar localization study, Jurkat, U937, and SH-SY5Y cells 
were seeded on coverslips coated with poly-D-lysine (Sigma-Aldrich). U937 cells were 
differentiated with 25 ng/ml PMA for 40 h and stimulated with 5 mg/ml LPS (both from 
Sigma- Aldrich) for 1, 4, and 24 h. Subsequently, cells were fixed in 4% paraformaldehyde-
PBS for 20 min, incubated in 0.2% Triton X-100 in PBS for 30 min, blocked in 3% BSA (all 
from Sigma-Aldrich) in 0.2% Triton X-100 in PBS for 30 min, and stained with anti-
ANKRD55 (1:500; Aviva Systems Biology) for 1 h at RT. Staining with Alexa Fluor 488–
conjugated anti-rabbit (1:500; Invitrogen) was performed for 1 h at RT, followed by 
staining with DAPI (1:1000). To confirm specificity of ANKRD55 staining, a blocking 
peptide for the ANKRD55 Ab (Aviva Systems Biology) was used (see Western blot analysis 
section). Images were obtained using a Leica TCS CW SP8 STED Super-Resolution 
microscope with a 63x immersion objective and excitation wavelengths of 408 and 488 




For colocalization study of recombinant ANKRD55 and interacting partners, HEK293 cells 
were plated on coverslips coated with poly-D-lysine (Sigma-Aldrich) and transfected with 
ANKRD55 001 using MACsfectin Reagent (Miltenyi Biotec) according to manufacturer’s 
instructions. 24 and 48h later and cells were fixed with 4% paraformaldehyde in PBS for 
20 min at RT. Those coverslips destined to nuclear colocalization were subjected to 
antigen retrieval treatment incubating the cells with R-Universal buffer (Cat. No. AP0501-
500; Aptum). Then cells were permeabilizated with 0.2% Triton X-100 in PBS for 10 min 
and blocked with 3% BSA (all from Sigma-Aldrich) in PBS for 30 min. Staining with anti-
FLAG rabbit polyclonal (1:200) and mouse monoclonal (Cat. No. 66008-2-Ig; 1:100), anti-
RPS3 (1:500), anti-TUBB (1:200), anti-VIM (1:500) from Proteintech, and anti-14-3-3 (pan) 
(1:200) from Cell Signaling for 1h at RT, followed by staining with Alexa Fluor 647 
conjugated anti-rabbit (ab150075; 1:500) and DyLight 550 conjugated anti-mouse 
(ab98713; 1:500) from Abcam for 1h at RT and counter-stained with DAPI (1:500; Sigma-
Aldrich). Images were obtained using a Leica TCS CW SP8 STED Super-Resolution 
microscope with a 63x immersion objective and excitation wavelengths of 405, 550 and 
650nm. 
5.5.2. Quantification of colocalization  
For the cytoplasmatic colocalization, quantification was carried out using LAS AF (Leica 
Application Suite Advanced Fluorescence) software and Pearson’s correlation coefficient. 
First, the background signal was extracted in all the studied images. Then, the Pearson’s 
correlation coefficient values from 30 regions of interest (ROIs) were annotated, 
corresponding each ROI to a unique cell (n=30 cellular ROIs/condition). In transfected 
cells the ROIs were selected from transfected cells.  
5.5.3. Statistical analysis 
Analysis of the colocalization quantification was performed with GraphPad v.6. The data 
is represented as mean ± SEM and the Mann–Whitney test was applied. The level of 
significance was set at p≤0.05, with p<0.0001 (****) as extremely significant, p<0.001 
(***) highly significant, p<0.01 (**) very significant, p<0.05 (*) significant and p>0.05 (ns) 




5.5.4. Validation by western blot 
ANKRD55 immunoprecipitates were analysed by western blot using antibodies against 
target proteins, as described above (see section Western blot analysis). 
6. Bioinformatics analysis 
ANKRD55 phosphosites were identified in silico using several tools: (i) PhosphoSitePlus316 
and dbPAF317 databases were consulted to look for any ANKRD55 phosphosites described 
in scientific literature or public databases, and (ii) 14-3-3-Pred web server 
(http://www.compbio.dundee.ac.uk/1433pred)318 was used to predict putative 14-3-3 
binding phosphosites on ANKRD55  by combining predictions from three different 
classifiers: ANN – Artificial Neural Network (cut-off = 0.55), PSSM – Position-Specific 
Scoring Matrix (cut-off = 0.80), and SVM – Support Vector Machine (cut-off = 0.25). 
The ability of ANKRD55 for binding to nucleotides, DNA and RNA was analyzed using the 
following web-servers: (i) DRNApred (http://biomine.cs.vcu.edu/servers/DRNApred)319 
for the prediction of DNA and RNA-binding proteins and (ii) NsitePred 
(http://biomine.ece.ualberta.ca/nSITEpred/)320 predicted binding residues from the 










1. CHARACTERIZATION OF ANKRD55 ISOFORMS EXPRESSION AND 
SUBCELLULAR DISTRIBUTION  
Previous mRNA-based functional studies in ANKRD55 showed different expression 
patterns between the immune and nervous systems265. As mentioned before, ANKRD55 
transcripts 001, 005 and 007 were expressed in human PBMCs. CD4+ T cells were 
identified as the main cellular source of the three transcripts in PBMCs, pointing to a role 
in cell-mediated immune responses. Moreover, transcript 001 was detected in SH-SY5Y 
and U937. Transcript 005 was detected in Jurkat and U937.  No amplification of 
transcripts 002, 006 and 007 were found in any of the studied cell lines265. Considering 
this data, we extended the analysis to assess the protein expression and subcellular 
distribution of endogenous ANKRD55 in immune and non-immune cells, which will 
provide valuable information to elucidate protein functions and underlying mechanism 
of ANKRD55.   
1.1. Endogenous ANKRD55 proteins locate primarily to the nucleus in primary 
CD4+ T cells and Jurkat, U937, and SH-SY5Y human cell lines  
We studied ANKRD55 endogenous expression and intracellular localization in primary 
CD4+ T cells and Jurkat, U937, and SH-SY5Y human cell lines by confocal microscopy, 
nuclear enrichment through sucrose gradient ultracentrifugation, and biochemical 
fractionation to obtain cytosolic, membranous organelles, and nuclear fractions.  
Considering the results about the expression of ANKRD55 in the primary mouse microglia 
cells265, where a significant upregulation of the expression of ANKRD55 was observed 
after 24h LPS stimulation as assessed by ELISA and WB and the immunocytochemical data 
showed that it occurred mainly in the nucleus we study this possible effect in the human 
cell line U937 differentiated into macrophages upon PMA-treatment and LPS stimulation. 
The results did not show any differences in expression and localization of ANKRD55 




In PMA/LPS-treated U937 cells (Supplementary Figure 1) and PMA-treated U937 cells, as 
well as in SH-SY5Y cells, the cytosol along with nucleus to a greater extent, showed a 
strong signal for ANKRD55 reactivity (Figure 10 A, B). The nuclear signal, but not the 
cytoplasmic one, largely disappeared, as demonstrate by confocal microscopy, in the 
presence of a specific ANKRD55-blocking peptide coinciding with the immunogen used 
to raise the Ab. Subcellular ANKRD55 distribution was more difficult to interpret in 
undifferentiated U937 cells (data not shown) and Jurkat cells (Figure 10C) because of the 
relatively large nucleus. However, the presence of a nuclear ANKRD55 signal was 






Figure 10. Intracellular localization of ANKRD55 in Jurkat, SH-SY5Y and PMA-treated U937 cells. 
Inmunostaining for ANKRD55 (Aviva Systems Biology Ab; green) and nuclei (DAPI; grey) in (A) PMA-treated U937, (B) 
SHSY5Y, and (C) Jurkat cells analyzed by confocal microscopy. To confirm the specificity, immunostaining was 





To validate the expression patterns of endogenous ANKRD55 observed using confocal 
microscopy, the subcellular localization of endogenous isoforms 001 and 005 of ANKRD55 
in primary CD4+ T cells and Jurkat, SH-SY5Y, and U937 cells was assessed in highly 
enriched nuclear fractions obtained by sucrose gradient centrifugation (Figure 11A). The 
data confirmed the location of isoforms 001 (68kDa) and 005 (37kDa) in the nucleus of 
U937 and Jurkat cells, as well as of primary CD4+ T cells, and revealed a high abundance 




of isoform 001 in the nucleus of SHSY5Y cells. Biochemical fractionation showed that 
isoform 001 of ANKRD55 was located mainly in the nucleus and membranous organelles 
of SH-SY5Y and Jurkat cell lines (Figure 11B). However, isoform 005 distributed between 
cytoplasm and membranous organelles in Jurkat cells, whereas in SH-SY5Y cells it was 
weakly detectable in cytosol and membrane organelle fractions but was virtually absent 
from the nuclei as shown through sucrose ultracentrifugation or biochemical 
fractionation (Figure 11 A, B). Instead, a smaller protein (30 kDa), not seen in any of the 
other cell types analyzed, was detectable in the nucleus but not in the cytosol and 
membrane organelles. Thus, this analysis revealed the predominantly nuclear location of 
ANKRD55 001 and 005. 
1.2. Overexpressed ANKRD55 isoforms are located in cytosol, membranous 
organelles and nucleus in HEK293 and HeLa human cell lines 
To further study the subcellular localization of ANKRD55 isoforms, we transiently 
overexpressed human ANKRD55 001 and 005 isoforms in HEK293 and HeLa cells and 
fractionated the cells into three subcellular compartments. In transfected HEK293 cells, 
Figure 11. Subcellular localization of endogenous ANKRD55 isoforms in CD4+ T cells and Jurkat, SH-SY5Y, and U937 cells. 
(A) Nuclei from human CD4+ T cells (healthy donor) and Jurkat, SH-SY5Y, and U937 cell lines were isolated by sucrose 
gradient centrifugation. ANKRD55 was detected by WB in the absence or presence (+BP) of ANKRD55 blocking peptide 
in nuclear (N) and total (T) cell extracts. Enrichment for nuclear proteins was validated using histone H3 and GAPDH. 
(B) Jurkat and SH-SY5Y cells were biochemically fractionated to obtain cytosolic (C), membranous organelles (M), and 
nuclear (N) fractions. ANKRD55 was detected with specific Ab (Aviva Systems Biology) by WB in the absence or presence 
(+BP) of ANKRD55 blocking peptide (Aviva Systems Biology). Enrichment for subcellular fractions was validated using 
histone H3 (nuclear), GRP94 (membranous organelles), and GAPDH (cytosol). Specific bands corresponding to isoforms 
001 and 005 are indicated by black and white arrowheads, respectively. Black cross in SH-SY5Y marks a lower-Mr 




similar levels of isoform 005 were detected in the three fractions. Isoform 001 (72 kDa) 
showed a more abundant signal than 005 (43 kDa) and, was as well present in the three 
compartments but slightly less abundant in the cytosol than in the other two fractions 
(Figure 12A). In HeLa cells, the isoform 001 from the cytosolic enriched fraction showed 
a stronger signal than that of the other two fractions. Isoform 005 detection was slightly 
weaker in nuclei than in the rest of the fractions (Figure 12B). Moreover, truncated 
immunoreactive products were present, probably generated by specific proteolytic 
events from the intact isoform proteins. These included (i) a 55-60-kDa band in HEK293 
and HeLa cells in isoform 001-transfected cells present in all 3 compartments though at 
levels differing from the full-length proteins, (ii) 20-kDa band in membranous organelles 
of HEK293 cells, and (iii) a series of bands with Mr<34 kDa especially enriched in the 
cytosol of isoform-005 transfected HeLa cells and membranous organelles and cytosol of 
HEK293 cells. Additionally, the results showed the endogenous isoform 001 in both cell 
lines demonstrating the capacity of HEK293 and Hela cells to produce ANKRD55 and 
therefore to engage its biological pathway(s). Thus, western blot analysis of biochemically 
fractionated cells revealed overexpression of the isoforms 001 and 005 of ANKRD55 in all 
three analyzed subcellular compartments of both cell lines.  
 
Figure 12. Subcellular localization of recombinant ANKRD55 isoforms in HEK293 and HeLa cells. (A) HEK293 and (B) HeLa 
cells were transfected with isoforms (001) and (005) of ANKRD55 or not (negative control) and these cells were 
cultivated under the same conditions, but without transfection agent. Cells were  fractionated at 48h after 
transfection. ANKRD55 was detected with specific Ab (Sigma-Aldrich) by WB. Enrichment for subcellular fractions was 
verified using histone H3 as nuclear marker (N), GRP94 as ER marker (MO) and GAPDH as cytosolic marker (C). Specific 
bands corresponding to overexpressed isoforms 001 and 005 are indicated by black and white arrowheads, 
respectively. Black cross marks endogenous ANKRD55 isoform 001. Black diamonds, and black and white triangles show 





2. FUNCTIONAL STUDY OF ANKRD55 THROUGH ITS INTERACTOME 
ANALYSIS 
To identify ANKRD55 interactomes, we performed an IP of tagged recombinant ANKRD55 
and its interacting partners followed by nLC-MS/MS analysis (Figure 13).  
2.1. ANKRD55 isoform 001 was overexpressed and immunoprecipitated from 
HEK293 and HeLa cells 
Initially, we planned to overexpress C-terminally FLAG-myc-tagged human ANKRD55 001 
and 005 by electroporation in Jurkat cells. However, we could not obtain a sufficient 
amount of recombinant proteins to perform IP and mass spectrometry analysis, due to 
either a low electroporation efficiency or to low levels of recombinant protein produced 
(Figure 14A). Therefore, we overexpressed and IPed FLAG/myc- and his-tagged ANKRD55 
isoforms from HEK293 and HeLa cells, which as we showed in Figure 12, produce much 
higher amounts of recombinant ANKRD55 (Figure 14 B-H). Briefly, to express the 
recombinant proteins, pCMV6 containing FLAG/myc tagged ANKRD55 001 cDNA was 
purchased from OriGene, ANKRD55 005 cDNA was subcloned into pCMV6 vector 
including FLAG/myc tags and pCMV6 including ANKRD55 transcripts were modified by 
annealed oligo cloning to exchange myc for his-tag.  
FLAG/myc-tagged ANKRD55 constructs were overexpressed in HEK293 cells and 
ANKRD55 complexes were IPed from highly enriched nuclear fractions, membranous 
organelles fraction and total protein extracts using anti-FLAG affinity resin at 48h post-







transfection. This was done in the presence or absence of DSP crosslinker treatment so 
as to verify whether any chemical modification of amines in the side chain of lysine (K) 
residues by the crosslinker in the FLAG-tag (which contains two such, DYKDDDK) would 
compromise purification efficiency based on anti-FLAG IP Recombinant ANKRD55 
isoforms and interacting proteins were eluted with acid buffer (method A described in 
immunoprecipitation section from materials and methods). The elution step was 
subjected to an optimization process using FLAG peptide and different alkaline and acid 
elution buffers. The results showed that acid elutions at pH 2 in absence or presence of 
SDS were the best options for our IP (Supplementary Figure 2). ANKRD55 isoform 001 
was efficiently IPed from total cell lysates as well as from the three cell fractions as shown 
by western blot (Figure 14 B, C, E). In contrast, recombinant isoform 005 was less 
efficiently IPed from HEK293 cells (Figure 14 B, C). As expected, endogenous ANKRD55 
was not detected in the control IP. DSP treatment, which stabilizes transient protein 
interactions, did not block the interaction of ANKRD55 and FLAG resin even if the signal 
was somewhat decreased with the treatment (Figure 14 B, C). The overexpression and IP 
of FLAG-tagged ANKRD55 isoform 001 was validated in total protein extracts and 
membranous organelles fraction of HeLa cells by WB with anti-FLAG (Figure 14 D, E).  
His-tagged ANKRD55 constructs were also overexpressed in HEK293 cells and ANKRD55 
complexes were IP from total protein extracts using Ni2+–NTA agarose 48h post-
transfection under non-denaturing conditions. IP of ANKRD55 isoform 001 was confirmed 
by WB using anti-His, whereas we could hardly detect recombinant isoform 005. Thus, IP 
of isoform 005 under non-denaturing conditions was unsuccessful (Figure 14F). The Ni2+-
NTA-based procedure was modified to include DSP crosslinker treatment and carried out 
under denaturing conditions by adding high molar concentrations of urea, a chaotropic 
reagent. This results in disruption of tertiary structure, full unfolding of the protein and 
enhances exposure of the his-tag to improve the efficiency of the IP procedure. The 
results demonstrated an improvement of the IP efficiency under denaturing conditions, 
but the signal was decreased with the DSP treatment (Figure 14G). The modified his-
tagged ANKRD55 isoform 001 IP was also validated in total protein extracts of HeLa cells 




isoform 001 more so than isoform 005 can be efficiently and specifically 







Figure 14. Overexpression and immunoprecipitation of recombinant ANKRD55 isoforms. (A) Jurkat cells were 
electroporated with isoform 001 and GFP was used as negative control. Isoform 001 was detected with specific Ab 
(Sigma-Aldrich) by WB. (B, C, E) HEK293 and (D, E) HeLa cells were transfected with FLAG-tagged isoforms (001) and 
(005) of ANKRD55. Cells were treated +/- DSP, when indicated, and IP was performed on enriched nuclear fractions 
(NE), total protein extracts (TPE) or membranous organelles fraction (MO) after 48h of transfection. Recombinant 
ANKRD55 isoforms were detected in NE, TPE, MO and eluted fractions (FLAG IP) with specific Ab (Sigma-Aldrich) and 
FLAG Ab by WB. (F, G) HEK293 and (H) HeLa cells were transfected with his-tagged isoforms 001 or 005 of ANKRD55. 
Cells were treated +/- DSP, when indicated, and ANKRD55 was IPed from TPE after 48h of transfection under non-
denaturing (Ni-NTA IP, F) or denaturing (8M urea Ni-NTA IP, G & H) conditions. Recombinant ANKRD55 isoforms were 
detected in TPE and eluted fractions with specific Ab (Aviva Systems Biology) or His Ab by WB. As negative control cells 
were cultivated under the same conditions, but without transfection agent (CTRL).  Specific bands corresponding to 
overexpressed isoforms 001 and 005 are indicated by black and white arrowheads, respectively. Black cross marks 
endogenous ANKRD55 isoform 001. Diamond marks a specific protein interacting with both the Ni2+-NTA agarose and 




2.2. Identification of ANKRD55 001-interacting proteins 
To determine the interacting partners of ANKRD55, two methods were used for mass 
spectrometry-based proteomics studies. First, bands specifically detected in the 
ANKRD55 IPed samples were cut and trypsin-digested in order to identify proteins 
responsible for those differences. Although this approach is highly valuable for the 
identification of the most abundant interactors, many putative interacting proteins may 
get lost since we only cut a limited number of bands. Therefore, a second approach was 
carried out where the whole gel lanes were cut, digested and analyzed by nLC-MS/MS. 
The substraction of specific ANKRD55-interacting proteins was carried out at mass 
spectrometry level. FLAG- and his-tagged ANKRD55 IPs from nuclear fractions, 
membranous organelles fraction and total protein extracts were loaded onto a SDS-PAGE 
and silver stained. The results showed several specific bands in FLAG-ANKRD55 001 and 
005 IP that were not present in control samples. For his-ANKRD55 001, only a single 
specific band was found that corresponded to the overexpressed ANKRD55 (Figure 15). 
Bands corresponding to the Mr of recombinant FLAG-ANKRD55 isoforms and interacting 
partners not present in the control samples were cut, trypsin digested and identified by 
nLC-MS/MS analysis (Table 6).  
Figure 15. Silver-staining analysis of ANKRD55 complexes. Silver-stained SDS-PAGE showing ANKRD55 IP with (A) Ni2+-
NTA agarose under denaturing conditions from total protein extracts (TPE) and FLAG resin from (B) membranous 
organelles fraction (MO), (C) total protein extracts (TPE), and (D) nuclear fractions (NE) of HEK293 and HeLa cells 
expressing FLAG/his-tagged ANKRD55 isoforms (001) and (005). As negative control cells were cultivated under the 
same conditions, but without transfection agent (CTRL). The proteins identified using nLC-MS/MS are listed in Table 6 










Table 6. Identified ANKRD55-interacting proteins from three different cell extracts by silver staining and nLC-MS/MS 
analysis 
  IP Band Gene 
symbol 


























  A 
  
ANKRD55  Q3KP44 68.41 Ankyrin repeat domain-containing protein 55 12 
HSPA9  P38646 73.68 Stress-70 protein, mitochondrial 4 
B 
  
ANKRD55 Q3KP44 68.41 Ankyrin repeat domain-containing protein 55 9 
HSPA9 P38646 73.68 Stress-70 protein, mitochondrial 4 
1 YWHAE P62258 29.17 14-3-3 protein epsilon 4 
2 YWHAE P62258 29.17 14-3-3 protein epsilon 3 
C 
  
ANKRD55 Q3KP44 68.41 Ankyrin repeat domain-containing protein 55 19 





LMNB1  P20700 66.408 Lamin-B1 21 
HSPA1A        P0DMV8 70  Heat shock 70 kDa protein 1A/1B 16 
LMNB2  Q03252 69.948 Lamin B2 15 
RPN1                      P04843 68.569 Dolichyl-diphosphooligosaccharide--protein 







VIM P08670 53.65 Vimentin 13 
CCT4 P50991 57.924 T-complex protein 1 subunit delta  7 
PKM P14618 57.937 Pyruvate kinase PKM 3 
CCT7 Q99832 59.367 T-complex protein 1 subunit eta 2 




TUBB  P07437 49.6 Tubulin beta chain 10 
TUBA1B                              P68363 50.1 Tubulin alpha-1B chain 9 




EEF1A1    P68104 50.14 Elongation factor 1-alpha 1 4 
TUFM  P49411 49.542 Elongation factor Tu, mitochondrial 4 




YWHAE  P62258 29.174 14-3-3 protein epsilon 13 
GNB2L1 P63244 
 
35.07 Guanine nucleotide-binding protein subunit 
beta-2-like 1   Receptor of activated protein C 
kinase 1 
4 










YWHAZ  P63104 27.745 14-3-3 protein zeta/delta 25 
PHB P35232 29.8 Prohibitin 3 
SLC25A5 P05141 32.852 ADP/ATP translocase 2 6 
YWHAE  P62258 29.174 14-3-3 protein epsilon 3 
SLC25A6 P12236 32.866 ADP/ATP translocase 3 5 
YWHAH  Q04917 28.219 14-3-3 protein eta 3 
YWHAB  P31946 28.082 14-3-3 protein beta/alpha 3 
YWHAQ          P27348 27.76 14-3-3 protein theta 2 







YWHAZ  P63104 27.745 14-3-3 protein zeta/delta 6 
YWHAG            P61981 28.3 14-3-3 protein gamma 5 
PHB P35232 29.8 Prohibitin 3 
YWHAH Q04917 28.219 14-3-3 protein eta 6 
YWHAQ          P27348 27.76 14-3-3 protein theta 5 






SLC25A6 P12236 32.866 ADP/ATP translocase 3 6 







CAD P27708 242.984 CAD protein 18 
MYH10 P35580 228.99 Myosin-10 4 
USP9X  Q93008 292.28 Probable ubiquitin carboxyl-terminal 
hydrolase FAF-X 
3 
GCN1L1 Q92616 292.75 Translational Activator GCN1 3 
PRKDC  P78527 469.089 DNA-dependent protein kinase catalytic 
subunit 
3 









       11 HSPA5 P11021 72.28 78 kDa glucose-regulated protein 2 
D 
  
ANKRD55 Q3KP44 36.9 Isoform 2 Ankyrin repeat domain-containing 
protein 55  
13 
EEF1A1 P68104 50.1 Elongation factor 1-alpha 1 2 






















                                                 A                                          
  
ANKRD55 Q3KP44 68.41 Ankyrin repeat domain-containing protein 55 13 






TUBB  P07437 49.60 Tubulin beta chain 12 
TUBB4B  P68371 49.80 Tubulin beta-4B chain 12 
TUBB4A  P04350 49.60 Tubulin beta-4A chain 10 
TUBA1B                              P68363 50.10 Tubulin alpha-1B chain 9 








EIF4A1 P60842 46.15 Eukaryotic initiation factor 4A-I 5 
EEF1A1    P68104 50.14 Elongation factor 1-alpha 1 4 
DDOST  P39656 50.801 Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase 48 kDa subunit 
5 
EIF4A3 P38919 46.871 Eukaryotic initiation factor 4A-III 5 
RPL3  P39023 46.109 60S ribosomal protein L3 3 
TUBB  P07437 49.60 Tubulin beta chain 3 






ACTB  P60709 41.737 Actin, cytoplasmic 1 10 
CKB P12277 42.644 Creatine kinase B-type 5 
OAT P04181 48.53 Ornithine aminotransferase, mitochondrial 3 
CS O75390 51.712 Citrate synthase, mitochondrial 3 
PAICS P22234 47.079 Multifunctional protein ADE2 3 
4 
  
GAPDH  P04406 36.05 Glyceraldehyde-3-phosphate dehydrogenase 3 
RPLP0             P05388 36.05 60S acidic ribosomal protein P0 3 
5 PRKDC P78527 469.089 DNA-dependent protein kinase catalytic 
subunit 
23 





SMC3 Q9UQE7 141.54 Structural maintenance of chromosomes 
protein 3 
13 











Some of the identified interacting proteins belong to 14-3-3 family (YWHAE, YWHAZ, 
YWHAH, YWHAB, YWHAQ, YWHAG), heat shock proteins (HSPA9, HSPA5, HSPA1A, 
HSP90B1, HSP90AB1, HSP90AA1, HSPA8, HSPD1), tubulin superfamily (TUBB, TUBA1B, 
TUBB4B, TUBB4A), CCT complex (CCT4, CCT7, TCP1) and initiation and elongation phases 
of eukaryotic translation (EEF1A1, EIF4A1, TUFM, EIF4A3, EEF1G, EEF2), among others. 
YWHAE was identified in presence or absence of cross-linker as well as in two 
independent experiments from HEK293 total protein extracts. HSPA5 was detected in the 
three different HEK293 cell extracts. PRKDC was found in three independent experiments 
from HEK293 nuclear extracts. Several tubulin isoforms were found in nuclear and total 
HEK293 cell extracts. HSP90AB1, HSP90AA1, and HSP90B1 were identified in HEK293 and 
HeLa membranous organelles extracts. Thus, what clearly emerges from this analysis is 













































HSP90B1  P14625 92.469 Endoplasmin 6 




HSP90AB1 P08238 83.264 Heat shock protein HSP 90-beta 26 
HSP90AA1  P07900 84.66 Heat shock protein HSP 90-alpha 23 








HSPA8 P11142 70.89 Heat shock cognate 71 kDa protein 21 
HSPA1A P0DMV8 70.052 Heat shock 70 kDa protein 1A 17 
HSPA9 P38646 73.68 Stress-70 protein, mitochondrial 8 
SLC25A13 Q9UJS0 74.176 Calcium-binding mitochondrial carrier 
protein Aralar2 
5 
HSPA5 P11021 72.28 78 kDa glucose-regulated protein 3 
XRCC6 P12956 69.843 X-ray repair cross-complementing protein 6 3 
IFT74 Q96LB3 69.239 Intraflagellar transport protein 74 homolog 3 












HSP90B1  P14625 92.469 Endoplasmin 9 
EEF2 P13639 95.338 Elongation factor 2 4 
GANAB Q14697 106.874 Neutral alpha-glucosidase AB 4 
6 
  
HSP90AB1 P08238 83.264 Heat shock protein HSP 90-beta 16 




PKM  P14618 57.937 Pyruvate kinase PKM  14 
HSPD1  P10809 61.055 60 kDa heat shock protein, mitochondrial 7 
TCP1 P17987 60.344 T-complex protein 1 subunit alpha 4 
8 
  
EIF4A1 P60842 46.154 Eukaryotic initiation factor 4A-I 5 
EEF1A1 P68104 50.14 Elongation factor 1-alpha 1 3 
9 
  
TUFM P49411 49.542 Elongation factor Tu, mitochondrial 10 




on the basis of which no clear conclusion can be made on its precise biological role. 
However, of these, 14-3-3 proteins appear to present the best-resolved interactors in 
silver-stained gels (various examples in Figure 15).  
2.3. The ANKRD55 interactome 
In our first approach, several interacting candidates were identified corresponding to 
discrete bands IPed with ANKRD55 from three different cell extracts. Therefore, we 
decided to compare and analyze in more detail ANKRD55 and control IPs to search for 
and identify further interacting partners and to confirm the ones previously identified. In 
essence, rather than focusing on single visualized gel bands as we did before, our goal 
here was to analyze the full lanes corresponding to ANKRD55 001 or mock (not 
transfected cells) eluates. Indeed, low abundant ANKRD55-interacting proteins could be 
present that are not resolved as single bands and may be missed by the first method. 
Together such bands tend to produce a darker stainable protein smear in ANKRD55 
compared to mock lanes (several such examples can be seen in Figure 15). By subtracting 
the ‘mock proteome’ from the ANKRD55 proteome, a specific and comprehensive 
ANKRD55 interactome can be deduced. For this second method, we focused our 
proteomic analysis on FLAG-tagged ANKRD55 isoform 001, which was more efficiently 
IPed than isoform 005, and showed highest number of potential interacting partners. 
FLAG-ANKRD55 isoform 001 was overexpressed in HEK293 cells and IPed from total 
protein extracts and nuclear extracts in triplicates (three independent experiments each 
that were performed on distinct days from distinct batches of cells). WB with FLAG 
antibody was performed to verify the quality of ANKRD55 overexpression and IP (Figure 
16A). ANKRD55 complexes were then separated by SDS-PAGE and stained using SYPRO 
Ruby. The full gel lanes starting from the boundary of the stacking gel with the resolving 
gel up to the gel front were cut into ten pieces (one contained ANKRD55 001 or its 
control), trypsin digested, and identified by nLC-MS/MS (Figure 16B).   
To build the ANKRD55 interactome, all potential ANKRD55 interacting partners were 
filtered according to their spectral count enrichment. Spectral counting accounts for the 
total number of MS/MS spectra matching to peptides that belong to a certain protein and 




and methods for more details). We reproducibly identified enrichment of 148 proteins in 
total protein extracts and 22 proteins in nuclear extracts over the three replicates, based 
on stringent selection criteria including both at least two unique peptides and a 5-fold 
increase in ANKRD55 spectral counts in the ANKRD55 IP compared to control IP in all 
three replicates. These proteins were selected for further functional analysis and 
validation (Figure 16C, Table 7). The average NSAF of these proteins was calculated in 
order to estimate their relative abundance within the IPed samples (see materials and 
methods for more details). Although not considered for further analyses, an additional, 
less robust, dataset of putative ANKRD55 interactors was substracted in addition to the 
set of reliably enriched proteins. For this purpose, proteins enriched with a more relaxed 
criteria of ANKRD55 IP/negative control IP spectral count ratio of at least 5 in only 2 out 
of 3 replicates were selected, providing additional 144 putative-ANKRD55 partners in 
total protein extracts and 34 in nuclear extracts (Supplementary Table 2).  
Figure 16. Isolation and identification of ANKRD55 interactome components by nLC-MS/MS. (A) Recombinant ANKRD55 
isoform (001) was detected in nuclear extracts (NE), total protein extracts (TPE) and eluted fractions (FLAG IP) with 
FLAG Ab by WB. As negative control cells were cultivated under the same conditions, but without transfection agent 
(CTRL). (B) A SYPRO Ruby-stained SDS-PAGE showing analysis strategy of ANKRD55 complexes IP with FLAG resin from 
NE and TPE of HEK293 cells expressing isoform 001. WB and SDS-PAGE are representative of three independent 
biological replicates. (C) Venn diagram represents total number and common significant interactors in each replicate 














   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
















 YWHAE P62258 29.17 14-3-3 protein epsilon 2.64 0.21 
YWHAB P31946 28.082 14-3-3 protein beta/alpha  1.14 0.00 
SLC25A5 P05141 32.852 ADP/ATP translocase 2  1.08 0.06 
YWHAH Q04917 28.219 14-3-3 protein eta 0.97 0.00 
RPS3 P23396 26.688 40S ribosomal protein S3 0.81 0.26 
YWHAG P61981 28.3 14-3-3 protein gamma  0.81 0.00 
TUBB6 Q9BUF5 49.857 Tubulin beta-6 chain 0.76 0.00 
SLC25A11  Q02978 34.062 Mitochondrial 2-oxoglutarate/malate carrier protein  0.66 0.08 
NTPCR Q9BSD7 20.713 Cancer-related nucleoside-triphosphatase  0.57 0.00 
RPS15A P62244 14.84 40S ribosomal protein S15a  0.53 0.00 
SLC25A13 Q9UJS0 74.176 Calcium-binding mitochondrial carrier protein Aralar2  0.47 0.00 
RPL9 P32969 21.863 60S ribosomal protein L9  0.46 0.00 
ARF4  P18085 20.511 ADP-ribosylation factor 4 0.46 0.00 
CCT4 P50991 57.924 T-complex protein 1 subunit delta  0.43 0.12 
PGAM5 Q96HS1 32.004 Serine/threonine-protein phosphatase PGAM5, mitochondrial 0.40 0.06 
MCM7 P33993 81.308 DNA replication licensing factor MCM7 0.39 0.00 
PCBP2 Q15366 38.58 Poly(rC)-binding protein 2 0.39 0.00 
PCBP1 Q15365 37.498 Poly(rC)-binding protein 1 0.37 0.00 
TIMM50 Q3ZCQ8 39.646 Mitochondrial import inner membrane translocase subunit TIM50 0.37 0.00 
RPL23 P62829 14.865 60S ribosomal protein L23  0.34 0.00 
PPP3CA Q08209 58.688 Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform  0.34 0.00 
PCNA P12004 28.769 Proliferating cell nuclear antigen 0.33 0.00 
CFL1  P23528 18.502 Cofilin-1  0.31 0.00 
CCT8 P50990 59.621 T-complex protein 1 subunit theta 0.31 0.05 
ATP5O P48047 23.277 ATP synthase subunit O, mitochondrial 0.31 0.00 
PPP2R1A P30153 65.309 Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A 
alpha isoform 
0.31 0.03 
RPS9  P46781 22.591 40S ribosomal protein S9 0.31 0.00 
DNAJA1  P31689 44.868 DnaJ homolog subfamily A member 1 0.30 0.00 
SLC25A12  O75746 74.762 Calcium-binding mitochondrial carrier protein Aralar1 0.30 0.00 
HSPA9 P38646 73.68 Stress-70 protein, mitochondrial 0.29 0.07 
SRPRB Q9Y5M8 29.702 Signal recognition particle receptor subunit beta 0.28 0.00 
CAD P27708 242.984 CAD protein 0.27 0.00 
RPS3A P61247 29.945 40S ribosomal protein S3a 0.27 0.00 
GNB2L1  P63244 35.077 Guanine nucleotide-binding protein subunit beta-2-like 1 0.27 0.00 
SFXN1  Q9H9B4 35.619 Sideroflexin-1  0.27 0.06 
DPM1  O60762 29.634 Dolichol-phosphate mannosyltransferase subunit 1 0.27 0.00 
ARL1  P40616 20.418 ADP-ribosylation factor-like protein 1 0.27 0.00 
SLC25A1 P53007 34.013 Tricarboxylate transport protein, mitochondrial  0.27 0.00 
RPL10  P27635 24.604 60S ribosomal protein L10 0.27 0.00 




RPLP0 P05388 36.05 60S acidic ribosomal protein P0 0.25 0.00 
RPN1  P04843 68.569 Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1  0.24 0.04 
PPP2R2A P63151 51.692 Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B 
alpha isoform  
0.24 0.00 
RPS2 P15880 31.324 40S ribosomal protein S2 0.24 0.00 
SLC25A3 Q00325 40.095 Phosphate carrier protein, mitochondrial  0.24 0.05 
VDAC2 P45880 31.567 Voltage-dependent anion-selective channel protein 2 0.24 0.00 
TTC26 A0AVF1 64.178 Intraflagellar transport protein 56  0.24 0.00 
EIF4A3 P38919 46.871 Eukaryotic initiation factor 4A-III 0.23 0.00 
DDX3X O00571 73.243 ATP-dependent RNA helicase DDX3X  0.23 0.00 
C1QBP Q07021 31.362 Complement component 1 Q subcomponent-binding protein, 
mitochondrial  
0.22 0.00 
RCN2 Q14257 36.876 Reticulocalbin-2 0.22 0.00 
RBM39 Q14498 59.38 RNA-binding protein 39  0.22 0.00 
CDK5 Q00535 33.304 Cyclin-dependent-like kinase 5 0.22 0.00 
OAT P04181 48.53 Ornithine aminotransferase, mitochondrial  0.21 0.00 
AIFM1  O95831 66.901 Apoptosis-inducing factor 1, mitochondrial  0.21 0.00 
RAB5C P51148 23.483 Ras-related protein Rab-5C  0.20 0.00 
RPL7A P62424 29.996 60S ribosomal protein L7a 0.20 0.00 
ATP1A1  P05023 112.896 Sodium/potassium-transporting ATPase subunit alpha-1  0.20 0.00 
SERPINH1  P50454 46.44 Serpin H1 0.20 0.00 
CSE1L P55060 110.417 Exportin-2  0.20 0.00 
IRS4 O14654 133.768 Insulin receptor substrate 4 0.19 0.00 
RARS P54136 75.379 Arginine--tRNA ligase, cytoplasmic  0.19 0.00 
IFT74  Q96LB3 69.239 Intraflagellar transport protein 74 homolog 0.19 0.00 
LRPPRC P42704 157.905 Leucine-rich PPR motif-containing protein, mitochondrial  0.19 0.03 
NCL P19338 76.614 Nucleolin 0.18 0.06 
RTCB Q9Y3I0   tRNA-splicing ligase RtcB homolog 0.18 0.04 
SSR1  P43307 32.235 Translocon-associated protein subunit alpha  0.18 0.00 
CLTC Q00610 191.615 Clathrin heavy chain 1  0.18 0.02 
PDHB  P11177 39.233 Pyruvate dehydrogenase E1 component subunit beta, mitochondrial  0.17 0.00 
ATAD3B  Q5T9A4 72.573 ATPase family AAA domain-containing protein 3B 0.17 0.00 
ETFA P13804 35.08 Electron transfer flavoprotein subunit alpha, mitochondrial  0.17 0.00 
PYCRL Q53H96 28.663 Pyrroline-5-carboxylate reductase 3 0.17 0.00 
PTBP1  P26599 57.221 Polypyrimidine tract-binding protein 1  0.17 0.00 
XPO1 O14980 123.386 Exportin-1  0.17 0.00 
HSD17B12 Q53GQ0 34.324 Very-long-chain 3-oxoacyl-CoA reductase 0.16 0.00 
FARSA  Q9Y285 57.564 Phenylalanine--tRNA ligase alpha subunit  0.16 0.04 
CBSL  P0DN79 60.587 Cystathionine beta-synthase-like protein 0.16 0.00 
ALDH18A1  P54886 87.302 Delta-1-pyrroline-5-carboxylate synthase 0.15 0.00 
IARS P41252 144.498 Isoleucine--tRNA ligase, cytoplasmic  0.15 0.00 
MCM6 Q14566 92.889 DNA replication licensing factor MCM6  0.15 0.00 
XPOT O43592 109.964 Exportin-T  0.15 0.00 
ATP5C1  P36542 32.996 ATP synthase subunit gamma, mitochondrial 0.14 0.00 




DNAJA2  O60884 45.746 DnaJ homolog subfamily A member 2  0.14 0.00 
MCM3 P25205 90.981 DNA replication licensing factor MCM3  0.14 0.00 
AARS  P49588 106.81 Alanine--tRNA ligase, cytoplasmic 0.14 0.00 
BSG P35613 42.2 Basigin  0.14 0.00 
DNM2 P50570 98.064 Dynamin-2  0.14 0.00 
CTPS1 P17812 66.69 CTP synthase 1  0.13 0.00 
CAND1  Q86VP6 136.376 Cullin-associated NEDD8-dissociated protein 1  0.13 0.00 
DDX21 Q9NR30 87.344 Nucleolar RNA helicase 2  0.13 0.00 
ATP2A2 P16615 114.757 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2  0.13 0.00 
SLC1A5 Q15758 56.598 Neutral amino acid transporter B(0)  0.12 0.00 
TIMM44 O43615 51.35 Mitochondrial import inner membrane translocase subunit TIM44 0.12 0.00 
RPL4  P36578 47.697 60S ribosomal protein L4 0.12 0.00 
FARSB Q9NSD9 66.116 Phenylalanine--tRNA ligase beta subunit  0.12 0.00 
FASN P49327 273.427 Fatty acid synthase 0.12 0.01 
PSMC3 P17980 49.204 Proteasome 26S Subunit, ATPase 3 0.12 0.00 
IMPDH2 P12268 55.805 Inosine-5'-monophosphate dehydrogenase 2  0.12 0.00 
EFTUD2  Q15029 109.436 116 kDa U5 small nuclear ribonucleoprotein component  0.11 0.00 
MMS19  Q96T76 113.29 MMS19 nucleotide excision repair protein homolog  0.11 0.00 
IPO4 Q8TEX9 118.715 Importin-4  0.11 0.00 
MARS P56192 101.116 Methionine--tRNA ligase, cytoplasmic 0.11 0.00 
KPNA2 P52292 57.862 Importin subunit alpha-1  0.11 0.00 
ATXN10 Q9UBB4 53.489 Ataxin-10 0.11 0.00 
GCN1L1  Q92616 292.75 Translational activator GCN1  0.10 0.00 
SNRNP200 O75643 244.508 U5 small nuclear ribonucleoprotein 200 kDa helicase 0.10 0.01 
NOP56 O00567 66.05 Nucleolar protein 56  0.10 0.00 
ABCD3 P28288 75.476 ATP-binding cassette sub-family D member 3 0.10 0.00 
ARAF P10398 67.585 Serine/threonine-protein kinase A-Raf  0.09 0.00 
COPG1 Q9Y678 97.718 Coatomer subunit gamma-1  0.09 0.00 
TRIP13 Q15645 48.551 Pachytene checkpoint protein 2 homolog 0.09 0.00 
SLC27A4 Q6P1M0 72.064 Long-chain fatty acid transport protein 4  0.09 0.00 
RARS2 Q5T160 65.505 Probable arginine--tRNA ligase, mitochondrial  0.08 0.00 
LARS Q9P2J5 134.466 Leucine--tRNA ligase, cytoplasmic 0.08 0.00 
MIB1 Q86YT6 110.136 E3 ubiquitin-protein ligase MIB1  0.08 0.00 
ADSL P30566 54.889 Adenylosuccinate lyase  0.08 0.00 
PRMT5 O14744 72.684 Protein arginine N-methyltransferase 5  0.07 0.00 
MYBBP1A Q9BQG0 148.855 Myb-binding protein 1A  0.07 0.00 
USP9X Q93008 292.28 Probable ubiquitin carboxyl-terminal hydrolase FAF-X  0.07 0.00 
ADCK3 Q8NI60 71.95 Atypical kinase ADCK3, mitochondrial  0.07 0.00 
UPF1  Q92900 124.345 Regulator of nonsense transcripts 1  0.06 0.00 
DYNC1H1 Q14204 532.408 Cytoplasmic dynein 1 heavy chain 1  0.06 0.00 
WDR6 Q9NNW5 121.725 WD repeat-containing protein 6 0.06 0.00 
USP7 Q93009 128.302 Ubiquitin carboxyl-terminal hydrolase 7 0.06 0.00 
CNOT1 A5YKK6 266.939 CCR4-NOT transcription complex subunit 1 0.06 0.00 




ACLY P53396 120.839 ATP-citrate synthase 0.06 0.00 
MTHFD1L  Q6UB35 105.79 Monofunctional C1-tetrahydrofolate synthase, mitochondrial  0.05 0.00 
PRPF8 Q6P2Q9 273.6 Pre-mRNA-processing-splicing factor 8 0.05 0.00 
IPO5 O00410 123.63 Importin-5  0.05 0.00 
VARS P26640 140.476 Valine--tRNA ligase 0.05 0.00 
SF3B3 Q15393 135.577 Splicing factor 3B subunit 3  0.05 0.00 
GANAB Q14697 106.874 Neutral alpha-glucosidase AB 0.05 0.00 
PNPLA6 Q8IY17 149.995 Neuropathy target esterase 0.05 0.00 
UBE3C Q15386 123.923 Ubiquitin-protein ligase E3C 0.04 0.00 
DDB1 Q16531 126.968 DNA damage-binding protein 1 0.04 0.00 
EIF3A Q14152 166.569 Eukaryotic translation initiation factor 3 subunit A 0.04 0.00 
NUP160 Q12769 162.121 Nuclear pore complex protein Nup160 0.04 0.00 
TLN1 Q9Y490 269.767 Talin-1  0.04 0.00 
UBR5 O95071 309.352 E3 ubiquitin-protein ligase UBR5  0.04 0.00 
PI4KA P42356 236.83 Phosphatidylinositol 4-kinase alpha  0.03 0.00 
NCAPD3  P42695 168.891 Condensin-2 complex subunit D3  0.03 0.00 
FLNA P21333 280.739 Filamin-A  0.03 0.00 
MDN1  Q9NU22 632.82 Midasin  0.03 0.00 
NUP205  Q92621 227.922 Nuclear pore complex protein Nup205 0.03 0.00 
LRBA P50851 319.108 Lipopolysaccharide-responsive and beige-like anchor protein 0.02 0.00 
ACACA Q13085 265.554 Acetyl-CoA carboxylase 1  0.02 0.00 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   













 VIM P08670 53.65 Vimentin 1.11 0.19 
PHB2 Q99623 33.296 Prohibitin-2 1.03 0.08 
DDX3X O00571 73.243 ATP-dependent RNA helicase DDX3X 0.81 0.11 
PGAM5 Q96HS1 32.004 Serine/threonine-protein phosphatase PGAM5, mitochondrial 0.81 0.00 
TUBA1C Q9BQE3 49.895 Tubulin alpha-1C chain 0.73 0.00 
RPS3 P23396 26.688 40S ribosomal protein S3 0.64 0.00 
SMC1A Q14683 143.23 Structural maintenance of chromosomes protein 1A 0.60 0.02 
DDX21 Q9NR30 87.344 Nucleolar RNA helicase 2 0.58 0.00 
ATAD3A Q9NVI7 71.369 ATPase family AAA domain-containing protein 3A 0.57 0.04 
SMC3 Q9UQE7 141.54 Structural maintenance of chromosomes protein 3 0.49 0.02 
PRKDC P78527 469.089 DNA-dependent protein kinase catalytic subunit 0.46 0.04 
NXF1 Q9UBU9 70.182 Nuclear RNA export factor 1 0.40 0.04 
RUVBL1 Q9Y265 50.22 RuvB-like 1 0.36 0.00 
RBM14 Q96PK6 69.492 RNA-binding protein 14 0.32 0.03 
AIFM1 O95831 66.901 Apoptosis-inducing factor 1, mitochondrial 0.30 0.00 
ELAVL1 Q15717 36.092 ELAV-like protein 1 0.29 0.00 
IRS4 O14654 133.768 Insulin receptor substrate 4 0.24 0.00 
WDR6 Q9NNW5 121.725 WD repeat-containing protein 6 0.22 0.00 
NUP205 Q92621 227.922 Nuclear pore complex protein Nup205 0.19 0.01 
NUP160 Q12769 162.121 Nuclear pore complex protein Nup160 0.16 0.00 
PDCD11 Q14690 208.701 Protein RRP5 homolog 0.09 0.00 





2.4. Functional analysis of ANKRD55-protein partners 
To interpret the potential functional role of ANKRD55-interacting proteins, ANKRD55 
interactome results were subjected to enrichment analysis using DAVID bioinformatics 
resource tool. We used functional annotation clustering to select the interesting Gene 
Ontology (GO) and other terms. The results from GO biological process, GO cellular 
compartment, GO molecular function and Uniprot (UP) keywords with a FDR<5% are 
shown in Figures 17 and 18. A more detailed summary of the functional annotation 
clustering with p<0.05 is provided in Supplementary Table 3.  
The functional analysis suggested that the ANKRD55-protein partners from total protein 
extracts were tightly related to nucleotide and ATP binding (p<1.18x10-13). GO categories 
were enriched in nuclear transport terms including Ran GTPase binding, intracellular 
protein transport, protein import into nucleus and nuclear pore (p<2.00x10-03). Total 
protein extracts dataset was also linked to processes that are associated with cell cycle 
and RNA, lipid and amino acid metabolism. Additionally, bioinformatics identified protein 
biosynthesis-related terms such as translation, structural constituent of ribosome, SRP-
dependent cotranslational protein targeting to membrane, tRNA aminoacylation for 
protein translation and regulation of translational fidelity. This enrichment could be due 
to ANKRD55 overexpression. GO cellular component annotated focal adhesion, 
ribosome, nuclear pore, and nuclear chromosome, among others, as the localization of 
the involved proteins in the total protein interactome.  
In the enrichment analysis of the ANKRD55-protein partners from nuclear extracts, ~20 
and 30% of proteins are related to sumoylation and RNA binding, respectively. GO 
categories were involved in processes that are associated with cell cycle including cell 
division, mitotic nuclear envelope disassembly, mitosis, DNA repair and damage. Nuclear 
extracts interactome was also linked to processes including RNA transport, nucleotide 
and ATP binding, among others. GO cellular component analysis indicated nuclear pore 





Figure 17. Functional enrichment analysis of ANKRD55 interactome from total protein extracts. The algorithm DAVID was 
used to analyze the ANKRD55 interactome using the GO terms Cellular Component (maroon), Biological Process (blue), 
Molecular Function (green) and Up Keywords (purple). The GO and other terms with FDR<5% are shown. Plotted as –
log (p-value) significance. 
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Figure 18. Functional enrichment analysis of ANKRD55 interactome from nuclear extracts. The algorithm DAVID was used 
to analyze the ANKRD55 interactome using the GO terms Cellular Component (maroon), Biological Process (blue), 
Molecular Function (green) and Up Keywords (purple). The GO and other terms with FDR<5% are shown. Plotted as –
log (p-value) significance. 
To further examine the ANKRD55 interactome, we performed an Ingenuity Pathway 
Analysis (IPA, QIAGEN) to identify major canonical pathways associated with ANKRD55-
interacting proteins. Sixty out of one hundred ninety-six pathways were significantly 
enriched in total protein extracts (p < 0.05; -log (p-value) > 1.30). The top ten pathways, 
ranked by significance included tRNA Charging, EIF2 Signaling, Regulation of eIF4 and 
p70S6K Signaling, RAN Signaling, mTOR Signaling, Cell cycle: G2/M DNA Damage 
Checkpoint Regulation, HIPPO Signaling, Cell Cycle Control of Chromosomal Replication, 
PI3K/AKT Signaling and p70S6K Signaling (Figure 19). In nuclear extract interactome 
analysis, SMC1A and SMC3 proteins were related to Mitotic Roles of Polo-Like Kinase and 
ATM Signaling; PRKDC and PHB2 to Estrogen Receptor Signaling, VIM and TUBA1C to 14-
3-3-mediated Signaling and PRKDC and TUBA1C to Sirtuin Signaling Pathway. All 
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information on the IPA canonical pathways analysis of both interactomes is included in 
Supplementary Table 4.   
2.5. Validation of selected ANKRD55 interacting partners 
We confirmed specific interactions of several identified candidate proteins with 
recombinant ANKRD55 isoform 001 by IP followed by WB using antibodies 
(Supplementary Table 5 for details) against the selected partners. From the cytosolic 
interactome, we selected (i) six of the first ten proteins ranked according to NSAF value 
(14-3-3 isoforms, RPS3, and TUBB6); (ii) CLTC with a lower NSAF value and mainly 
localized to the vesicles, in addition to cytosol and mitotic spindle, and (iii) proteins that 
were found to be present as well in the NE interactome (SMC1A and PRKDC). From the 
nuclear interactome, three proteins (VIM, SMC1A and SMC3) from the top ten in the list 
were analyzed. Several of these proteins had at first been identified in individual bands 
cut from silver-stained gels including PRKDC, SMC1A and SMC3 (see Table 6). Regarding 
TUBB6, we used an anti-β-tubulin antibody which can recognize different β-tubulin 
isoforms including TUBB3, TUBB2B, TUBB, TUBB4B, TUBB2A, and TUBB4A (three of these 
were identified in two out of three interactome replicates, and several of these had been 
identified as well as in individual bands analyzed in the first approach, see Table 6). These 
β-tubulin isoforms showed more than 92% of homology with the immunogen used for 
the antibody production. We transiently expressed FLAG-ANKRD55 in HEK293 cells and 
performed IP from total protein extracts and nuclear extracts. Anti-FLAG IP experiments 
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Figure 19. Top canonical signaling pathways enrichment in the ANKRD55 interactome from total protein extract.  IPA 




and WB demonstrated that endogenous SMC1A, TUBB6, RPS3, 14-3-3 isoforms, PRKDC, 
and CLTC in total protein extracts (Figure 20 A, B) and SMC1A, SMC3, and VIM in nuclear 
extracts interacted specifically with FLAG-ANKRD55 (Figure 20C). In contrast, neither 
ANKRD55 nor interacting partners were detected in the control IP. The IP of FLAG-
ANKRD55 with 14-3-3 isoforms and PRKDC was also validated in total protein extracts of 
HeLa cells by WB (Figure 20D). 
2.6. Immunofluorescence colocalization study on ANKRD55 interactome 
Proteins that interact tend to reside within the same or adjacent subcellular 
compartments321. Fluorescence colocalization microscopy is frequently used to assess 
potential links between distinct molecules322. For this reason, we study the subcellular 
localization of recombinant ANKRD55 and a selection of interacting partners at different 
time points to verify if they share at least one common subcellular localization.  
Figure 20. Validation of ANKRD55 isoform 001 interacting proteins. Overexpressed FLAG-ANKRD55 isoform 001 (001) 
and endogenous candidate proteins were IPed from enriched nuclear fractions (NE) and total protein extracts (TPE) 
after 48h of transfection in HEK293 and HeLa cells. As negative control cells were cultivated under the same 
conditions, but without transfection agent (CTRL).  Recombinant ANKRD55 and endogenous proteins were detected 





The results showed a highly significant colocalization (p< 0.0001) between recombinant 
ANKRD55 isoform 001 and RPS3 in the cytoplasm (Figure 21), and β-tubulin (Figure 22) 
and 14-3-3 isoforms (Figure 23) in the cytoplasm and cell membrane upon comparison of 
transfected and non-transfected cells. Moreover, the colocalization with TUBB increased 
with time, decreased with RPS3 and there were no differences between two-time points 
for 14-3-3 isoforms (Figure 21B, 22B, 23B).   
It is necessary to mention that overexpressed ANKRD55 itself showed different staining 
patterns in the colocalization experiments with RPS3 and β-tubulin, where it was localized 
mainly in the cytoplasm, versus 14-3-3 where it occurred more pronouncedly in the 
vicinity of the cell membrane. These staining differences are due to the type of antibodies 
used to mark ANKRD55. In the former analysis the anti-FLAG antibody used was 
monoclonal and, therefore, arguably more specific than the one used in the colocalization 
with 14-3-3 which was polyclonal and not antigen-purified (Figure 23).  
As we can see in Figures 21A, 22A and 23A, it was not possible to visualize recombinant 
ANKRD55 in the nuclei. Given that in previous analysis the presence of ANKRD55, in its 
endogenous and overexpressed form, was validated in the nucleus of several cell lines 
including HEK293 (Figures 10, 11 and 12) it was thought that the signal in 
immunofluorescence may have been too weak to facilitate visualization with the previous 
protocol. Thus, the procedure was modified to include an antigen retrieval treatment to 
try to increase the fluorescent signal of the nuclei. 
The modification of the immunofluorescence protocol was successful, so it was 
subsequently applied to study the nuclear colocalization of overexpressed ANKRD55 
together with β-tubulin (Figure 24) and VIM (Figure 25) as representatives of the 
validated proteins of ANKRD55 interactomes (Table 7). 
After antigen retrieval treatment, the results showed recombinant ANKRD55 in the nuclei 
of cells in division. Therefore, the nuclear colocalization with β-tubulin (Figure 24) and 
VIM (Figure 25) could only be studied in this stage, and quantification was not performed 
due to the small sample size. It should be mentioned that cells in mitosis transfected with 




the fixed cells. In the images, we can see a positive colocalization with diffuse β-tubulin 
in the nucleus and specific in the spindle (Figure 24), and with diffuse VIM in the nucleus 



















Figure 21. Recombinant ANKRD55 colocalized with endogenous RPS3 in HEK293 cells. A) Representative microphotographs of immunostaining for ANKRD55 (FLAG Ab; red), 40S ribosomal protein 
S3 (RPS3 Ab; green) and nuclei (DAPI; white) in non-transfected (CTRL) and transfected 24h (24h) and 48h (48h) HEK293 cells with ANKRD55 isoform 001. B) Colocalization quantification using 

























Figure 22. Recombinant ANKRD55 colocalized with endogenous β-tubulin in HEK293 cells. A) Representative microphotographs of immunostaining for ANKRD55 (FLAG Ab; red), tubulin beta chain 
(TUBB Ab; green) and nuclei (DAPI; white) in non-transfected (CTRL) and transfected 24h (24h) and 48h (48h) HEK293 cells with ANKRD55 isoform 001. B) Colocalization quantification using 












Figure 23. Recombinant ANKRD55 colocalized with endogenous 14-3-3 protein isoforms in HEK293 cells. A) Representative microphotographs of immunostaining for ANKRD55 (FLAG Ab; red), 14-3-
3- protein isoforms (14-3-3 (pan) Ab; green) and nuclei (DAPI; white) in non-transfected (CTRL) and transfected 24h (24h) and 48h (48h) HEK293 cells with ANKRD55 isoform 001. B) Colocalization 




























Figure 24. Recombinant ANKRD55 colocalized with endogenous β-tubulin in HEK293 cells. Representative microphotographs of immunostaining for ANKRD55 (FLAG Ab; red), tubulin beta chain 
(TUBB Ab; green) and nuclei (DAPI; white) in non-transfected (CTRL) and transfected 24h (24h) and 48h (48h) HEK293 cells with ANKRD55 isoform 001 subjected to antigen retrieval treatment. 





Figure 25. Recombinant ANKRD55 colocalized with endogenous VIM in HEK293 cells Representative microphotographs of immunostaining for ANKRD55 (FLAG Ab; red), vimentin (VIM Ab; green) and 
nuclei (DAPI; white) in non-transfected (CTRL) and transfected 24h (24h) and 48h (48h) HEK293 cells with ANKRD55 isoform 001 subjected to antigen retrieval treatment. Original image included 




2.7. ANKRD55 is a phosphoprotein 
 An important subset of proteins identified in this interactome analysis belong to the 14-
3-3 protein family. 14-3-3 proteins are ubiquitously expressed 
phosphoserine/phosphothreonine (pS/pT)-binding proteins that are members of a large 
family of isoforms323. In general, they bind to their ligands through RSXpS/TXP or 
RXXXpS/TXP sequences324, but they can also bind their ligands in a phosphorylation-
independent manner325,326. Thus, we determined whether ANKRD55 was 
phosphorylated.  
 Our primary sources for this step were phosphoproteome repositories, such as 
PhosphoSitePlus316 and dbPAF317 databases. The identified phosphorylation sites are 
summarized in Table 8. Moreover, 14-3-3-Pred web server318 was used to predict 
putative 14-3-3 binding phosphosites on ANKRD55.  Two out of ninety predicted 
phosphorylation sites (S436 and S597) fulfill the cut-off (Supplementary Table 6).  Finally, 
we identified specific pS/pT sites in overexpressed and IPed ANKRD55 isoform 001 from 
HEK293 from nuclear and total proteins extracts by TiO2-based phosphopeptide 
enrichment prior to nLC–MS/MS analysis. The phosphorylation sites at T6 and S436 in 
ANKRD55 were confirmed and the S475 site was found in nuclear and total protein 
extracts previously identified in mouse ANKRD55 (Table 8). In conclusion, the data 
revealed five phosphorylation sites in human ANKRD55 at T6, T11, T189, S436 and S475. 
14-3-3-Pred web server predicted with the highest score S436 as 14-3-3 binding 
phosphosites. ANKRD55 identified phosphorylation sites are summarized in Table 8.  
Table 8. Summary of the identified Ser/Thr Phosphorylation Sites in ANKRD55. The first five columns show the 
phosphorylation sites identified in the phosphoproteome repositories including position and sequence of the peptide, 
specie in which it was found, reference for the experiment data and database. The last column includes our 
experimental data about the ANKRD55 phosphosites: N, nuclear extracts and T, total protein extracts. 
Position Peptides Species References Sources Identified phoshorylation sites 
T6 MMRQAtMDFSTPS Human 327 PhosphoSitePlus N/T 
T11 QATMDFStPSVFDQQ Human 327 PhosphoSitePlus 
 
T189 GADPtLVDK Human 328 dbPAF 
 
S436 TQsLPPITLGNNFLTASHR Human 329 dbPAF T 
S473 MAQRSQKsRSEQDLL Mouse 330,331 PhosphoSitePlus 
 





ANKRD55 mainly has been identified as a risk gene for several autoimmune diseases in 
multiple GWAS191–193,196,198–200,202. However, the functions of ANKRD55 have not been 
elucidated. Knowledge of protein localization is invaluable for understanding their 
function as well as the interaction of different proteins336. It has been revealed that over 
80% of proteins do not operate alone but in complexes337. The functionality of 
unidentified proteins can be predicted on the evidence of their interaction with a protein, 
whose function is already revealed338. Moreover, ANKRD55 belongs to a family containing 
AR, which exclusively functions to mediate PPIs, consequently should take part in diverse 
PPI as has been reported for other members of the ANK family.  
First, we identified the endogenous and recombinant ANKRD55 subcellular localization 
using an Ab that recognizes 001 and 005 isoforms. Endogenous ANKRD55 
immunoreactivity was detected in the nucleus of SH-SY5Y, Jurkat, and U937 cell lines by 
immunofluorescence microscopy. ANKRD55 reactivity was also present in the cytosol of 
all of the studied cell types, although, unlike the nuclear signal, the cytosolic one did not 
disappear upon addition of an ANKRD55-specific blocking peptide (Figure 10). 
Immunoblotting of sucrose gradient–purified nuclei confirmed the presence of 005 and 
001 in the nucleus of primary CD4+ T cells and in those of the Jurkat and U937 cell lines, 
as well as of 001 in the nucleus of SH-SY5Y cells (Figure 11A).  Biochemical fractionation 
also validated that isoform 001 of ANKRD55 was located mainly in the nucleus as well as 
in membranous organelles of SH-SY5Y and Jurkat cell lines. However, isoform 005 
distributed between cytoplasm and membranous organelles in Jurkat cells, whereas in 
SH-SY5Y cells it was weakly detectable in cytosol and membrane organelle fractions but 
was virtually absent from the nuclei as shown through sucrose ultracentrifugation or 
biochemical fractionation. Instead, a smaller immunoreactive protein (30 kDa), which is 
detectable in the nucleus but not in the cytosol and is not seen in any of the other cell 
types analyzed, may correspond to a lineage-specific immunoreactive truncation product 
of a larger nuclear isoform because an ANKRD55 splice variant coding for a protein of this 




005 were detected in cytosol, membranous organelles and nucleus of HeLa and HEK293 
cells by biochemical fractionation. Additionally, truncated immunoreactive products 
were present, probably generated by specific proteolytic events from the intact isoform 
proteins (Figure 12).   
Then, we characterized ANKRD55 interactome from total protein extracts and nuclear 
extracts which revealed unusual combination of functionally very distinct proteins. A 
larger group of ANKRD55-interacting partners was present in total protein extract than in 
nuclear interactome. Functional analysis suggested that the ANKRD55-protein partners 
from nuclear (eight and seven proteins) and total protein extracts (fifty-two and forty-
three proteins) are related to nucleotide and ATP binding, respectively (Figures 17 and 
18). 30% of proteins from nuclear interactome are related to RNA binding. Bioinformatics 
analysis predicted the binding ability of ANKRD55 to DNA, ATP, ADP and GTP nucleotides, 
but not to RNA (Supplementary Table 8).  
GO categories from total protein extracts were enriched in nuclear transport terms 
providing a possible explanation for the nucleocytoplasmic transport of ANKRD55, which 
seems to be mediated by importins/exportins transport system enriched in the 
interactome (CSE1L, XPO1, IPO4, XPOT, IPO5, NUP160, NUP205, KPNA2, COPG1, CDK5, 
YWHAH, CLTC) (Figure 17). However, a number of AR, such as IκBα, ASPP2, and GABPβ, 
have been reported to enter the nucleus via an unknown mechanism independent of a 
canonical nuclear localization signal339. As demonstrated by Lu et al. (2014), this 
mechanism is characterized by the presence of components of the RanGDP/AR pathway 
which represents a general importin-independent nuclear import pathway frequently 
used by AR-containing proteins340. Ran GTPase binding, which obtained high significance 
in the GO, is known to regulate protein trafficking through the nuclear envelope and is 
present in both nuclear transport systems.  
Both interactomes were also linked to processes that are associated with the cell cycle 
(Figures 17 and 18). ANKRD55-interacting partners validation by confocal microscopy 
reported that ANKRD55 is localized in the nucleus only during mitosis (Figures 24 and 25). 
In the different phases of mitosis, ANKRD55 showed a more intense signal located in the 




nucleoplasm. The mitotic spindle has a crucial role in ensuring the accurate segregation 
of chromosomes into the two daughter cells during cell division.  It is a self-organized and 
dynamic macromolecular structure that is constructed from microtubules, microtubule-
associated proteins and motor proteins341. Its assembly is dependent on the tightly 
regulated nucleation of microtubules, which form the major structural component of the 
mitotic spindle. Microtubules are assembled from dimers of α- and β-tubulin, a process 
that is initiated from γ-tubulin ring complexes341,342. These data agree with the results 
obtained in the ANKRD55 interactomes due to the identification of diverse α- and β-
tubulin isoforms and other proteins involved in mitotic spindle (Table 7 and 
Supplementary Table 2). Moreover, in the images of nuclear immunofluorescence, β-
tubulin presented a specific marking in the mitotic spindle that colocalized with 
ANKRD55. This indicates that the mitotic spindle, although it has been a well-defined 
structure for years, ANKRD55 could be an associated protein. Thus, for a better study of 
ANKRD55 presence in the cell nucleus during the different phases of mitosis and a better 
understanding about its nuclear function, in the future the cells should be subjected to 
appropriate treatments to arrest them in the different phases of mitosis. SMC1A and 
SMC3 were also validated as part of the interactome of ANKRD55 (Figure 20 A and C). In 
fact, both proteins are members of cohesin complex crucial for chromatid cohesion. By 
holding the two sister chromatids together from their formation during replication until 
their separation in anaphase, cohesin creates a counterforce to the pulling of the mitotic 
spindle, which allows correct chromosome alignment and segregation343. Therefore, 
although these colocalizations have not been performed by immunofluorescence, one 
would expect the colocalization in the mitotic pole of SMC1A, SMC3 and ANKRD55. This 
association between the ANKRD55-interacting proteins and the mitotic spindle is also 
supported by the presence of RPS3 protein involved in spindle dynamics344. Similarly, the 
Ran GTPase binding, enriched in the GO (Figure 17), has been related to the spindle 
formation345. 
Intriguingly, numerous members of diverse protein families, such as 14-3-3, 
mitochondrial carriers, minichromosome maintenance proteins (MCM), serine/threonine 




Within the 14-3-3 protein family, the isoforms present in the analysis of the total protein 
extract were epsilon, beta/alpha, eta and gamma. 14-3-3 proteins, being pS/pT-binding 
proteins, led us to identify and confirm three phosphorylation sites in ANKRD55.  14-3-3 
proteins modulate the action of proteins that are involved in cell cycle and transcriptional 
control, signal transduction, intracellular trafficking and regulation of ion channels346 
through a variety of mechanisms: (i) direct conformational change of the target protein; 
(ii) physical occlusion of sequence specific or structural features; and (iii) scaffolding that 
anchors proteins within close proximity of one another347. 14-3-3 proteins have been 
detected in the CSF of patients with MS346 and could be a useful marker to identify a 
subgroup of demyelinating diseases patients348. Additionally, reactive astrocytes in 
chronic demyelinating lesions of MS patients intensely expressed 14-3-3 beta, epsilon, 
zeta, eta and sigma isoforms, among which the epsilon isoform is a highly specific marker 
for reactive astrocytes348 as well as 14-3-3 gamma plays a pivotal role in signaling 
pathways for oligodendrocytes protection in neuroinflammation349.  
Although ribosomal proteins (RP) are known for playing an essential role in ribosome 
assembly and protein translation, their ribosome-independent functions are also 
increasingly being appreciated350. Eleven RP were identified in ANKRD55 interactomes. 
Mutations in RPL10 are associated with T-cell acute lymphoblastic leukemia351 and 
autism, probably by affecting brain development352. RPL23 has been found to regulate 
the MDM2/MDMX–p53 cascade, consequently suppressing tumor cell 
proliferation353,354. RPS9 induces CDK1355, RPS3A activates NF-κB356, RPLP0 is involved in 
gynecologic tumors357, RPL4358 inhibits and RPL9359 promotes virus production.  RPS3, a 
validated ANKRD55-interacting partner in both cytosolic and nuclear interactomes, was 
shown to induce apoptosis by collaborating with E2F1360. Phospho-RPS3 was shown to 
translocate into the nucleus and upregulate prosurvival gene expression via association 
with NF-κB in non-small cell lung cancer cells361,362. RPS3 is also involved in immune 
signaling by selectively modulating NF-κB target gene expression. NF-kB is a family of 
transcription factors that were originally identified to regulate genes crucial for immune 
response, but later on were found to also regulate genes implicated in cell survival or 




pathway363, this RP is regarded as one of the most fascinating RP with pivotal 
multifunctions364.  
The HUGO Gene Nomenclature Committee (HGNC) provides a list of transporter families 
of the solute carrier (SLC) gene series (http://www.genenames.org)365 which include over 
300 members organized into 60 families. Solute carriers are eukaryotic membrane 
proteins that control the uptake and efflux of various solutes, including amino acids, 
sugars, and drugs366. Six members of mitochondrial carrier family (MCF) or SLC25 protein 
family were identified in the ANKRD55 interactome. Additionally, three further members 
of the same family were detected in two out of three replicates and in the first approach 
that was based on excision of silver stained gel bands. All SLC25 members have common 
sequence features: a tripartite structure, a 3-fold repeated signature motif, and six 
transmembrane α-helices (two in each of the three repeats). These structural features 
are different from those of any other transporter family and facilitate to unequivocally 
recognize them. The characterized SLC25 family members transport an extensive range 
of solutes367. Those identified in the interactome transport: SLC25A1, citrate, isocitrate, 
malate and phosphoenolpyruvate; SLC25A3, phosphate; SLC25A5, ADP and ATP; 
SLC25A11, 2-oxoglutarate and malate; SLC25A12 and SLC25A13; aspartate and 
glutamate. Mutations in SLC25 genes mainly cause rare metabolic disorders. Their 
symptoms follow from the specific metabolism affected368. However, a disease caused by 
a mutation in the SLC25A12 gene (present in the ANKRD55 interactome) is related with 
global hypomyelination and impaired neuronal aspartate transport, which prevents 
myelin formation by failing to provide N-acetylaspartate (NAA)  to oligodendrocytes369. 
Slc25a12 knockout mice showed impaired myelination, a marked decrease of the myelin 
lipid precursor NAA and lower aspartate concentration in the brain369,370. These results 
provide genetic evidence in support of an important role for SLC25A12 in myelin 
formation371. Other members from different SLC families were also identified. SLC1A5, a 
glutamine and essential amino acids transporter, is involved in several human cancers, 
amyotrophic lateral sclerosis372, and schizophrenia373; SLC27A4, a fatty acid transporter, 




MCM2 to 7 is a heterohexamer complex that contains six MCM homologues, and three 
of these were identified in the ANKRD55 interactome (MCM3, 6 and 7). MCMs have been 
determined to be DNA helicases involved in the initiation of DNA replication. Some 
studies have determined that there are more MCMs bound onto chromatin than required 
by replication origins, and the phenomenon is coined as the ‘MCM paradox’375,376. MCM7, 
a key component of the MCM complex, forms a double trimeric complex with MCM4 and 
MCM6. The double trimeric complex initiates DNA replication through unwinding DNA 
double strands. During the S phase, the complex participates in elongating DNA strands. 
Recently, MCM7 was reported to co-localize with tubulin in mitotic cells with MCM7 
depletion resulting in aberrant mitosis. This is in line with observations that MCM7 exerts 
certain functions on spindle formation to prevent cytokinesis during early mitosis by 
regulating CDK1 activity377. Therefore, although these colocalizations have not been 
performed by immunofluorescence, one would expect the colocalization in the mitotic 
pole of MCM7 and ANKRD55. 
Regarding the two approaches we used for identification of ANKRD55-interacting 
partners, almost 60% of proteins identified with the first approach that was based on 
excision of silver stained gel bands, were confirmed in at least two out of the three 
replicates from full-gel interactome analysis. Seven out of fifty-nine were identified in a 
different cell extract and sixteen were not validated. Moreover, we checked for freely 
available protein-protein databases (BioGRID378, STRING379 and HuRI) to confirm some of 
the identified interactions. The BioPlex 2.0 dataset300,380, which has been deposited into 
the BioGRID database, described thirteen ANKRD55-interacting partners; seven were 
included in at least two out of three replicates from our interactome analysis (YWHAE, 
YWHAQ, IFT52, IFT74, MIB1, YWHAZ, and YWHAG). Intriguingly, HIF1AN, an ANKRD55-
interacting partner described only in the BioPlex 2.0 dataset, catalyzes hydroxylation of 
highly conserved asparaginyl residues within AR of NFKB1, NFKBIA, NOTCH1, ASB4, 
PPP1R12A and several other AR-containing proteins381. Therefore, this could suggest the 
hydroxylation of asparaginyl residues from ANKRD55. However, in our experimental set-
up, we did not clearly detect HIF1AN in ANKRD55 interactomes by mass spectrometry, 




analysis using specific antibodies (Supplementary Figure 3), or that of another BioGrid 
partner, ZSCAN1 (data not shown). 
STRING database also shared ANKRD55-partners, specifically RPS3 and ACLY in Homo 
sapiens and Rps3 and Hsp90ab1 in Mus Musculus. Human Reference Protein Interactome 
Project (HuRI) included unpublished thirty ANKRD55-interacting partners; none of these 
were classified in our protein list (Supplementary Table 7). However, some of the HuRI 
ANKRD55 partners are involved in ciliogenesis and its regulation (CFAP206, LRGUK, and 
DEUP1), just as some proteins from our ANKRD55 interactome (MIB1, IFT74, ARF4, CCT4, 
CCT8, TTC26, FLNA, and IFT52), and ANKRD55 itself was described as a novel intraflagellar 
transport complex protein382. Moreover, the BioGRID database also identified other 
members included in the same process (IFT46, TTC30A, and TTC30B). HuRi also described 
the interaction between ANKRD55 and relevant proteins in T-cell development, 
differentiation and activation (BACH2383,384, BANP385 and LEF1386,387) as well as CARD9388, 
PHLPP1389 and CTPS1390 from other interactome studies.  
We observed that ANKRD55 interacted with other autoimmune risk genes, such as 
TIMMDC1, KPNB1, ANAPC1, COPB1, BACH2 (HuRI) and LEF1 (HuRI) MS risk genes and 
C1QBP RA risk genes. Additionally, we also noticed that some ANKRD55 partners (PRMT5, 
DDX17, CDK5, NDUFA13, KPNA2, IPO7, MYBBP1A, RQCD1, PGAM5, GNB2L1, CNOT1, 
RUVBL1, RUVBL2, DHX30, IRS4, RPS3, ILF2, WDR36, ELAVL1, YBX1, SMC1A) interacted 
with MS and RA risk genes (Supplementary Table 9).  
The large number of identified interactors suggests that ANKRD55 can act as a scaffold, 
probably exerting its function(s) in multiple protein complexes. No clear conclusion can 
be made on its precise biological role. However, based on interactome and subcellular 
localization analysis, ANKRD55 potentially is transported into the nucleus by the classical 
nuclear import pathway and it is involved somehow in: (i) mitosis, probably associated to 
mitotic spindle dynamics, as described for ANKRD53391, another AR-containing protein;  
(ii) the control of the uptake and efflux of various solutes, (iii) ciliogenesis and its 
regulation. ANKRD55 could also be important in the T-cell development, activation and 








































































The present work resulted in the following main conclusions:  
1. The three ANKRD55 transcripts were uniquely and highly expressed in CD4+ T cells.  
Individual transcript levels were highly correlated and the homozygotes for the risk 
allele (CC) expressed significantly higher levels of 001 and 005 transcripts in CD4+ T 
cells. rs6859219 regulated the expression of ANKRD55 in CD4+ T cells, qualifying 
rs6859219 as a novel eQTL for ANKRD55.  
2. Preliminary data showed that rs71624119 is located in an enhancer region and 
regulated ANKRD55 transcript 001 in HEK293‐T‐Cas9p300 cells.  
3. Endogenous ANKRD55 proteins is located primarily to the nucleus in primary CD4+ T 
cells and Jurkat, U937, and SH‐SY5Y human cell lines.  
4. Overexpressed ANKRD55 isoforms are located in cytosol, membranous organelles 
and nucleus in HEK293 and HeLa human cell lines. 
5. Retrieval of 005 and 001 ANKRD55 interactomes from transfected HEK293 and HeLa 
cell lines was optimized by experimentally testing and adjusting immunoprecipitation 
conditions. 
6.  For ANKRD55 interactome analysis a two-stage approach was adopted: (i) mass 
spectrometry of individual protein bands IPed with ANKRD55 in silver-stained gels; 
and (ii) mass spectrometry of gel slabs corresponding to the complete running lane 
of Sypro-stained gels. In this last approach, following subtraction of proteins of mock 
from those of 001 ANKRD55-transfected cells under stringent parameters, 148 
specifically interacting proteins were found in total protein extracts and 22 in nuclear 
extracts. 
7. The functional analysis suggested that the ANKRD55‐protein partners from total 
protein extracts were related to nucleotide and ATP binding, enriched in nuclear 
transport terms and associated with cell cycle and RNA, lipid and amino acid 
metabolism. The enrichment analysis of the ANKRD55‐protein partners from nuclear 
extracts are related to sumoylation, RNA binding, processes associated with cell cycle, 
RNA transport, nucleotide and ATP binding, among others.  
8. The interaction between overexpressed ANKRD55 isoform 001 and endogenous 
RPS3, SMC1A, SMC3, CLTC, PRKDC, VIM, β-tubulin isoforms, and 14-3-3 isoforms were 













































La esclerosis múltiple (EM) es una enfermedad inflamatoria desmielinizante del sistema 
nervioso central (SNC), que produce una discapacidad crónica progresiva en la mayoría 
de las personas con este trastorno. Esta condición tiene una presentación heterogénea 
que puede involucrar los sistemas motor, sensorial, visual y autónomo. La variación en 
las manifestaciones clínicas se correlaciona con la diseminación espaciotemporal de las 
zonas dañadas de la patología dentro del SNC, afectando tanto a los tractos de la 
sustancia blanca como a la sustancia gris cortical y profunda. Estas lesiones son una marca 
distintiva de la EM y son causadas por la infiltración de células inmunes a través de la 
barrera hematoencefálica, que promueven la inflamación, desmielinización, gliosis y 
degeneración neuroaxonal, lo que conduce a la interrupción de la señalización neuronal. 
La clasificación de las formas clínicas de la EM no es sencilla debido a la heterogeneidad 
del curso de la enfermedad y la sintomatología. La clasificación distingue tres patrones 
clínicos que son: 1) EM recurrente-remitente, 2) EM progresiva secundaria y 3) EM 
progresiva primaria. Por lo general, se diagnostica entre los 20 y 40 años. La enfermedad 
tiene una prevalencia heterogénea en todo el mundo, es más alta en América del Norte 
y Europa, y más baja en Asia Oriental y África subsahariana.  La EM se presenta con más 
frecuencia en mujeres que en hombres (3:1).  
Aunque algunos sugieren que la EM es principalmente un proceso neurodegenerativo 
con la intervención secundaria del sistema inmune, diversas evidencias apuntan a 
mecanismos de enfermedades mediadas por el sistema inmune debido a los siguientes 
hallazgos: 1) presencia de linfocitos T y B en las lesiones desmielinizantes; 2) las 
respuestas inmunes específicas de antígeno del SNC se detectan en la sangre periférica 
de pacientes con EM; 3) la enfermedad puede ser suprimida por terapias 
inmunomoduladoras; y 4) los estudios genéticos apuntan hacia el sistema inmune 
adaptativo, particularmente su componente de linfocitos T CD4+. 
La patogenia de la EM se explica mediante un modelo multifactorial que incorpora 
interacciones entre influencias genéticas, epigenéticas, infecciosas, nutricionales, 
climáticas u otras influencias ambientales. Todos estos factores pueden intervenir en la 
inmunidad adaptativa y/o innata, que se cree que es la vía principal modulada por las 




aumentan el riesgo de EM incluyen la exposición al humo del tabaco, la infección por el 
virus de Epstein-Barr, la obesidad de los adolescentes, la falta de exposición al sol o los 
bajos niveles de vitamina D. Varios estudios de asociación de genoma completo (GWAS) 
y estudios a gran escala dirigidos en los últimos 10 años, mostraron evidencia estadística 
inequívoca de la asociación de 200 variantes de susceptibilidad autosómicas fuera del 
complejo mayor de histocompatibilidad (MHC), una variante del cromosoma X y 32 
asociaciones independientes dentro del MHC. Estos datos apoyan un modelo de herencia 
poligénica para la EM, en el que el riesgo está determinado por un único alelo de efecto 
moderado y muchos alelos de efecto mucho menor. 
Una variante intrónica en ANKRD55, rs6859219, se identificó como factor de riesgo 
genético para la EM. Otros estudios han relacionado a ANKRD55 con varias enfermedades 
autoinmunes, como la artritis reumatoide (AR), enfermedad de Crohn, diabetes tipo 1, 
enfermedad celiaca, miopatías inflamatorias, y otro tipo de enfermedades, como el 
trastorno de estrés postraumático, enfermedad de Alzheimer (disminución cognitiva) y 
diabetes tipo 2. Recientemente, ANKRD55 se asoció con niveles de IgA. Además, otra 
variante cercana a este gen también se vinculó con cambios en la N-glicosilación de IgG, 
que se altera en la AR. Curiosamente, la defectuosa N-glicosilación también está 
implicada en la EM. 
El locus ANKRD55, ubicado en el cromosoma 5q11.2, codifica para la proteína con 
dominio de repetición de anquirina 55, cuya función actualmente se desconoce. La 
versión 75 de la base de datos Ensembl, incluye seis variantes de transcripción: cuatro 
son codificantes para proteínas (001, 002, 005 y 006), y las dos restantes transcritos no 
codificantes (007 y 008). Sin embargo, solo los transcritos codificantes de Ensembl 001 
(correspondientes a la forma completa) y 005, están incluidos en las bases de datos 
UniProt. ANKRD55 pertenece a una familia que contiene dominios de repetición de 
anquirina (RA). Este motivo está formado por 30-34 residuos aminoacídicos, es uno de 
los más comunes de la naturaleza, modular y de interacción proteína-proteína (PPI). La 
RA se ha encontrado en proteínas con diversas funciones, como la transcripción, 
regulación del ciclo celular, integridad del citoesqueleto, respuesta inflamatoria, 




El propósito de este estudio es conocer más, en torno a las funciones biológicas de 
ANKRD55 asociadas con la EM y AR y aumentar nuestro conocimiento sobre su papel en 
las enfermedades autoinmunes. Para abordar el objetivo del proyecto, perseguimos los 
siguientes objetivos específicos: 1) Identificación de la principal fuente celular de 
ANKRD55 en células mononucleares de sangre periférica (PBMC); 2) determinación de la 
variante intrónica de ANKRD55 asociada a la EM y AR como expression quantitative trait 
loci (eQTL) para tres transcritos de ANKRD55 en cinco subpoblaciones de PBMC; 3) 
estudio de cinco variantes intrónicas de ANKRD55 asociadas a la EM y AR, localizadas en 
regiones enhancer bioinformaticamente predichos, por su capacidad para regular la 
expresión de ANKRD55 y los genes con los que posiblemente interacciona, IL6ST e IL31RA; 
4) análisis de la localización subcelular de la forma endógena y recombinante de 
ANKRD55 en células inmunes y no inmunes; 5) identificación y validación de posibles 
proteínas con las que interacciona ANKRD55 en varios compartimentos subcelulares. 
Teniendo en cuenta que ANKRD55 es un factor de riesgo genético para diversas 
enfermedades autoinmunes, es probable que tenga un papel en el sistema inmunológico. 
Previamente en el grupo de investigación de Neurogenomiks analizamos la asociación de 
rs6859219 con la expresión de ANKRD55 por qPCR en pacientes con EM y controles 
sanos. Cuando los individuos se agruparon por genotipo, los homocigotos para el alelo 
de riesgo (CC), mostraron una expresión significativamente mayor de los tres transcritos 
ANKRD55 que los portadores del alelo protector (AA). No se encontraron diferencias 
significativas entre los pacientes con EM y los controles. A causa de la mezcla 
heterogénea de tipos celulares que componen las PBMC, nos propusimos identificar la 
principal fuente celular de expresión de ANKRD55. Para ello, se aislaron subpoblaciones 
de células CD4+, CD8+, CD14+, CD19+ y CD56+ de PBMC de 23 controles sanos. Los 
resultados mostraron que los tres transcritos de ANKRD55 se expresaron de forma única 
y elevada en las células T CD4+. Los niveles de transcritos individuales estaban altamente 
correlacionados y los homocigotos para el alelo de riesgo expresaron niveles 
significativamente más altos de transcritos 001 y 005 en células T CD4+. Por ello, 
encontramos que rs6859219 regulaba la expresión de ANKRD55 en PBMC y linfocitos T 




Posteriormente, analizamos cinco variantes enhancer bioinformáticamente predichas de 
ANKRD55 para determinar su capacidad moduladora de la expresión de ANKRD55 y los 
genes con los que posiblemente interacciona, IL6ST e IL31RA. En este caso, se usó el 
sistema CRISPR/dCas9 acoplado a la histona acetiltransferasa p300 que consigue la 
acetilación del residuo 27 de lisina de la histona H3, aumentando la transcripción. Los 
datos preliminares de dos experimentos independientes mostraron que la expresión del 
transcrito ANKRD55 001, se incrementó en las células HEK293-T-Cas9p300, que expresan 
de forma estable el constructo que modifica la región que incluye el rs71624119.  
En 2017, el primer análisis sobre la organización de las proteínas en una célula utilizando 
dos enfoques diferentes, imágenes de alto contenido y proteómica espacial, reveló que 
aproximadamente la mitad de las proteínas se pueden encontrar en más de un 
compartimento subcelular. La mala localización de proteínas puede estar asociada con 
disfunción celular y enfermedad. Por lo tanto, el conocimiento de la distribución espacial 
de las proteínas a nivel subcelular es esencial para comprender su función, las 
interacciones y los mecanismos celulares. Además, las funciones celulares están 
mediadas por complejas redes de interacciones físicas y funcionales entre 
macromoléculas, como ADN, ARN, proteínas y lípidos, así como moléculas más pequeñas, 
como los metabolitos. Muchas proteínas ejercen sus funciones dentro de las células en 
el contexto de complejos de proteínas. Por lo tanto, identificar las PPI, definidas como un 
contacto físico directo entre dos proteínas, es fundamental para obtener información 
sobre su función biológica, ya que una proteína no caracterizada que se une a una 
proteína cuyo papel en la célula se entiende, es probable que posea una función 
relacionada. 
Por este motivo, estudiamos la expresión endógena de ANKRD55 y la localización 
intracelular en células T CD4+ primarias y en las líneas celulares humanas Jurkat, U937 y 
SH-SY5Y mediante microscopía confocal, enriquecimiento nuclear mediante 
ultracentrifugación en gradiente de sacarosa y fraccionamiento bioquímico para obtener 
fracción citosólica, orgánulos membranosos y fracción nuclear. Los resultados mostraron 
que las isoformas endógenas de ANKRD55 se ubican principalmente en el núcleo de las 




Para estudiar más a fondo la localización subcelular de las isoformas de ANKRD55, 
sobreexpresamos transitoriamente las isoformas humanas de ANKRD55 001 y 005 en 
células HEK293 y HeLa y fraccionamos las células en tres compartimentos subcelulares. 
Las dos isoformas sobreexpresadas de ANKRD55 se detectaron en citosol, orgánulos 
membranosos y núcleos en ambas líneas celulares. Además, había presentes productos 
inmunorreactivos truncados, probablemente generados por eventos proteolíticos 
específicos de las proteínas de isoformas intactas. Los resultados también mostraron la 
isoforma endógena 001 en ambas líneas celulares, lo que demuestra la capacidad de las 
células HEK293 y Hela para producir ANKRD55 y, por lo tanto, comprometerse con su(s) 
vía(s) biológica(s).  
Para identificar los interactomas de ANKRD55, realizamos una inmunoprecipitación (IP) 
de ANKRD55 recombinante incluyendo FLAG tag y las proteínas con las que interacciona, 
seguido de un análisis mediante cromatografía líquida de nano flujo acoplada a análisis 
de espectrometría de masas en tándem (nLC-MS/MS). Este análisis se realizó en dos 
etapas: 1) espectrometría de masas de bandas de proteínas individuales 
inmunoprecipitadas con ANKRD55 en geles teñidos con plata de distintos extractos 
proteicos de las líneas celulares HEK293 y HeLa; y 2) espectrometría de masas de cortes 
de gel correspondientes a la IP cargada en geles teñidos con Sypro de extracto proteico 
total y extracto nuclear de HEK293. En este último enfoque, después de eliminar, bajo 
parámetros estrictos, las proteínas presentes en el control negativo a las de células 
transfectadas con ANKRD55 001, se encontraron 148 proteínas que interactúan 
específicamente en extractos de proteínas totales y 22 en extractos nucleares. La 
interacción entre la isoforma 001 de ANKRD55 sobreexpresada y la forma endógena de 
RPS3, SMC1A, SMC3, CLTC, PRKDC, VIM, isoformas de β-tubulina e isoformas de 14-3-3 
fueron validadas mediante WB y microscopía confocal. 
El análisis funcional a través de la herramienta DAVID, sugirió que las proteínas que 
interaccionan con ANKRD55 de los extractos de proteínas totales, se relacionan con la 
unión de nucleótidos y ATP, están enriquecidas en términos de transporte nuclear y se 
asociaron con el ciclo celular y metabolismo de ARN, lípidos y aminoácidos. El análisis de 




se relaciona con la sumoilación, unión de ARN, procesos asociados con el ciclo celular, el 
transporte de ARN, unión de nucleótidos y ATP, entre otros. 
Un importante subconjunto de proteínas identificadas en este análisis pertenece a la 
familia de proteínas 14-3-3. Las proteínas 14-3-3 son proteínas de unión a fosfoserina / 
fosfotreonina expresadas de forma ubicua que son miembros de una gran familia de 
isoformas. Por ello, analizamos si ANKRD55 se encontraba fosforilada. Los resultados 
mostraron que la isoforma 001 de ANKRD55 incluye cinco sitios de fosforilación de 
serina/treonina. 
La identificación de un gran número de proteínas que interaccionan con ANKRD55, 
sugiere que ANKRD55 puede actuar como un scaffold, probablemente ejerciendo su(s) 
función(es) en complejos compuestos por múltiples proteínas. Por ello, no se puede 
concluir de forma clara su papel biológico preciso. Sin embargo, según el análisis de 
localización subcelular y el interactoma, ANKRD55 se transporta potencialmente al 
núcleo por la vía de importación nuclear clásica y está involucrada de alguna forma en: 
1) mitosis, probablemente asociado a la dinámica del huso mitótico; 2) el control de 
captación y flujo de salida de varios solutos y 3) ciliogénesis y su regulación. ANKRD55 
puede ser importante en el desarrollo, activación y diferenciación de los linfocitos T, una 
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Supplementary Table 2. Identification of ANKRD55-interacting partners in a minimum of two replicates of nuclear and 
total protein extracts by nLC-MS/MS 
  Gene symbol Accession MW (kDa) Protein NSAF 
ANKRD55 CTRL 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   















 TUBB P07437 49.60 Tubulin beta chain 2.23 1.48 
TUBB4B P68371 49.80 Tubulin beta-4B chain 1.92 1.35 
TUBA1B P68363 50.152 Tubulin alpha-1B chain  1.60 0.00 
YWHAZ P63104 27.745 14-3-3 protein zeta/delta 1.60 0.67 
YWHAQ P27348 27.76 14-3-3 protein theta 1.32 0.67 
HSPA1A P0DMV8 63.89 Isoform 2 of Heat shock 70 kDa protein 1A/1B 1.31 0.77 
TUBB2A  Q13885 49.907 Tubulin beta-2A chain  1.14 0.00 
EIF4A1 P60842 46.15 Eukaryotic initiation factor 4A-I 1.10 0.81 
HSPD1 P10809 61.055 60 kDa heat shock protein, mitochondrial  0.75 0.19 
RPS18 P62269 17.719 40S ribosomal protein S18  0.66 1.44 
SLC25A6 P12236 32.866 ADP/ATP translocase 3 0.61 0.00 
RUVBL1 Q9Y265 50.22 RuvB-like 1 0.55 0.24 
CCT2 P78371 57.488 T-complex protein 1 subunit beta  0.50 0.10 
ARF3 P61204 20.601 ADP-ribosylation factor 3  0.47 0.00 
PKM  P14618 57.937 Pyruvate kinase PKM 0.47 0.21 
TUFM P49411 49.542 Elongation factor Tu, mitochondrial 0.47 0.24 
PPIA P62937 18.012 Peptidyl-prolyl cis-trans isomerase A  0.46 0.33 
CCT6A P40227 58.024 T-complex protein 1 subunit zeta 0.37 0.00 
PRDX1 Q06830 22.11 Peroxiredoxin-1  0.37 1.10 
RPS16 P62249 16.445 40S ribosomal protein S16  0.37 0.38 
UQCRC2 P22695 48.443 Cytochrome b-c1 complex subunit 2, mitochondrial 0.36 0.00 
RPS14 P62263 16.273 40S ribosomal protein S14  0.35 0.36 
RPS4X P62701 29.598 40S ribosomal protein S4, X isoform 0.31 0.21 
ATAD3A Q9NVI7 71.369 ATPase family AAA domain-containing protein 3A 0.29 0.17 
CCT5 P48643 59.671 T-complex protein 1 subunit epsilon  0.29 0.20 
DDX39A  O00148 49.13 ATP-dependent RNA helicase DDX39A 0.28 0.00 
ALDH1B1 P30837 57.206 Aldehyde dehydrogenase X, mitochondrial  0.27 0.00 
DARS P14868 57.136 Aspartate--tRNA ligase, cytoplasmic 0.26 0.00 
HSP90AB1 P08238 83.264 Heat shock protein HSP 90-beta 0.26 0.53 
CCT7 Q99832 59.367 T-complex protein 1 subunit eta 0.26 0.10 
DHX9 Q08211 140.95 ATP-dependent RNA helicase A 0.26 0.09 
ILF2 Q12905 43.06 Interleukin enhancer-binding factor 2 0.24 0.00 
RPS20 P60866 13.373 40S ribosomal protein S20  0.24 0.00 
Supplementary Table 1. Specific primers for ANKRD55 expression vector cloning 
Vector name Primer Sequence 5'-3' 
pCMV6 005        
FLAG/myc tag 
005 SgfI Fw ATTCGCGATCGCCATGGACAGCAACCTG 
005 MluI Rv ACCACGCGTATTTTCATCACTGGTGGGGTTGGCAGA 
pCMV6 001/005 
FLAG/his tag 
His pCMV6 Fw TCGAGCATCATCACCACCACCATGCAGCAAATGAT 




RPS11 P62280 18.431 40S ribosomal protein S11 0.22 0.00 
EEF2  P13639 95.338 Elongation factor 2 0.22 0.06 
RPN2 P04844 69.284 Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit 2  
0.21 0.00 
DDX17 Q92841 80.272 Probable ATP-dependent RNA helicase DDX17  0.21 0.00 
CCT3 P49368 60.534 T-complex protein 1 subunit gamma  0.20 0.00 
NDUFA13 Q9P0J0 16.698 NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 13  
0.19 0.00 
PRPS1 P60891 34.834 Ribose-phosphate pyrophosphokinase 1  0.19 0.00 
SLC25A10 Q9UBX3 31.282 Mitochondrial dicarboxylate carrier  0.18 0.00 
MTHFD1 P11586 101.559 C-1-tetrahydrofolate synthase, cytoplasmic 0.18 0.23 
DDOST P39656 50.801 Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase 48 kDa subunit 
0.17 0.00 
RPL11 P62913 20.12 60S ribosomal protein L11 0.17 0.00 
HNRNPH1 P31943 49.229 Heterogeneous nuclear ribonucleoprotein H  0.16 0.00 
CDIPT  O14735 23.539 CDP-diacylglycerol--inositol 3-
phosphatidyltransferase  
0.15 0.00 
PABPC1 P11940 70.67 Polyadenylate-binding protein 1 0.15 0.00 
OTUB1 Q96FW1 31.284 Ubiquitin thioesterase OTUB1  0.14 0.00 
MCM5 P33992 82.286 DNA replication licensing factor MCM5 0.14 0.00 
SRSF3 P84103 19.33 Serine/arginine-rich splicing factor 3  0.13 0.00 
EPRS P07814 170.591 Bifunctional glutamate/proline--tRNA ligase  0.13 0.14 
TARDBP Q13148 44.74 TAR DNA-binding protein 43  0.13 0.00 
ANXA2P2 A6NMY6 38.659 Putative annexin A2-like protein  0.13 0.00 
TIMM23 O14925 21.943 Mitochondrial import inner membrane translocase 
subunit Tim23  
0.13 0.00 
FAF2 Q96CS3 52.623 FAS-associated factor 2  0.13 0.00 
PSMD2 Q13200   26S proteasome non-ATPase regulatory subunit 2  0.12 0.06 
DIMT1 Q9UNQ2 35.236 Probable dimethyladenosine transferase  0.12 0.00 
PCMT1 P22061 24.636 Protein-L-isoaspartate(D-aspartate) O-
methyltransferase  
0.12 0.00 
RQCD1 Q92600 33.631 Cell differentiation protein RCD1 homolog  0.12 0.00 
KPNB1 Q14974 97.17 Importin subunit beta-1 0.12 0.06 
YBX1 P67809 35.924 Nuclease-sensitive element-binding protein 1  0.12 0.00 
SURF4 O15260 30.394 Surfeit locus protein 4  0.12 0.00 
PSMC4  P43686 47.366 26S protease regulatory subunit 6B  0.12 0.13 
TUBG1 P23258 51.17 Tubulin gamma-1 chain  0.12 0.00 
SRM P19623 102.335 Spermidine synthase  0.11 0.00 
STUB1 Q9UNE7 34.856 E3 ubiquitin-protein ligase CHIP  0.11 0.00 
ACOT8 O14734 35.914 Acyl-coenzyme A thioesterase 8 0.11 0.00 
PSMC6 P62333 44.173 26S protease regulatory subunit 10B  0.10 0.00 
HNRNPU Q00839 90.584 Heterogeneous nuclear ribonucleoprotein U  0.10 0.00 
PSMD3 O43242 60.978 26S proteasome non-ATPase regulatory subunit 3  0.10 0.00 
HAX1 O00165 31.621 HCLS1-associated protein X-1  0.09 0.00 
PSMD12 O00232 52.904 26S proteasome non-ATPase regulatory subunit 12  0.09 0.00 
SEC61A1 P61619 52.265 Protein transport protein Sec61 subunit alpha 
isoform 1  
0.09 0.00 






MSH2 P43246 104.743 DNA mismatch repair protein Msh2  0.09 0.00 
SLC25A18 Q9H1K4 33.849 Mitochondrial glutamate carrier 2  0.09 0.00 
HNRNPA0 Q13151 30.841 Heterogeneous nuclear ribonucleoprotein A0  0.09 0.00 
SMC3 Q9UQE7 141.54 Structural maintenance of chromosomes protein 3 0.09 0.00 
COPB1 P53618 107.142 Coatomer subunit beta  0.09 0.00 
DHRS7B Q6IAN0 35.119 Dehydrogenase/reductase SDR family member 7B  0.09 0.00 
RPL8 P62917 28.025 60S ribosomal protein L8 0.08 0.00 
AASDHPPT Q9NRN7 35.776 L-aminoadipate-semialdehyde dehydrogenase-
phosphopantetheinyl transferase  
0.08 0.00 
SCO2 O43819 29.81 Protein SCO2 homolog, mitochondrial  0.08 0.00 
TRIM28 Q13263 88.55 Transcription intermediary factor 1-beta  0.08 0.07 
GALK1 P51570 42.272 Galactokinase 0.08 0.00 
MATR3 P43243 94.623 Matrin-3  0.08 0.00 
IFT52 Q9Y366 49.706 Intraflagellar transport protein 52 homolog  0.08 0.00 
TIMMDC1  Q9NPL8 32.178 Complex I assembly factor TIMMDC1, mitochondrial  0.08 0.00 
RFC3 P40938 40.556 Replication factor C subunit 3  0.07 0.00 
EIF3L Q9Y262 66.727 Eukaryotic translation initiation factor 3 subunit L  0.07 0.00 
CDC45 O75419 65.569 Cell division control protein 45 homolog  0.07 0.00 
WDR36 Q8NI36 105.322 WD repeat-containing protein 36  0.07 0.00 
LBR Q14739 70.703 Lamin-B receptor  0.07 0.00 
COPA P53621 138.346 Coatomer subunit alpha  0.07 0.00 
STT3A P46977 80.53 Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit STT3A  
0.07 0.00 
AGK Q53H12 47.137 Acylglycerol kinase, mitochondrial  0.07 0.00 
DHX15 O43143 90.933 Pre-mRNA-splicing factor ATP-dependent RNA 
helicase DHX15  
0.07 0.00 
KHSRP Q92945 73.115 Far upstream element-binding protein 2  0.06 0.00 
EI24  O14681 38.965 Etoposide-induced protein 2.4 homolog  0.06 0.00 
UMPS P11172 52.222 Uridine 5'-monophosphate synthase  0.06 0.00 
GARS  P41250 83.166 Glycine--tRNA ligase  0.06 0.00 
POLD1 P28340 123.631 DNA polymerase delta catalytic subunit  0.06 0.00 
FAR1 Q8WVX9 59.357 Fatty acyl-CoA reductase 1  0.06 0.00 
MCM4 P33991 96.558 DNA replication licensing factor MCM4 0.06 0.00 
DDX1 Q92499 82.432 ATP-dependent RNA helicase DDX1  0.06 0.00 
UNC45A  Q9H3U1 103.077 Protein unc-45 homolog A  0.06 0.00 
COPB2 P35606 102.487 Coatomer subunit beta'  0.06 0.00 
HSPH1 Q92598 96.865 Heat shock protein 105 kDa  0.05 0.00 
SARS P49591 58.777 Serine--tRNA ligase, cytoplasmic  0.05 0.00 
TELO2 Q9Y4R8 91.747 Telomere length regulation protein TEL2 homolog  0.05 0.00 
TRAP1 Q12931 80.11 Heat shock protein 75 kDa, mitochondrial  0.05 0.00 
NSUN2 Q08J23 86.471 tRNA (cytosine(34)-C(5))-methyltransferase  0.05 0.00 
PTPN1 P18031 49.967 Tyrosine-protein phosphatase non-receptor type 1  0.05 0.00 
NCLN Q969V3 62.974 Nicalin  0.05 0.00 
ASNS P08243 64.37 Asparagine synthetase [glutamine-hydrolyzing]  0.05 0.00 
MSH6 P52701 152.786 DNA mismatch repair protein Msh6  0.04 0.00 




CCDC8 Q9H0W5 59.374 Coiled-coil domain-containing protein 8  0.04 0.00 
TNPO1 Q92973 102.355 Transportin-1  0.04 0.00 
POLR2B P30876 133.897 DNA-directed RNA polymerase II subunit RPB2  0.04 0.00 
IQGAP1 P46940 189.252 Ras GTPase-activating-like protein IQGAP1  0.04 0.00 
DIS3 Q9Y2L1 109.003 Exosome complex exonuclease RRP44  0.04 0.00 
AARS2 Q5JTZ9 107.34 Alanine--tRNA ligase, mitochondrial  0.04 0.00 
IPO9 Q96P70 115.963 Importin-9  0.03 0.00 
TFRC P02786 84.871 Transferrin receptor protein 1 0.03 0.00 
IARS2 Q9NSE4 113.792 Isoleucine--tRNA ligase, mitochondrial  0.03 0.00 
DHX37 Q8IY37 129.545 Probable ATP-dependent RNA helicase DHX37  0.03 0.00 
RPTOR Q8N122 149.038 Regulatory-associated protein of mTOR  0.03 0.00 
ESYT2 A0FGR8 102.357 Extended synaptotagmin-2  0.03 0.00 
SMC4 Q9NTJ3 147.182 Structural maintenance of chromosomes protein 4  0.03 0.00 
IPO7 O95373 119.517 Importin-7  0.03 0.00 
PPP6R3 Q5H9R7 97.669 Serine/threonine-protein phosphatase 6 regulatory 
subunit 3  
0.02 0.00 
WDR11 Q9BZH6 136.685 WD repeat-containing protein 11  0.02 0.00 
USO1 O60763 107.895 General vesicular transport factor p115  0.02 0.00 
MYO1B O43795 131.985 Unconventional myosin-Ib  0.02 0.00 
RFC1 P35251 128.255 Replication factor C subunit 1  0.02 0.00 
DHX30 Q7L2E3 133.938 Putative ATP-dependent RNA helicase DHX30  0.02 0.00 
TARBP1 Q13395 181.675 Probable methyltransferase TARBP1  0.02 0.00 
HEATR1 Q9H583 242.37 HEAT repeat-containing protein 1  0.02 0.00 
TBC1D4  O60343 146.563 TBC1 domain family member 4  0.02 0.00 
BTAF1 O14981 206.887 TATA-binding protein-associated factor 172  0.02 0.00 
HUWE1 Q7Z6Z7 481.891 E3 ubiquitin-protein ligase HUWE1  0.01 0.00 
ANAPC1 Q9H1A4 216.5 Anaphase-promoting complex subunit 1  0.01 0.00 
NUP188 Q5SRE5 196.043 Nucleoporin NUP188 homolog  0.01 0.00  
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   














HSPA1A P0DMV8 63.89 Isoform 2 of Heat shock 70 kDa protein 1A/1B 1.59 0.29 
EIF4A1 P60842 46.15 Eukaryotic initiation factor 4A-I 0.89 0.16 
DHX9 Q08211 140.95 ATP-dependent RNA helicase A 0.82 0.24 
NONO Q15233 54.232 Non-POU domain-containing octamer-binding 
protein 
0.73 0.26 
HSPA8  P11142 70.89 Heat shock cognate 71 kDa protein 0.70 0.14 
TUBB  P07437 49.60 Tubulin beta chain 0.62 0.00 
RPL22 P35268 14.787 60S ribosomal protein L22  0.60 0.40 
RUVBL2 Q9Y230 51.157 RuvB-like 2 0.59 0.05 
DDX47 Q9H0S4 50.647 Probable ATP-dependent RNA helicase DDX47 0.36 0.00 
MATR3 P43243 94.623 Matrin-3  0.36 0.17 
HNRNPH3 P31942 36.926 Heterogeneous nuclear ribonucleoprotein H3  0.33 0.15 
EIF4A3 P38919 46.871 Eukaryotic initiation factor 4A-III 0.32 0.00 
C1QBP Q07021 31.362 Complement component 1 Q subcomponent-
binding protein, mitochondrial  
0.32 0.00 
MIB1 Q86YT6 110.136 E3 ubiquitin-protein ligase MIB1  0.30 0.00 
ATAD3B Q5T9A4 72.573 ATPase family AAA domain-containing protein 3B 0.27 0.00 
LBR Q14739 70.703 Lamin-B receptor  0.21 0.00 
SF3B3 Q15393 135.577 Splicing factor 3B subunit 3  0.19 0.02 






RPL3  P39023 46.109 60S ribosomal protein L3 0.18 0.00 
TCP1 P17987 60.344 T-complex protein 1 subunit alpha 0.17 0.00 
RCC1 P18754 44.969 Regulator of chromosome condensation  0.14 0.00 
PRPF31 Q8WWY3 55.456 U4/U6 small nuclear ribonucleoprotein Prp31 0.14 0.00 
LAS1L Q9Y4W2 83.065 Ribosomal biogenesis protein LAS1L  0.12 0.00 
SNRNP200 O75643 244.508 U5 small nuclear ribonucleoprotein 200 kDa 
helicase 
0.12 0.00 
NAT10 Q9H0A0 115.73 RNA cytidine acetyltransferase  0.10 0.00 
AMOT Q4VCS5 118.09 Angiomotin  0.09 0.00 
MYO1C O00159 121.682 Unconventional myosin-Ic  0.09 0.00 
EFTUD2  Q15029 109.436 116 kDa U5 small nuclear ribonucleoprotein 
component 
0.08 0.00 
DSG2 Q14126 122.294 Desmoglein-2 0.07 0.00 
SMARCA5 O60264 121.905 SWI/SNF-related matrix-associated actin-dependent 
regulator of chromatin subfamily A member 5  
0.06 0.00 
PRPF8 Q6P2Q9 273.6 Pre-mRNA-processing-splicing factor 8 0.05 0.00 
DHX30 Q7L2E3 133.938 Putative ATP-dependent RNA helicase DHX30  0.05 0.00 
NUMA1 Q14980 238.26 Nuclear mitotic apparatus protein 1 0.05 0.00 







Supplementary Table 3.  Functional enrichment analysis of ANKRD55 interactome from nuclear and total protein extracts. The algorithm DAVID was used to analyze the ANKRD55 interactome. The 
GO and other terms with p value<0.05 are shown and grouped by enrichment score.  
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   















 Annotation Cluster 1 - Enrichment Score: 12.73 
        
Category Term Count % PValue Genes Fold 
Enrichment 
Bonferroni Benjamini FDR 
UP_KEYWORDS Nucleotide-binding 52 34,90 1,26E-18 P17812, Q9Y5M8, O43615, O00571, 
Q5T9A4, Q15029, P10398, P18085, 
Q9Y3I0, P53396, Q00535, P05023, 
Q9BUF5, Q14566, Q9Y285, Q6P1M0, 
Q5T160, P49588, P41252, P50570, 
P28288, P38646, Q8NI60, P42356, 
Q9NU22, Q9P2J5, Q9NSD9, Q14683, 
P56192, Q9BSD7, P45880, Q6UB35, 
P54136, P16615, P78527, P27708, 
P40616, P17980, P50990, P50991, 
P38919, Q92900, Q9NR30, O75643, 
P54886, P51148, P25205, P33993, 
P26640, Q13085, Q14204, Q15645 
4,02 2,93E-16 9,75E-17 1,61E-15 
UP_KEYWORDS ATP-binding 43 28,86 5,74E-16 P17812, P56192, O43615, Q9BSD7, 
Q5T9A4, O00571, P10398, Q6UB35, 
P54136, P16615, P78527, P27708, 
Q9Y3I0, P17980, P53396, Q00535, 
P50990, P50991, P38919, P05023, 
Q92900, Q14566, Q9Y285, Q9NR30, 
Q5T160, P49588, O75643, P41252, 
P54886, P28288, P38646, P25205, 
P33993, P26640, Q13085, Q8NI60, 
P42356, Q14204, Q14683, Q9NSD9, 
9P2J5, Q9NU22, Q15645 
















GOTERM_MF_DIRECT GO:0005524~ATP binding 45 30,20 1,18E-13 P17812, P31689, P56192, O43615, 
Q9BSD7, Q5T9A4, O00571, P10398, 
Q6UB35, P54136, P16615, P78527, 
P27708, Q9Y3I0, P17980, P53396, 
Q00535, P50990, P50991, P38919, 
P05023, Q92900, Q14566, Q9Y285, 
Q9NR30, Q5T160, P49588, O75643, 
P41252, O60884, P54886, P28288, 
P38646, P25205, P33993, P26640, 
Q13085, Q8NI60, P42356, Q14204, 
Q14683, Q9NSD9, Q9P2J5, Q9NU22, 
Q15645 
3,48 4,39E-11 2,19E-11 1,62E-10 
UP_SEQ_FEATURE nucleotide phosphate-binding 
region:ATP 
22 14,77 1,33E-05 Q9NR30, O43615, O75643, Q9BSD7, 
O00571, Q5T9A4, P28288, P10398, 
Q6UB35, P25205, P33993, Q13085, 
Q14204, Q14683, Q9NU22, P17980, 
Q00535, Q15645, P53396, P38919, 
Q92900, Q14566 
2,98 7,91E-03 1,13E-03 1,96E-02 
Annotation Cluster 2 - Enrichment Score: 8.13 
        
Category Term Count % PValue Genes Fold 
Enrichment 
Bonferroni Benjamini FDR 
GOTERM_BP_DIRECT GO:0006412~translation 20 13,42 6,31E-13 P15880, P36578, P53007, P05388, 
Q92616, P27635, Q15029, P32969, 
P05141, Q00325, P62424, O75746, 
Q9NSD9, P61247, P62829, Q02978, 
P62244, P23396, Q9UJS0, P46781 
9,09 6,09E-10 6,09E-10 9,93E-10 
GOTERM_BP_DIRECT GO:0000184~nuclear-transcribed 
mRNA catabolic process, 
nonsense-mediated decay 
15 10,07 1,85E-12 P15880, P36578, P63151, P05388, 
P30153, P27635, P32969, P62424, 
P61247, P62829, P38919, P62244, 
P23396, Q92900, P46781 




GOTERM_CC_DIRECT GO:0005925~focal adhesion 21 14,09 5,15E-11 P15880, P36578, Q9Y490, P35613, 
P05388, P50570, P21333, P31946, 
P23528, P61981, P38646, P32969, 
P42356, P62258, P62424, P61247, 
P62829, Q00610, P23396, Q15366, 
P46781 
6,61 1,31E-08 2,61E-09 6,70E-08 
GOTERM_MF_DIRECT GO:0003735~structural 
constituent of ribosome 
17 11,41 8,05E-11 P15880, P36578, P53007, P05388, 
P27635, P32969, P05141, Q00325, 
P62424, O75746, P61247, P62829, 
Q02978, P62244, P23396, Q9UJS0, 
P46781 
8,85 3,00E-08 7,51E-09 1,11E-07 
GOTERM_BP_DIRECT GO:0019083~viral transcription 13 8,72 2,29E-10 Q12769, P15880, P36578, Q92621, 
P62424, P05388, P61247, P62829, 
P27635, P62244, P23396, P46781, 
P32969 
13,35 2,21E-07 7,36E-08 3,60E-07 
UP_KEYWORDS Ribonucleoprotein 17 11,41 4,44E-10 P15880, P36578, O75643, P05388, 
P27635, Q15029, O00567, P32969, 
P62424, P61247, P62829, Q6P2Q9, 
P62244, P23396, Q15366, Q15365, 
P46781 
7,93 1,04E-07 1,73E-08 5,71E-07 
GOTERM_BP_DIRECT GO:0006614~SRP-dependent 
cotranslational protein targeting 
to membrane 
12 8,05 5,08E-10 Q9Y5M8, P15880, P36578, P62424, 
P05388, P61247, P62829, P27635, 
P62244, P23396, P46781, P32969 
14,68 4,90E-07 1,22E-07 7,99E-07 
GOTERM_BP_DIRECT GO:0006364~rRNA processing 15 10,07 4,88E-09 P15880, Q9NR30, P36578, P05388, 
P27635, O00567, P32969, P62424, 
Q9NU22, P61247, P62829, P38919, 
P62244, P23396, P46781 
8,06 4,71E-06 7,85E-07 7,68E-06 
GOTERM_BP_DIRECT GO:0006413~translational 
initiation 
12 8,05 2,84E-08 P15880, P36578, P62424, P05388, 
P61247, Q14152, P62829, P27635, 
P62244, P23396, P46781, P32969 




GOTERM_CC_DIRECT GO:0005840~ribosome 12 8,05 1,05E-07 P15880, P36578, P62424, P05388, 
Q92616, P61247, P62829, P27635, 
P62244, P23396, P46781, P32969 
8,90 2,66E-05 2,05E-06 1,36E-04 
UP_KEYWORDS Ribosomal protein 11 7,38 9,41E-07 P15880, P36578, P62424, P05388, 
P61247, P62829, P27635, P62244, 
P23396, P46781, P32969 
8,21 2,19E-04 1,57E-05 1,21E-03 
KEGG_PATHWAY hsa03010:Ribosome 11 7,38 4,00E-05 P15880, P36578, P62424, P05388, 
P61247, P62829, P27635, P62244, 
P23396, P46781, P32969 
5,22 6,06E-03 3,04E-03 4,79E-02 
GOTERM_CC_DIRECT GO:0022627~cytosolic small 
ribosomal subunit 
6 4,03 4,13E-05 P15880, P61247, O00571, P62244, 
P23396, P46781 
15,39 1,04E-02 6,56E-04 5,38E-02 
GOTERM_CC_DIRECT GO:0022625~cytosolic large 
ribosomal subunit 
6 4,03 2,21E-04 P36578, P62424, P05388, P62829, 
P27635, P32969 
10,86 5,46E-02 3,11E-03 2,87E-01 
Annotation Cluster 3 - Enrichment Score: 6.987 
        
Category Term Count % PValue Genes Fold 
Enrichment 
Bonferroni Benjamini FDR 
GOTERM_MF_DIRECT GO:0098641~cadherin binding 
involved in cell-cell adhesion 
16 10,74 3,00E-08 P15880, Q9Y490, P35613, Q92616, 
O00571, P49327, P21333, P31946, 
O00567, P54136, P42356, P62258, 
P62424, P63244, P50990, Q15365 
6,38 1,12E-05 1,87E-06 4,14E-05 
GOTERM_CC_DIRECT GO:0005913~cell-cell adherens 
junction 
16 10,74 5,55E-08 P15880, Q9Y490, P35613, Q92616, 
O00571, P49327, P21333, P31946, 
O00567, P54136, P42356, P62258, 
P62424, P63244, P50990, Q15365 
6,10 1,41E-05 1,28E-06 7,23E-05 
GOTERM_BP_DIRECT GO:0098609~cell-cell adhesion 14 9,40 6,56E-07 P15880, P35613, Q92616, O00571, 
P49327, P31946, O00567, P54136, 








Annotation Cluster 4 - Enrichment Score: 6.97 
        
Category Term Count % PValue Genes Fold 
Enrichment 
Bonferroni Benjamini FDR 
UP_KEYWORDS Mitochondrion 28 18,79 2,69E-08 P31689, P53007, O43615, Q3ZCQ8, 
P45880, Q07021, O00571, Q5T9A4, 
Q6UB35, O95831, P05141, O75746, 
P13804, Q02978, P36542, P23396, 
Q9UJS0, Q96HS1, Q5T160, P54886, 
P04181, P38646, P11177, Q8NI60, 
P42704, Q9H9B4, P48047, Q00325 
3,46 6,26E-06 8,95E-07 3,45E-05 
UP_KEYWORDS Mitochondrion inner membrane 14 9,40 8,07E-08 P53007, O43615, Q3ZCQ8, Q5T9A4, 
P54886, O95831, P05141, P48047, 
Q00325, O75746, Q02978, P36542, 
P23396, Q9UJS0 
7,16 1,88E-05 1,88E-06 1,04E-04 
GOTERM_CC_DIRECT GO:0005743~mitochondrial 
inner membrane 
17 11,41 5,65E-07 P53007, O43615, Q3ZCQ8, P45880, 
Q5T9A4, P28288, P54886, O95831, 
P05141, Q9H9B4, P48047, Q00325, 
O75746, Q02978, P36542, P23396, 
Q9UJS0 
4,75 1,43E-04 1,02E-05 7,36E-04 
Annotation Cluster 5 - Enrichment Score: 5.30 
        
Category Term Count % PValue Genes Fold 
Enrichment 
Bonferroni Benjamini FDR 
INTERPRO IPR016024:Armadillo-type fold 19 12,75 3,28E-10 Q96T76, P55060, Q92616, Q8TEX9, 
P30153, Q9UBB4, Q93008, Q86VP6, 
P78527, P42695, Q9Y678, P42356, 
O14980, P52292, Q9BQG0, P50851, 
Q00610, O43592, O00410 
6,83 1,57E-07 1,57E-07 4,70E-07 
UP_SEQ_FEATURE repeat:HEAT 2 10 6,71 3,96E-10 Q96T76, P42695, Q9Y678, O14980, 
Q92616, Q8TEX9, P30153, Q86VP6, 
P78527, O00410 




UP_SEQ_FEATURE repeat:HEAT 1 10 6,71 3,96E-10 Q96T76, P42695, Q9Y678, O14980, 
Q92616, Q8TEX9, P30153, Q86VP6, 
P78527, O00410 
23,22 2,37E-07 2,37E-07 5,85E-07 
UP_SEQ_FEATURE repeat:HEAT 4 9 6,04 8,45E-10 Q96T76, P42695, Q9Y678, O14980, 
Q92616, Q8TEX9, P30153, Q86VP6, 
O00410 
28,18 5,06E-07 2,53E-07 1,25E-06 
UP_SEQ_FEATURE repeat:HEAT 3 9 6,04 2,99E-09 Q96T76, P42695, Q9Y678, O14980, 
Q92616, Q8TEX9, P30153, Q86VP6, 
O00410 
24,24 1,79E-06 5,98E-07 4,42E-06 
INTERPRO IPR011989:Armadillo-like helical 14 9,40 2,65E-08 Q96T76, P55060, Q92616, Q8TEX9, 
P30153, Q9UBB4, Q86VP6, P78527, 
P42695, Q9Y678, O14980, P52292, 
O43592, O00410 
7,86 1,27E-05 6,33E-06 3,79E-05 
UP_SEQ_FEATURE repeat:HEAT 6 7 4,70 7,47E-08 Q96T76, O14980, Q92616, Q8TEX9, 
P30153, Q86VP6, O00410 
31,42 4,47E-05 1,12E-05 1,10E-04 
UP_SEQ_FEATURE repeat:HEAT 5 7 4,70 1,98E-07 Q96T76, O14980, Q92616, Q8TEX9, 
P30153, Q86VP6, O00410 
26,93 1,19E-04 1,98E-05 2,92E-04 
UP_SEQ_FEATURE repeat:HEAT 7 5 3,36 2,69E-05 Q96T76, O14980, Q92616, P30153, 
Q86VP6 
28,05 1,60E-02 1,61E-03 3,98E-02 
UP_SEQ_FEATURE repeat:HEAT 9 4 2,68 1,68E-04 O14980, Q92616, P30153, Q86VP6 35,91 9,56E-02 7,15E-03 2,47E-01 
UP_SEQ_FEATURE repeat:HEAT 10 4 2,68 1,68E-04 O14980, Q92616, P30153, Q86VP6 35,91 9,56E-02 7,15E-03 2,47E-01 
UP_SEQ_FEATURE repeat:HEAT 8 4 2,68 3,50E-04 O14980, Q92616, P30153, Q86VP6 28,35 1,89E-01 1,30E-02 5,15E-01 
UP_SEQ_FEATURE repeat:HEAT 15 3 2,01 1,11E-03 Q92616, P30153, Q86VP6 57,71 4,85E-01 3,83E-02 1,62E+00 
UP_SEQ_FEATURE repeat:HEAT 14 3 2,01 1,88E-03 Q92616, P30153, Q86VP6 44,88 6,76E-01 5,76E-02 2,74E+00 
UP_SEQ_FEATURE repeat:HEAT 12 3 2,01 2,34E-03 Q92616, P30153, Q86VP6 40,40 7,54E-01 6,78E-02 3,40E+00 
UP_SEQ_FEATURE repeat:HEAT 13 3 2,01 2,34E-03 Q92616, P30153, Q86VP6 40,40 7,54E-01 6,78E-02 3,40E+00 
UP_SEQ_FEATURE repeat:HEAT 11 3 2,01 2,85E-03 Q92616, P30153, Q86VP6 36,72 8,19E-01 7,81E-02 4,12E+00 
INTERPRO IPR000357:HEAT 3 2,01 4,53E-03 Q8TEX9, P30153, O00410 29,14 8,86E-01 1,44E-01 6,29E+00 




Annotation Cluster 6 - Enrichment Score: 5.25 
        
Category Term Count % PValue Genes Fold 
Enrichment 
Bonferroni Benjamini FDR 
INTERPRO IPR027417:P-loop containing 
nucleoside triphosphate 
hydrolase 
24 16,11 3,77E-07 P17812, Q9Y5M8, Q9NR30, O75643, 
Q9BSD7, P50570, O00571, Q5T9A4, 
Q15029, P28288, Q6UB35, P51148, 
P25205, P33993, P18085, Q14204, 
Q14683, Q9NU22, P40616, P17980, 
Q15645, P38919, Q92900, Q14566 
3,45 1,80E-04 3,60E-05 5,39E-04 
INTERPRO IPR003593:AAA+ ATPase domain 9 6,04 1,22E-05 P33993, Q14204, Q9BSD7, Q9NU22, 
P17980, Q15645, Q5T9A4, P28288, 
P25205 
8,35 5,81E-03 7,28E-04 1,74E-02 
UP_SEQ_FEATURE nucleotide phosphate-binding 
region:ATP 
22 14,77 1,33E-05 Q9NR30, O43615, O75643, Q9BSD7, 
O00571, Q5T9A4, P28288, P10398, 
Q6UB35, P25205, P33993, Q13085, 
Q14204, Q14683, Q9NU22, P17980, 
Q00535, Q15645, P53396, P38919, 
Q92900, Q14566 
2,98 7,91E-03 1,13E-03 1,96E-02 
SMART SM00382:AAA 9 6,04 1,53E-05 P33993, Q14204, Q9BSD7, Q9NU22, 
P17980, Q15645, Q5T9A4, P28288, 
P25205 
7,92 1,28E-03 1,28E-03 1,64E-02 
Annotation Cluster 7 - Enrichment Score: 5.25 
        
Category Term Count % PValue Genes Fold 
Enrichment 
Bonferroni Benjamini FDR 
UP_KEYWORDS Aminoacyl-tRNA synthetase 9 6,04 2,41E-10 P26640, Q9Y285, P56192, Q5T160, 
P49588, Q9P2J5, Q9NSD9, P41252, 
P54136 
32,71 5,61E-08 1,12E-08 3,09E-07 
GOTERM_BP_DIRECT GO:0006418~tRNA 
aminoacylation for protein 
translation 
9 6,04 1,55E-09 P26640, Q9Y285, P56192, Q5T160, 
P49588, Q9P2J5, Q9NSD9, P41252, 
P54136 




UP_KEYWORDS Ligase 16 10,74 3,24E-08 P17812, Q9Y285, Q86YT6, P56192, 
Q6P1M0, Q5T160, P49588, P41252, 
P54136, Q6UB35, P26640, Q13085, 
P27708, Q9Y3I0, Q9P2J5, Q9NSD9 
6,37 7,56E-06 8,39E-07 4,17E-05 
INTERPRO IPR009080:Aminoacyl-tRNA 
synthetase, class 1a, anticodon-
binding 
6 4,03 3,44E-08 P26640, P56192, Q5T160, Q9P2J5, 
P41252, P54136 
58,27 1,64E-05 5,48E-06 4,92E-05 
INTERPRO IPR001412:Aminoacyl-tRNA 
synthetase, class I, conserved site 
6 4,03 7,93E-08 P26640, P56192, Q5T160, Q9P2J5, 
P41252, P54136 
50,50 3,79E-05 9,47E-06 1,13E-04 
UP_SEQ_FEATURE short sequence motif:"HIGH" 
region 
6 4,03 1,62E-07 P26640, P56192, Q5T160, Q9P2J5, 
P41252, P54136 
44,88 9,70E-05 1,94E-05 2,39E-04 
INTERPRO IPR014729:Rossmann-like 
alpha/beta/alpha sandwich fold 
7 4,70 8,88E-07 P26640, P56192, Q5T160, Q9P2J5, 
P41252, P13804, P54136 
21,04 4,24E-04 7,08E-05 1,27E-03 
UP_KEYWORDS Protein biosynthesis 10 6,71 1,58E-06 P26640, Q9Y285, P56192, Q5T160, 
P49588, Q9P2J5, Q9NSD9, P41252, 
Q14152, P54136 
9,09 3,67E-04 2,30E-05 2,03E-03 
KEGG_PATHWAY hsa00970:Aminoacyl-tRNA 
biosynthesis 
9 6,04 6,46E-06 P26640, Q9Y285, P56192, Q5T160, 
P49588, Q9P2J5, Q9NSD9, P41252, 
P54136 
8,81 9,82E-04 9,82E-04 7,74E-03 
GOTERM_MF_DIRECT GO:0004812~aminoacyl-tRNA 
ligase activity 
5 3,36 1,14E-05 P26640, Q9Y285, P56192, Q9P2J5, 
P41252 
34,01 4,24E-03 5,31E-04 1,57E-02 
GOTERM_MF_DIRECT GO:0002161~aminoacyl-tRNA 
editing activity 
4 2,68 7,13E-05 P26640, P49588, Q9P2J5, P41252 46,25 2,62E-02 2,95E-03 9,84E-02 
GOTERM_MF_DIRECT GO:0000049~tRNA binding 6 4,03 7,46E-05 Q9Y285, P56192, P49588, P41252, 
O43592, P54136 
13,60 2,74E-02 2,78E-03 1,03E-01 
UP_SEQ_FEATURE short sequence motif:"KMSKS" 
region 
4 2,68 2,05E-04 P26640, P56192, Q9P2J5, P41252 33,66 1,16E-01 8,17E-03 3,03E-01 
GOTERM_BP_DIRECT GO:0006450~regulation of 
translational fidelity 





tRNA synthetase, class I, 
anticodon-binding 
3 2,01 9,03E-04 P26640, Q9P2J5, P41252 63,13 3,51E-01 3,85E-02 1,28E+00 
INTERPRO IPR009008:Valyl/Leucyl/Isoleucyl-
tRNA synthetase, class Ia, editing 
domain 
3 2,01 9,03E-04 P26640, Q9P2J5, P41252 63,13 3,51E-01 3,85E-02 1,28E+00 
INTERPRO IPR002300:Aminoacyl-tRNA 
synthetase, class Ia 
3 2,01 9,03E-04 P26640, Q9P2J5, P41252 63,13 3,51E-01 3,85E-02 1,28E+00 
Annotation Cluster 8 - Enrichment Score: 4.95 
        
Category Term Count % PValue Genes Fold 
Enrichment 
Bonferroni Benjamini FDR 
UP_KEYWORDS Mitochondrion 28 18,79 2,69E-08 P31689, P53007, O43615, Q3ZCQ8, 
P45880, Q07021, O00571, Q5T9A4, 
Q6UB35, O95831, P05141, O75746, 
P13804, Q02978, P36542, P23396, 
Q9UJS0, Q96HS1, Q5T160, P54886, 
P04181, P38646, P11177, Q8NI60, 
P42704, Q9H9B4, P48047, Q00325 
3,46 6,26E-06 8,95E-07 3,45E-05 
UP_KEYWORDS Transit peptide 16 10,74 7,73E-06 Q5T160, P53007, O43615, Q3ZCQ8, 
Q07021, Q6UB35, P04181, P38646, 
O95831, P11177, Q8NI60, P42704, 
P48047, Q00325, P13804, P36542 
4,12 1,80E-03 1,00E-04 9,93E-03 
UP_SEQ_FEATURE transit peptide:Mitochondrion 15 10,07 1,38E-05 Q5T160, P53007, O43615, Q3ZCQ8, 
Q07021, Q6UB35, P38646, O95831, 
P11177, Q8NI60, P42704, P48047, 
Q00325, P13804, P36542 
4,19 8,23E-03 1,03E-03 2,04E-02 
GOTERM_CC_DIRECT GO:0005759~mitochondrial 
matrix 
9 6,04 5,10E-03 P11177, Q5T160, O43615, Q07021, 
P13804, P36542, Q6UB35, P23396, 
P04181 
 




Annotation Cluster 9 - Enrichment Score: 3.84 
        
Category Term Count % PValue Genes Fold 
Enrichment 
Bonferroni Benjamini FDR 
UP_KEYWORDS Neurodegeneration 13 8,72 1,44E-06 P56192, Q5T160, P49588, P50570, 
P54886, O00567, Q9UBB4, O95831, 
Q8NI60, Q14204, Q8IY17, Q00535, 
P12004 
6,13 3,36E-04 2,24E-05 1,85E-03 
UP_KEYWORDS Charcot-Marie-Tooth disease 5 3,36 4,93E-04 O95831, P56192, P49588, Q14204, 
P50570 
13,54 1,09E-01 4,78E-03 6,32E-01 
UP_KEYWORDS Neuropathy 5 3,36 4,07E-03 O95831, P56192, P49588, Q14204, 
P50570 
7,67 6,13E-01 2,75E-02 5,10E+00 
Annotation Cluster 10 - Enrichment Score: 3.44 
        
Category Term Count % PValue Genes Fold 
Enrichment 
Bonferroni Benjamini FDR 
UP_KEYWORDS Mitochondrion inner membrane 14 9,40 8,07E-08 P53007, O43615, Q3ZCQ8, Q5T9A4, 
P54886, O95831, P05141, P48047, 
Q00325, O75746, Q02978, P36542, 
P23396, Q9UJS0 
7,16 1,88E-05 1,88E-06 1,04E-04 
UP_SEQ_FEATURE repeat:Solcar 3 6 4,03 3,65E-05 P05141, P53007, O75746, Q00325, 
Q02978, Q9UJS0 
15,84 2,16E-02 1,98E-03 5,39E-02 
UP_SEQ_FEATURE repeat:Solcar 1 6 4,03 4,83E-05 P05141, P53007, O75746, Q00325, 
Q02978, Q9UJS0 
14,96 2,85E-02 2,41E-03 7,12E-02 
UP_SEQ_FEATURE repeat:Solcar 2 6 4,03 4,83E-05 P05141, P53007, O75746, Q00325, 
Q02978, Q9UJS0 
14,96 2,85E-02 2,41E-03 7,12E-02 
INTERPRO IPR018108:Mitochondrial 
substrate/solute carrier 
6 4,03 5,96E-05 P05141, P53007, O75746, Q00325, 
Q02978, Q9UJS0 
14,29 2,81E-02 2,84E-03 8,52E-02 
INTERPRO IPR023395:Mitochondrial carrier 
domain 
6 4,03 5,96E-05 P05141, P53007, O75746, Q00325, 
Q02978, Q9UJS0 
14,29 2,81E-02 2,84E-03 8,52E-02 
INTERPRO IPR002067:Mitochondrial carrier 
protein 




GOTERM_BP_DIRECT GO:0006094~gluconeogenesis 4 2,68 6,45E-03 P53007, O75746, Q02978, Q9UJS0 10,46 9,98E-01 2,00E-01 9,67E+00 
Annotation Cluster 11 - Enrichment Score: 3.05 
        
Category Term Count % PValue Genes Fold 
Enrichment 
Bonferroni Benjamini FDR 
INTERPRO IPR001494:Importin-beta, N-
terminal 
5 3,36 8,08E-06 P55060, O14980, Q8TEX9, O43592, 
O00410 
37,13 3,85E-03 5,51E-04 1,16E-02 
GOTERM_MF_DIRECT GO:0008536~Ran GTPase 
binding 
5 3,36 1,20E-04 P55060, O14980, Q8TEX9, O43592, 
O00410 
19,27 4,39E-02 4,07E-03 1,66E-01 
UP_SEQ_FEATURE domain:Importin N-terminal 4 2,68 1,35E-04 P55060, O14980, Q8TEX9, O00410 38,47 7,76E-02 6,20E-03 1,99E-01 
SMART SM00913:SM00913 4 2,68 2,81E-04 P55060, O14980, Q8TEX9, O43592 29,93 2,33E-02 7,84E-03 3,01E-01 
GOTERM_CC_DIRECT GO:0005643~nuclear pore 6 4,03 2,89E-04 Q12769, Q92621, P52292, Q8TEX9, 
O43592, O00410 
10,26 7,08E-02 3,86E-03 3,76E-01 
GOTERM_BP_DIRECT GO:0000059~protein import into 
nucleus, docking 
3 2,01 2,00E-03 Q92621, Q8TEX9, O00410 43,13 8,55E-01 9,68E-02 3,11E+00 
GOTERM_BP_DIRECT GO:0006886~intracellular 
protein transport 
8 5,37 4,44E-03 Q9Y678, O14980, Q8TEX9, Q00535, 
Q04917, Q00610, O43592, O00410 
3,90 9,86E-01 1,52E-01 6,76E+00 
GOTERM_CC_DIRECT GO:0034399~nuclear periphery 3 2,01 1,23E-02 Q92621, Q8TEX9, O00410 17,59 9,57E-01 1,10E-01 1,49E+01 
Annotation Cluster 12 - Enrichment Score: 2.79 
        
Category Term Count % PValue Genes Fold 
Enrichment 
Bonferroni Benjamini FDR 
INTERPRO IPR023410:14-3-3 domain 4 2,68 1,63E-05 P62258, Q04917, P31946, P61981 72,14 7,77E-03 8,66E-04 2,33E-02 
INTERPRO IPR023409:14-3-3 protein, 
conserved site 
4 2,68 1,63E-05 P62258, Q04917, P31946, P61981 72,14 7,77E-03 8,66E-04 2,33E-02 
INTERPRO IPR000308:14-3-3 protein 4 2,68 1,63E-05 P62258, Q04917, P31946, P61981 72,14 7,77E-03 8,66E-04 2,33E-02 
SMART SM00101:14_3_3 4 2,68 1,85E-05 P62258, Q04917, P31946, P61981 68,41 1,55E-03 7,78E-04 1,99E-02 
UP_SEQ_FEATURE site:Interaction with 
phosphoserine on interacting 
protein 
4 2,68 2,14E-05 P62258, Q04917, P31946, P61981 67,33 1,28E-02 1,43E-03 3,17E-02 




KEGG_PATHWAY hsa04110:Cell cycle 10 6,71 1,10E-04 P33993, P62258, Q14683, Q04917, 
P31946, P12004, P61981, P78527, 
Q14566, P25205 
5,21 1,65E-02 5,54E-03 1,31E-01 
GOTERM_MF_DIRECT GO:0019904~protein domain 
specific binding 
8 5,37 2,15E-03 A5YKK6, P62258, P40616, O14980, 
Q04917, P31946, P05023, P61981 
4,45 5,51E-01 5,98E-02 2,92E+00 
GOTERM_BP_DIRECT GO:1900740~positive regulation 
of protein insertion into 
mitochondrial membrane 
involved in apoptotic signaling 
pathway 
4 2,68 2,16E-03 P62258, Q04917, P31946, P61981 15,34 8,75E-01 9,44E-02 3,34E+00 
GOTERM_BP_DIRECT GO:0061024~membrane 
organization 
4 2,68 2,60E-03 P62258, Q04917, P31946, P61981 14,38 9,19E-01 1,04E-01 4,02E+00 
KEGG_PATHWAY hsa04114:Oocyte meiosis 7 4,70 6,39E-03 P62258, Q14683, P30153, Q08209, 
Q04917, P31946, P61981 
4,15 6,23E-01 2,16E-01 7,39E+00 
GOTERM_BP_DIRECT GO:0000086~G2/M transition of 
mitotic cell cycle 
6 4,03 6,74E-03 P63151, P62258, Q14204, P50570, 
P30153, P61981 
5,04 9,99E-01 2,01E-01 1,01E+01 
GOTERM_BP_DIRECT GO:0006605~protein targeting 3 2,01 4,46E-02 P62258, P31946, P61981 8,85 1,00E+00 6,32E-01 5,12E+01 
Annotation Cluster 13 - Enrichment Score: 2.40 
        
Category Term Count % PValue Genes Fold 
Enrichment 
Bonferroni Benjamini FDR 
GOTERM_MF_DIRECT GO:0051082~unfolded protein 
binding 
7 4,70 3,73E-04 P31689, Q9NU22, P50990, P50991, 
O60884, P50454, P38646 
7,36 1,30E-01 1,15E-02 5,13E-01 
UP_KEYWORDS Chaperone 7 4,70 3,37E-03 P31689, Q9NU22, P50990, P50991, 
O60884, P50454, P38646 
4,81 5,44E-01 2,43E-02 4,24E+00 
GOTERM_BP_DIRECT GO:0006457~protein folding 7 4,70 4,75E-03 P31689, Q14697, P49588, P50990, 
P50991, O60884, P38646 
4,47 9,90E-01 1,56E-01 7,22E+00 









Annotation Cluster 14 - Enrichment Score: 2.35 
        
Category Term Count % PValue Genes Fold 
Enrichment 
Bonferroni Benjamini FDR 
UP_KEYWORDS DNA repair 9 6,04 1,30E-03 Q96T76, Q16531, Q9NVI1, Q14683, 
O95071, P23396, P12004, Q93009, 
P78527 
4,24 2,61E-01 1,15E-02 1,65E+00 
UP_KEYWORDS DNA damage 9 6,04 4,02E-03 Q96T76, Q16531, Q9NVI1, Q14683, 
O95071, P23396, P12004, Q93009, 
P78527 
3,53 6,08E-01 2,80E-02 5,04E+00 
GOTERM_BP_DIRECT GO:0006281~DNA repair 7 4,70 1,64E-02 Q96T76, Q16531, Q9NVI1, Q14683, 
O95071, P23396, Q92900 
3,43 1,00E+00 3,83E-01 2,29E+01 
Annotation Cluster 15 - Enrichment Score: 2.24 
Category Term Count % PValue Genes Fold 
Enrichment 
Bonferroni Benjamini FDR 
GOTERM_BP_DIRECT GO:0055129~L-proline 
biosynthetic process 
3 2,01 7,28E-04 Q53H96, P54886, P04181 69,01 5,04E-01 4,89E-02 1,14E+00 
GOTERM_BP_DIRECT GO:0008652~cellular amino acid 
biosynthetic process 
4 2,68 1,42E-03 P0DN79, Q53H96, P54886, P04181 
 
17,69 7,45E-01 8,19E-02 2,21E+00 
Annotation Cluster 16 - Enrichment Score: 1.97 
Category Term Count % PValue Genes Fold 
Enrichment 
Bonferroni Benjamini FDR 
UP_KEYWORDS Helicase 8 5,37 7,97E-05 P33993, Q9NR30, O75643, O00571, 
P38919, Q92900, Q14566, P25205 
7,73 1,84E-02 8,84E-04 1,02E-01 
GOTERM_CC_DIRECT GO:0000784~nuclear 
chromosome, telomeric region 
7 4,70 6,53E-04 P33993, Q16531, P12004, Q92900, 
P78527, Q14566, P25205 
6,63 1,53E-01 8,26E-03 8,47E-01 
INTERPRO IPR018525:Mini-chromosome 
maintenance, conserved site 
3 2,01 9,03E-04 P33993, Q14566, P25205 63,13 3,51E-01 3,85E-02 1,28E+00 







3 2,01 2,13E-03 P33993, Q14566, P25205 42,08 6,40E-01 7,55E-02 3,01E+00 
GOTERM_CC_DIRECT GO:0042555~MCM complex 3 2,01 2,24E-03 P33993, Q14566, P25205 41,05 4,34E-01 2,56E-02 2,88E+00 
SMART SM00350:MCM 3 2,01 2,33E-03 P33993, Q14566, P25205 39,91 1,78E-01 4,79E-02 2,48E+00 
GOTERM_BP_DIRECT GO:0000082~G1/S transition of 
mitotic cell cycle 
5 3,36 1,18E-02 P33993, Q08209, P12004, Q14566, 
P25205 
5,64 1,00E+00 3,09E-01 1,70E+01 
KEGG_PATHWAY hsa03030:DNA replication 4 2,68 1,74E-02 P33993, P12004, Q14566, P25205 7,18 9,30E-01 3,58E-01 1,89E+01 
GOTERM_MF_DIRECT GO:0003678~DNA helicase 
activity 
3 2,01 1,79E-02 P33993, Q14566, P25205 14,45 9,99E-01 2,74E-01 2,20E+01 
BIOCARTA h_mcmPathway:CDK Regulation 
of DNA Replication 
3 2,01 2,77E-02 P33993, Q14566, P25205 10,83 8,30E-01 5,87E-01 2,48E+01 
UP_KEYWORDS DNA replication 4 2,68 3,04E-02 P33993, P12004, Q14566, P25205 5,88 9,99E-01 1,51E-01 3,27E+01 
GOTERM_BP_DIRECT GO:0006270~DNA replication 
initiation 
3 2,01 3,10E-02 P33993, Q14566, P25205 10,78 1,00E+00 5,15E-01 3,91E+01 
GOTERM_BP_DIRECT GO:0006260~DNA replication 5 3,36 4,55E-02 P33993, P12004, Q92900, Q14566, 
P25205 
3,71 1,00E+00 6,31E-01 5,19E+01 
Annotation Cluster 17 - Enrichment Score: 1.90 
Category Term Count % PValue Genes Fold 
Enrichment 
Bonferroni Benjamini FDR 
GOTERM_CC_DIRECT GO:0005643~nuclear pore 6 4,03 2,89E-04 Q12769, Q92621, P52292, Q8TEX9, 
O43592, O00410 
10,26 7,08E-02 3,86E-03 3,76E-01 
GOTERM_BP_DIRECT GO:0006607~NLS-bearing 
protein import into nucleus 
3 2,01 1,66E-02 P52292, Q8TEX9, O00410 15,00 1,00E+00 3,79E-01 2,32E+01 
COG_ONTOLOGY Intracellular trafficking and 
secretion 
4 2,68 2,08E-02 Q9Y678, P52292, Q8TEX9, O00410 6,43 2,71E-01 2,71E-01 1,36E+01 
GOTERM_MF_DIRECT GO:0008139~nuclear localization 
sequence binding 








Annotation Cluster 18 - Enrichment Score: 1.88 
Category Term Count % PValue Genes Fold 
Enrichment 
Bonferroni Benjamini FDR 
GOTERM_BP_DIRECT GO:0035338~long-chain fatty-
acyl-CoA biosynthetic process 
5 3,36 4,63E-04 Q13085, P53007, P53396, P49327, 
Q53GQ0 
13,69 3,60E-01 3,65E-02 7,25E-01 
GOTERM_BP_DIRECT GO:0031325~positive regulation 
of cellular metabolic process 
3 2,01 7,28E-04 Q13085, P53396, P49327 69,01 5,04E-01 4,89E-02 1,14E+00 
GOTERM_BP_DIRECT GO:0006633~fatty acid 
biosynthetic process 
5 3,36 1,05E-03 Q13085, P53396, P49327, P28288, 
Q53GQ0 
11,06 6,36E-01 6,51E-02 1,63E+00 
Annotation Cluster 19 - Enrichment Score: 1.86 
Category Term Count % PValue Genes Fold 
Enrichment 
Bonferroni Benjamini FDR 
GOTERM_BP_DIRECT GO:0008380~RNA splicing 8 5,37 5,99E-04 Q14498, P26599, Q07021, P30153, 
Q15029, Q15393, Q6P2Q9, P38919 
5,54 4,39E-01 4,35E-02 9,38E-01 
UP_KEYWORDS mRNA splicing 8 5,37 2,80E-03 Q14498, P26599, O75643, Q07021, 
Q15029, Q15393, Q6P2Q9, P38919 
4,25 4,79E-01 2,08E-02 3,54E+00 
GOTERM_BP_DIRECT GO:0000398~mRNA splicing, via 
spliceosome 
8 5,37 3,18E-03 P26599, O75643, Q15029, Q15393, 
Q6P2Q9, P38919, Q15366, Q15365 
4,14 9,54E-01 1,20E-01 4,89E+00 
GOTERM_CC_DIRECT GO:0071013~catalytic step 2 
spliceosome 
5 3,36 6,56E-03 O75643, Q15029, Q15393, Q6P2Q9, 
P38919 
6,69 8,12E-01 6,23E-02 8,21E+00 
UP_KEYWORDS mRNA processing 8 5,37 1,03E-02 Q14498, P26599, O75643, Q07021, 
Q15029, Q15393, Q6P2Q9, P38919 
3,33 9,11E-01 6,32E-02 1,25E+01 
UP_KEYWORDS Spliceosome 5 3,36 1,34E-02 O75643, Q15029, Q15393, Q6P2Q9, 
P38919 
5,44 9,57E-01 7,75E-02 1,59E+01 
GOTERM_BP_DIRECT GO:0006397~mRNA processing 6 4,03 1,96E-02 Q14498, P26599, Q07021, Q15029, 
Q15393, Q6P2Q9 
3,86 1,00E+00 3,95E-01 2,68E+01 
GOTERM_CC_DIRECT GO:0016607~nuclear speck 6 4,03 2,36E-02 Q14498, Q3ZCQ8, O00571, Q15029, 
Q6P2Q9, P38919 






4 2,68 4,05E-02 O75643, Q15029, Q15393, Q6P2Q9 5,24 1,00E+00 2,66E-01 4,16E+01 
Annotation Cluster 20 - Enrichment Score: 1.85 
Category Term Count % PValue Genes Fold 
Enrichment 
Bonferroni Benjamini FDR 
UP_KEYWORDS mRNA transport 5 3,36 7,24E-03 Q12769, Q92621, P42704, O14980, 
P38919 
6,52 8,16E-01 4,72E-02 8,91E+00 
GOTERM_BP_DIRECT GO:0075733~intracellular 
transport of virus 
4 2,68 9,70E-03 Q12769, Q92621, O14980, P52292 9,02 1,00E+00 2,69E-01 1,42E+01 
GOTERM_CC_DIRECT GO:0005635~nuclear envelope 5 3,36 3,98E-02 Q12769, Q92621, P55060, Q9Y3I0, 
O14980 
3,87 1,00E+00 2,75E-01 4,11E+01 
Annotation Cluster 21 - Enrichment Score: 1.72 
Category Term Count % PValue Genes Fold 
Enrichment 
Bonferroni Benjamini FDR 
UP_KEYWORDS mRNA transport 5 3,36 7,24E-03 Q12769, Q92621, P42704, O14980, 
P38919 
6,52 8,16E-01 4,72E-02 8,91E+00 
KEGG_PATHWAY hsa03013:RNA transport 8 5,37 1,62E-02 Q12769, O14744, Q92621, O14980, 
Q14152, O43592, P38919, Q92900 
3,00 9,17E-01 3,92E-01 1,78E+01 
Annotation Cluster 22 - Enrichment Score: 1.57 
Category Term Count % PValue Genes Fold 
Enrichment 
Bonferroni Benjamini FDR 
UP_KEYWORDS Helicase 8 5,37 7,97E-05 P33993, Q9NR30, O75643, O00571, 
P38919, Q92900, Q14566, P25205 
7,73 1,84E-02 8,84E-04 1,02E-01 
GOTERM_MF_DIRECT GO:0004004~ATP-dependent 
RNA helicase activity 
5 3,36 2,36E-03 Q9NR30, O75643, O00571, P38919, 
Q92900 
8,89 5,85E-01 6,09E-02 3,20E+00 
INTERPRO IPR011545:DNA/RNA helicase, 
DEAD/DEAH box type, N-terminal 
4 2,68 1,71E-02 Q9NR30, O75643, O00571, P38919 7,32 1,00E+00 3,85E-01 2,19E+01 
INTERPRO IPR014014:RNA helicase, DEAD-
box type, Q motif 




UP_SEQ_FEATURE short sequence motif:Q motif 3 2,01 3,51E-02 Q9NR30, O00571, P38919 10,10 1,00E+00 5,90E-01 4,10E+01 
GOTERM_MF_DIRECT GO:0004386~helicase activity 4 2,68 3,68E-02 O75643, O00571, P38919, Q92900 5,44 1,00E+00 3,93E-01 4,04E+01 
Annotation Cluster 23 - Enrichment Score: 1.44 
Category Term Count % PValue Genes Fold 
Enrichment 
Bonferroni Benjamini FDR 
GOTERM_BP_DIRECT GO:0008652~cellular amino acid 
biosynthetic process 
4 2,68 1,42E-03 P0DN79, Q53H96, P54886, P04181 17,69 7,45E-01 8,19E-02 2,21E+00 
UP_KEYWORDS Amino-acid biosynthesis 3 2,01 1,49E-02 P0DN79, Q53H96, P54886 15,94 9,70E-01 8,38E-02 1,76E+01 
Annotation Cluster 24 - Enrichment Score: 1.24 
Category Term Count % PValue Genes Fold 
Enrichment 




4 2,68 1,36E-02 P63151, Q3ZCQ8, P30153, Q08209 7,97 9,94E-01 2,35E-01 1,72E+01 
GOTERM_BP_DIRECT GO:0006470~protein 
dephosphorylation 
5 3,36 2,38E-02 Q96HS1, P63151, Q3ZCQ8, P30153, 
Q08209 
4,56 1,00E+00 4,48E-01 3,15E+01 
Annotation Cluster 25 - Enrichment Score: 1.19 
Category Term Count % PValue Genes Fold 
Enrichment 
Bonferroni Benjamini FDR 
UP_KEYWORDS Cell cycle 13 8,72 2,62E-03 Q9NVI1, Q9NNW5, Q5T9A4, Q93008, 
P25205, P33993, P42695, Q14683, 
Q00535, P63244, Q00610, P23396, 
Q14566 
2,76 4,57E-01 2,02E-02 3,31E+00 
Annotation Cluster 26 - Enrichment Score: 1.08 
Category Term Count % PValue Genes Fold 
Enrichment 
Bonferroni Benjamini FDR 
GOTERM_MF_DIRECT GO:0003924~GTPase activity 7 4,70 1,57E-02 P18085, P40616, P50570, O00571, 
Q15029, Q9BUF5, P51148 




INTERPRO IPR024156:Small GTPase 
superfamily, ARF type 
3 2,01 2,61E-02 Q9Y5M8, P18085, P40616 11,84 1,00E+00 5,05E-01 3,15E+01 
UP_SEQ_FEATURE nucleotide phosphate-binding 
region:GTP 
7 4,70 2,76E-02 Q9Y5M8, P18085, P40616, P50570, 
Q15029, Q9BUF5, P51148 
3,04 1,00E+00 5,18E-01 3,39E+01 
UP_KEYWORDS GTP-binding 7 4,70 3,79E-02 Q9Y5M8, P18085, P40616, P50570, 
Q15029, Q9BUF5, P51148 
2,82 1,00E+00 1,71E-01 3,91E+01 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   













 Annotation Cluster 1 - Enrichment Score: 2.79 
Category Term Count % PValue Genes Fold 
Enrichment 
Bonferroni Benjamini FDR 
GOTERM_BP_DIRECT GO:0016925~protein 
sumoylation 
5 21,74 1,22E-05 Q12769, Q92621, P49792, Q14683, 
Q9UQE7 
32,62 2,69E-03 1,34E-03 1,56E-02 
GOTERM_CC_DIRECT GO:0005643~nuclear pore 4 17,39 7,47E-05 Q12769, Q9UBU9, Q92621, P49792 46,02 6,33E-03 6,33E-03 8,04E-02 
UP_KEYWORDS mRNA transport 4 17,39 1,90E-04 Q12769, Q9UBU9, Q92621, P49792 33,77 1,76E-02 2,53E-03 2,08E-01 
GOTERM_BP_DIRECT GO:0006406~mRNA export from 
nucleus 
4 17,39 2,52E-04 Q12769, Q9UBU9, Q92621, P49792 30,53 5,40E-02 1,38E-02 3,20E-01 
GOTERM_BP_DIRECT GO:0019083~viral transcription 4 17,39 3,52E-04 Q12769, Q92621, P49792, P23396 27,26 7,45E-02 1,54E-02 4,47E-01 
GOTERM_BP_DIRECT GO:0016032~viral process 5 21,74 4,64E-04 Q12769, Q9UBU9, Q92621, P49792, 
P08670 
12,76 9,71E-02 1,69E-02 5,89E-01 
GOTERM_BP_DIRECT GO:0006409~tRNA export from 
nucleus 
3 13,04 7,22E-04 Q12769, Q92621, P49792 71,56 1,47E-01 2,25E-02 9,16E-01 
GOTERM_BP_DIRECT GO:0010827~regulation of 
glucose transport 
3 13,04 7,68E-04 Q12769, Q92621, P49792 69,39 1,56E-01 2,09E-02 9,74E-01 
UP_KEYWORDS Nuclear pore complex 3 13,04 1,30E-03 Q12769, Q92621, P49792 53,69 1,14E-01 1,20E-02 1,41E+00 
GOTERM_BP_DIRECT GO:0007077~mitotic nuclear 
envelope disassembly 
3 13,04 1,37E-03 Q12769, Q92621, P49792 52,04 2,60E-01 2,96E-02 1,72E+00 
GOTERM_BP_DIRECT GO:0075733~intracellular 
transport of virus 
3 13,04 1,83E-03 Q12769, Q92621, P49792 44,90 3,32E-01 3,60E-02 2,31E+00 




GOTERM_BP_DIRECT GO:1900034~regulation of 
cellular response to heat 
3 13,04 3,91E-03 Q12769, Q92621, P49792 30,53 5,78E-01 6,93E-02 4,87E+00 
KEGG_PATHWAY hsa03013:RNA transport 4 17,39 5,53E-03 Q12769, Q9UBU9, Q92621, P49792 10,04 1,39E-01 1,39E-01 4,49E+00 
GOTERM_BP_DIRECT GO:0031047~gene silencing by 
RNA 
3 13,04 8,38E-03 Q12769, Q92621, P49792 20,63 8,43E-01 1,33E-01 1,02E+01 
GOTERM_CC_DIRECT GO:0005635~nuclear envelope 3 13,04 1,42E-02 Q12769, Q92621, P49792 15,63 7,05E-01 1,15E-01 1,43E+01 
Annotation Cluster 2 - Enrichment Score: 8.13 
Category Term Count % PValue Genes Fold 
Enrichment 
Bonferroni Benjamini FDR 
GOTERM_BP_DIRECT GO:0006281~DNA repair 5 21,74 1,86E-04 Q96PK6, Q14683, Q9UQE7, Q9Y265, 
P23396 
16,24 4,00E-02 1,35E-02 2,36E-01 
UP_KEYWORDS DNA repair 5 21,74 2,40E-04 Q14683, Q9UQE7, Q9Y265, P23396, 
P78527 
15,27 2,21E-02 2,79E-03 2,63E-01 
UP_KEYWORDS DNA damage 5 21,74 4,82E-04 Q14683, Q9UQE7, Q9Y265, P23396, 
P78527 
12,71 4,39E-02 4,97E-03 5,27E-01 
GOTERM_BP_DIRECT GO:0051301~cell division 5 21,74 8,39E-04 Q14683, Q9BQE3, Q9UQE7, Q9Y265, 
P23396 
10,90 1,69E-01 2,03E-02 1,06E+00 
UP_KEYWORDS Mitosis 4 17,39 2,63E-03 Q14683, Q9UQE7, Q9Y265, P23396 13,66 2,17E-01 1,86E-02 2,84E+00 
UP_KEYWORDS Cell cycle 5 21,74 4,58E-03 Q14683, Q9NNW5, Q9UQE7, Q9Y265, 
P23396 
6,88 3,48E-01 2,35E-02 4,90E+00 
UP_KEYWORDS Cell division 4 17,39 7,85E-03 Q14683, Q9UQE7, Q9Y265, P23396 9,23 5,19E-01 3,60E-02 8,26E+00 
GOTERM_BP_DIRECT GO:0007067~mitotic nuclear 
division 
3 13,04 3,79E-02 Q9UQE7, Q9Y265, P23396 9,23 1,00E+00 4,12E-01 3,89E+01 
Annotation Cluster 3 - Enrichment Score: 2.66 
Category Term Count % PValue Genes Fold 
Enrichment 
Bonferroni Benjamini FDR 
GOTERM_MF_DIRECT GO:0003723~RNA binding 7 30,43 4,03E-05 Q96PK6, Q15717, Q9UBU9, P49792, 
O00571, P23396, Q14690 




UP_KEYWORDS RNA-binding 7 30,43 5,33E-05 Q96PK6, Q15717, Q9NR30, Q9UBU9, 
P49792, O00571, P23396 
9,42 4,95E-03 8,26E-04 5,83E-02 
INTERPRO IPR012677:Nucleotide-binding, 
alpha-beta plait 
4 17,39 3,13E-03 Q96PK6, Q15717, Q9NR30, Q9UBU9 12,78 2,22E-01 1,18E-01 3,28E+00 
GOTERM_MF_DIRECT GO:0003729~mRNA binding 3 13,04 1,04E-02 Q15717, Q9UBU9, P23396 18,42 6,53E-01 1,40E-01 1,10E+01 
UP_KEYWORDS Methylation 5 21,74 2,02E-02 Q15717, Q9UBU9, P49792, O00571, 
P23396 
4,47 8,50E-01 7,92E-02 2,00E+01 
Annotation Cluster 4 - Enrichment Score: 2.53 
Category Term Count % PValue Genes Fold 
Enrichment 
Bonferroni Benjamini FDR 
UP_KEYWORDS DNA repair 5 21,74 2,40E-04 Q14683, Q9UQE7, Q9Y265, P23396, 
P78527 
15,27 2,21E-02 2,79E-03 2,63E-01 
UP_KEYWORDS DNA damage 5 21,74 4,82E-04 Q14683, Q9UQE7, Q9Y265, P23396, 
P78527 
12,71 4,39E-02 4,97E-03 5,27E-01 
UP_KEYWORDS Nucleotide-binding 8 34,78 1,96E-03 Q9NR30, Q9NVI7, Q14683, Q9BQE3, 
O00571, Q9UQE7, Q9Y265, P78527 
4,00 1,66E-01 1,51E-02 2,12E+00 
INTERPRO IPR027417:P-loop containing 
nucleoside triphosphate 
hydrolase 
6 26,09 2,54E-03 Q9NR30, Q9NVI7, Q14683, O00571, 
Q9UQE7, Q9Y265 
5,76 1,84E-01 1,84E-01 2,67E+00 
UP_KEYWORDS ATP-binding 7 30,43 2,75E-03 Q9NR30, Q9NVI7, Q14683, O00571, 
Q9UQE7, Q9Y265, P78527 
4,50 2,26E-01 1,81E-02 2,97E+00 
UP_SEQ_FEATURE nucleotide phosphate-binding 
region:ATP 
6 26,09 3,84E-03 Q9NR30, Q9NVI7, Q14683, O00571, 
Q9UQE7, Q9Y265 
5,27 4,66E-01 2,69E-01 4,56E+00 
GOTERM_MF_DIRECT GO:0005524~ATP binding 7 30,43 8,10E-03 Q9NR30, Q9NVI7, Q14683, O00571, 
Q9UQE7, Q9Y265, P78527 
3,59 5,60E-01 1,28E-01 8,64E+00 
UP_KEYWORDS Helicase 3 13,04 1,01E-02 Q9NR30, O00571, Q9Y265 18,77 6,11E-01 4,40E-02 1,05E+01 








Annotation Cluster 5 - Enrichment Score: 1.03 
Category Term Count % PValue Genes Fold 
Enrichment 
Bonferroni Benjamini FDR 
UP_KEYWORDS Mitochondrion inner membrane 4 17,39 2,86E-03 O95831, Q9NVI7, P23396, Q99623 13,26 2,34E-01 1,76E-02 3,09E+00 
UP_KEYWORDS Mitochondrion 6 26,09 5,71E-03 O95831, Q96HS1, Q9NVI7, O00571, 
P23396, Q99623 
4,80 4,13E-01 2,76E-02 6,08E+00 
GOTERM_CC_DIRECT GO:0005743~mitochondrial 
inner membrane 
4 17,39 1,35E-02 O95831, Q9NVI7, P23396, Q99623 7,51 6,86E-01 1,21E-01 1,36E+01 
Annotation Cluster 6 Enrichment Score: 
0.9551892733349611 
        
Category Term Count % PValue Genes Fold 
Enrichment 
Bonferroni Benjamini FDR 
UP_KEYWORDS Mitochondrion 6 26,09 5,71E-03 O95831, Q96HS1, Q9NVI7, O00571, 
P23396, Q99623 














Supplementary Table 4. IPA canonical signaling pathways enrichment in the ANKRD55 interactome from nuclear and total protein extract. Significantly enriched pathways (-Log (p-value)>1.30) are 
shown. 
 















  tRNA Charging 11,40 LARS,RARS,RARS2,AARS,VARS,MARS,IARS,FARSA,FARSB 
EIF2 Signaling 9,49 PTBP1,RPL4,RPS3A,EIF4A3,RPS9,EIF3A,RPL10,RPS15A,RPL23,RPS2,RPS3,RPL7A,RPL9,RPLP0 
Regulation of eIF4 and p70S6K Signaling 5,91 PPP2R1A,RPS3A,PPP2R2A,EIF4A3,RPS9,EIF3A,RPS15A,RPS2,RPS3 
RAN Signaling 5,36 CSE1L,XPO1,KPNA2,IPO5 
mTOR Signaling 5,03 PPP2R1A,RPS3A,PPP2R2A,EIF4A3,RPS9,EIF3A,RPS15A,RPS2,RPS3 
Cell Cycle: G2/M DNA Damage Checkpoint Regulation 4,66 PRKDC,YWHAG,YWHAH,YWHAE,YWHAB 
HIPPO signaling 4,56 PPP2R1A,YWHAG,YWHAH,YWHAE,YWHAB,PPP2R2A 
Cell Cycle Control of Chromosomal Replication 4,42 MCM3,MCM6,PCNA,CDK5,MCM7 
PI3K/AKT Signaling 3,69 PPP2R1A,YWHAG,YWHAH,YWHAE,YWHAB,PPP2R2A 
Proline Biosynthesis I 3,57 PYCR3,ALDH18A1 
p70S6K Signaling 3,56 PPP2R1A,YWHAG,YWHAH,YWHAE,YWHAB,PPP2R2A 
ERK/MAPK Signaling 3,37 PPP2R1A,YWHAG,YWHAH,ARAF,YWHAB,PPP2R2A,TLN1 
Proline Biosynthesis II (from Arginine) 3,18 PYCR3,OAT 
Arginine Degradation VI (Arginase 2 Pathway) 3,18 PYCR3,OAT 
ERK5 Signaling 2,99 YWHAG,YWHAH,YWHAE,YWHAB 
Myc Mediated Apoptosis Signaling 2,89 YWHAG,YWHAH,YWHAE,YWHAB 
Caveolar-mediated Endocytosis Signaling 2,87 RAB5C,FLNA,DNM2,COPG1 
Citrulline Biosynthesis 2,80 OAT,ALDH18A1 
14-3-3-mediated Signaling 2,71 YWHAG,YWHAH,YWHAE,TUBB6,YWHAB 
Purine Nucleotides De Novo Biosynthesis II 2,62 ADSL,IMPDH2 
Sirtuin Signaling Pathway 2,43 PRKDC,ATP5F1C,TIMM44,TIMM50,ACLY,SLC25A5,VDAC2 
Pyrimidine Ribonucleotides De Novo Biosynthesis 2,41 CAD,CTPS1,DDX3X 
ATM Signaling 2,36 USP7,PPP2R1A,PPP2R2A,SMC1A 




Dopamine-DARPP32 Feedback in cAMP Signaling 2,29 PPP2R1A,CDK5,PPP2R2A,ATP2A2,PPP3CA 
IGF-1 Signaling 2,24 YWHAG,YWHAH,YWHAE,YWHAB 
Protein Kinase A Signaling 2,23 YWHAG,YWHAH,YWHAE,YWHAB,FLNA,RACK1,TIMM50,PPP3CA 
Role of CHK Proteins in Cell Cycle Checkpoint Control 2,17 PCNA,PPP2R1A,PPP2R2A 
Acetyl-CoA Biosynthesis III (from Citrate) 2,17 ACLY 
Huntington's Disease Signaling 2,15 ATP5F1C,CDK5,CLTC,RACK1,HSPA9,DNM2 
Induction of Apoptosis by HIV1 2,09 SLC25A13,SLC25A3,SLC25A5 
Mitotic Roles of Polo-Like Kinase 2,00 PPP2R1A,PPP2R2A,SMC1A 
ILK Signaling 1,96 PPP2R1A,CFL1,PPP2R2A,FLNA,IRS4 
Cysteine Biosynthesis III (mammalia) 1,95 CBS/CBSL,PRMT5 
Remodeling of Epithelial Adherens Junctions 1,94 RAB5C,TUBB6,DNM2 
Clathrin-mediated Endocytosis Signaling 1,88 RAB5C,CLTC,USP9X,PPP3CA,DNM2 
Palmitate Biosynthesis I (Animals) 1,87 FASN 
Uridine-5'-phosphate Biosynthesis 1,87 CAD 
Fatty Acid Biosynthesis Initiation II 1,87 FASN 
Cysteine Biosynthesis/Homocysteine Degradation 1,87 CBS/CBSL 
Cardiac β-adrenergic Signaling 1,81 PPP2R1A,PPP2R2A,RACK1,ATP2A2 
Inosine-5'-phosphate Biosynthesis II 1,70 ADSL 
Biotin-carboxyl Carrier Protein Assembly 1,70 ACACA 
Cell Cycle Regulation by BTG Family Proteins 1,59 PPP2R1A,PPP2R2A 
Superpathway of Methionine Degradation 1,59 CBS/CBSL,PRMT5 
Arginine Degradation I (Arginase Pathway) 1,57 OAT 
Salvage Pathways of Pyrimidine Ribonucleotides 1,55 PYCR3,CDK5,ARAF 
Mitochondrial Dysfunction 1,54 ATP5F1C,ATP5PO,AIFM1,VDAC2 
CTLA4 Signaling in Cytotoxic T Lymphocytes 1,53 PPP2R1A,PPP2R2A,CLTC 
CDK5 Signaling 1,53 PPP2R1A,CDK5,PPP2R2A 




Folate Polyglutamylation 1,48 MTHFD1L 
Protein Ubiquitination Pathway 1,47 USP7,USP9X,HSPA9,DNAJA1,PSMC3 
Stearate Biosynthesis I (Animals) 1,45 FASN,SLC27A4 
Pyrimidine Ribonucleotides Interconversion 1,43 CTPS1,DDX3X 
Virus Entry via Endocytic Pathways 1,42 FLNA,CLTC,DNM2 
p53 Signaling 1,41 PRKDC,PCNA,COQ8A 
Arginine Biosynthesis IV 1,40 OAT 
Acetyl-CoA Biosynthesis I (Pyruvate Dehydrogenase Complex) 1,33 PDHB 













 Mitotic Roles of Polo-Like Kinase 2,66 SMC3,SMC1A 
ATM Signaling 2,33 SMC3,SMC1A 
Estrogen Receptor Signaling 2,10 PRKDC,PHB2 
14-3-3-mediated Signaling 2,08 VIM,TUBA1C 
DNA Double-Strand Break Repair by Non-Homologous End Joining 1,84 PRKDC 
Granzyme B Signaling 1,78 PRKDC 
RAN Signaling 1,75 RANBP2 
ILK Signaling 1,75 IRS4,VIM 
Tumoricidal Function of Hepatic Natural Killer Cells 1,60 AIFM1 
Role of JAK2 in Hormone-like Cytokine Signaling 1,46 IRS4 
Sirtuin Signaling Pathway 1,43 PRKDC,TUBA1C 
Pyrimidine Ribonucleotides Interconversion 1,34 DDX3X 





Supplementary Table 5. List of antibodies for the validation of selected ANKRD55 interacting partners. Abbreviations: 
WB, western blot and IF, immunofluoresce. 
Antibody Catalog Number Host Applications 




WB and IF in combination with FLAG rabbit for 
recombinant ANKRD55 




WB and IF in combination with FLAG rabbit for 
recombinant ANKRD55 
14-3-3 (pan) 8312 
Cell Signaling 
Rabbit polyclonal WB and IF in combination with FLAG rabbit and 
mouse for recombinant ANKRD55, respectively. 




WB and IF in combination with FLAG rabbit for 
recombinant ANKRD55 




WB in combination with FLAG rabbit for 
recombinant ANKRD55 
SMC1A 21695-1-AP            
Proteintech 




Rabbit monoclonal WB in combination with FLAG rabbit for 
recombinant ANKRD55 
PRKDC NBP2-22128SS              
Novus Biologicals 
Mouse monoclonal WB in combination with FLAG rabbit for 
recombinant ANKRD55 




WB in combination with FLAG rabbit for 
recombinant ANKRD55 











Supplementary Table 6. List of potential 14-3-3 binding sites on ANKRD55. Abbreviations: ANN, Artificial Neural Network 





ANN PSSM SVM Consensus – 
average of the 
three scores 
10 QATMDFsTPSV 0.314 0.299 -0.494 0.04 
11 ATMDFStPSVF 0.03 -0.49 -2.021 -0.827 
13 MDFSTPsVFDQ 0.145 -0.078 -0.918 -0.284 
22 DQQRGDsSEEV 0.444 0.691 -0.435 0.233 
23 QQRGDSsEEVD 0.206 0.186 -0.474 -0.028 
29 SEEVDLtMVYQ 0.036 -0.231 -1.947 -0.714 
36 MVYQAAsNGDV 0.577 0.239 -0.278 0.18 
44 GDVNALtAVIR 0.141 -0.023 -0.952 -0.278 
52 VIREDPsILEC 0.144 -0.0 -1.138 -0.331 
59 ILECCDsEGCT 0.607 0.107 -0.203 0.17 
63 CDSEGCtPLMH 0.018 -0.704 -2.349 -1.011 
70 PLMHAVsGRQA 0.543 0.029 -0.006 0.189 
76 SGRQADtVKLL 0.389 0.187 -0.343 0.077 
96 QDAYGRtSLCL 0.034 -0.18 -1.503 -0.55 




102 TSLCLAtYLGW 0.088 -0.259 -1.337 -0.503 
112 WLEGCVsLLRN 0.609 0.064 -0.058 0.205 
135 LPLHAAtAEPD 0.279 -0.0 -0.637 -0.12 
144 PDMRLLtVLLQ 0.199 0.674 -0.486 0.129 
150 TVLLQQsNISE 0.04 -0.197 -1.524 -0.56 
153 LQQSNIsEINH 0.131 -0.072 -0.871 -0.271 
164 QDNEGMtPLHW 0.016 -0.492 -2.028 -0.835 
178 HNQPQHtQMLL 0.141 0.065 -0.985 -0.259 
189 KKGADPtLVDK 0.392 -0.039 -0.383 -0.01 
197 VDKDFKtALHW 0.108 -0.114 -1.083 -0.363 
205 LHWAVQsGNRI 0.184 -0.008 -0.851 -0.225 
212 GNRILCsIILS 0.208 0.098 -0.82 -0.172 
216 LCSIILsHHQG 0.204 -0.045 -0.716 -0.186 
222 SHHQGPsIINY 0.048 -0.243 -1.723 -0.639 
230 INYDDEsGKTC 0.065 -0.39 -1.526 -0.617 
233 DDESGKtCVHI 0.138 -0.145 -0.843 -0.283 
244 AAAAGFsDIIH 0.098 -0.27 -1.256 -0.476 
267 LDVDDRtPLHW 0.019 -0.557 -2.135 -0.891 
283 KAECVQsLLEL 0.342 -0.002 -0.609 -0.089 
291 LELGMDsNLRD 0.099 -0.336 -1.465 -0.567 
299 LRDINEsTPLA 0.503 0.584 -0.063 0.341 
300 RDINEStPLAY 0.035 -0.397 -1.677 -0.68 
311 ALYCGHtACVK 0.233 0.001 -1.003 -0.256 
318 ACVKLLsQESR 0.091 -0.166 -1.56 -0.545 
321 KLLSQEsRTEP 0.118 -0.242 -1.424 -0.516 
323 LSQESRtEPTR 0.609 0.691 0.236 0.512 
326 ESRTEPtRPPP 0.383 0.301 -0.481 0.068 
331 PTRPPPsQSSR 0.126 -0.144 -1.152 -0.39 
333 RPPPSQsSRPQ 0.139 -0.122 -0.943 -0.309 
334 PPPSQSsRPQK 0.174 0.082 -0.937 -0.227 
366 AHQKDPsRDRY 0.306 -0.156 -1.196 -0.349 
375 RYREEDtSEVN 0.258 0.152 -1.059 -0.216 
376 YREEDTsEVND 0.217 0.263 -0.629 -0.05 
383 EVNDIItTFDS 0.167 -0.028 -0.809 -0.223 
384 VNDIITtFDSI 0.168 -0.05 -0.474 -0.118 
387 IITTFDsIVGT 0.15 -0.22 -0.992 -0.354 
391 FDSIVGtNCQE 0.056 -0.355 -1.697 -0.665 
410 VEFKKKtSDNS 0.248 0.003 -0.822 -0.19 
411 EFKKKTsDNSK 0.258 -0.011 -0.426 -0.06 
414 KKTSDNsKYLL 0.311 0.03 -0.529 -0.062 
434 GLPPIRtQSLP 0.071 -0.193 -1.485 -0.536 
436 PPIRTQsLPPI 0.917 1.494 1.525 1.312 
441 QSLPPItLGNN 0.313 -0.052 -0.429 -0.056 
448 LGNNFLtASHR 0.049 -0.23 -1.341 -0.508 
450 NNFLTAsHRAT 0.201 -0.065 -0.708 -0.191 
454 TASHRAtSHAG 0.367 0.076 -0.509 -0.022 




460 TSHAGLsSAPH 0.018 -0.594 -2.171 -0.916 
461 SHAGLSsAPHH 0.1 0.127 -1.307 -0.36 
470 HHMAQRsQKSR 0.04 -0.127 -1.801 -0.629 
473 AQRSQKsRSEQ 0.174 -0.029 -0.931 -0.262 
475 RSQKSRsEQDL 0.715 0.46 0.213 0.463 
484 DLLNNRtGCQM 0.174 -0.163 -0.794 -0.261 
496 LDNPWKsDSNQ 0.115 -0.138 -1.207 -0.41 
498 NPWKSDsNQVF 0.314 0.214 -0.59 -0.021 
503 DSNQVFsYKVW 0.154 -0.111 -1.025 -0.327 
508 FSYKVWtVSSS 0.13 -0.129 -1.107 -0.369 
510 YKVWTVsSSDK 0.336 -0.027 -0.44 -0.043 
511 KVWTVSsSDKL 0.076 -0.036 -1.299 -0.42 
512 VWTVSSsDKLL 0.193 0.168 -0.595 -0.078 
521 LLDRLLsVRPG 0.45 0.713 0.067 0.41 
530 PGHQEVsVPPH 0.485 0.241 -0.251 0.158 
542 RHLHNPsSGQN 0.227 -0.09 -0.867 -0.244 
543 HLHNPSsGQNF 0.064 -0.102 -0.985 -0.341 
551 QNFQHLsPNRH 0.052 -0.568 -1.567 -0.695 
563 IRDLPFtRNNL 0.229 0.136 -0.648 -0.094 
577 PDQKFLsGEPL 0.109 -0.137 -1.059 -0.363 
583 SGEPLRtNRVL 0.055 -0.281 -1.598 -0.608 
592 VLPAIPsQRRH 0.102 -0.44 -1.49 -0.609 
597 PSQRRHsTAAE 0.846 1.106 0.778 0.91 
598 SQRRHStAAEE 0.635 0.964 0.134 0.577 
603 STAAEEsEHSA 0.107 -0.217 -1.398 -0.503 
606 AEESEHsANPT 0.177 -0.123 -1.123 -0.356 
610 EHSANPtSDEN 0.155 -0.15 -1.096 -0.364 
611 HSANPTsDEN- 0.122 -0.034 -0.822 -0.245 
 
Supplementary Table 7. List of identified ANKRD55-interacting proteins in protein-protein databases 
Gene 
Symbol 
Accession Protein name Resources Specie 







HIF1AN Q9NWT6 Hypoxia-inducible factor 1-alpha 
inhibitor 
BioGrid 
IFT52 Q9Y366 Intraflagellar transport protein 52 
homolog 
BioGrid 
ANKS1A Q49AR9 Ankyrin repeat and SAM domain-
containing protein 1A 
HuRI (HI-III) 
PTK6 Q13882 Protein-tyrosine kinase 6 HuRI (HI-III) 
HSF2BP O75031 Heat shock factor 2-binding protein HuRI (HI-III) 
BANP Q8N9N5 Protein BANP HuRI (HI-III) 
CABP5 Q9NP86 Calcium-binding protein 5 HuRI (HI-III) 
CLIC3 O95833 Chloride intracellular channel protein 
3 
HuRI (HI-III) 
ABI2 Q9NYB9 Abl interactor 2 HuRI (HI-III) 




HGS O14964 Hepatocyte growth factor-regulated 
tyrosine kinase substrate 
HuRI (HI-III) 
FRS3 O43559 Fibroblast growth factor receptor 
substrate 3 
HuRI (HI-III) 
NCK2 O43639 Cytoplasmic protein NCK2 HuRI (HI-III) 
TRIM23 P36406 E3 ubiquitin-protein ligase TRIM23 HuRI (HI-III) 
TRIP6 Q15654 Thyroid receptor-interacting protein 6 BioGrid, HuRI (HI-III, 
unpublished GS test 
space) 
NOXA1  Q86UR1  NADPH oxidase activator 1 HuRI (HI-III) 
TTC30A  Q86WT1 Tetratricopeptide repeat protein 30A BioGrid 
CFAP206  Q8IYR0 Cilia- and flagella-associated protein 
206 
HuRI (HI-III) 
TTC30B  Q8N4P2  Tetratricopeptide repeat protein 30B BioGrid 
TEKT4  Q8WW24 Tektin-4 HuRI (HI-III) 
ZMYND19  Q96E35  Zinc finger MYND domain-containing 
protein 19 
HuRI (HI-III) 
IFT74 Q96LB3  Intraflagellar transport protein 74 
homolog 
BioGrid 
PFDN5  Q99471 Prefoldin subunit 5 HuRI (HI-III) 
BACH2  Q9BYV9  Transcription regulator protein 
BACH2 
HuRI (HI-III) 
IFT46 Q9NQC8 Intraflagellar transport protein 46 
homolog 
BioGrid 
ZSCAN1 Q8NBB4 Zinc finger and SCAN domain-
containing protein 1 
BioGrid 
YWHAZ  P63104  14-3-3 protein zeta/delta BioGrid, 
MIB1  Q86YT6 E3 ubiquitin-protein ligase MIB1 BioGrid 
YWHAG P61981  14-3-3 protein gamma BioGrid 
RABGEF1 Q9UJ41 Rab5 GDP/GTP exchange factor HuRI (HI-III) 
LEF1 Q9UJU2 Lymphoid enhancer-binding factor 1 HuRI (HI-III, unpublished 
GS test space) 
SUFU Q9UMX1 Suppressor of fused homolog HuRI (HI-III, unpublished 
GS test space) 
CARD9 Q9H257 Caspase recruitment domain-
containing protein 9 
HuRI (HI-III, unpublished 
GS test space) 
DEUP1 Q05D60 Deuterosome assembly protein 1 HuRI (HI-III, unpublished 
GS test space) 
LRP2BP P98164 Low-density lipoprotein receptor-
related protein 2 
HuRI (HI-III, unpublished 
GS test space) 
SF3A3 Q12874 Splicing factor 3A subunit 3 HuRI (HI-III, unpublished 
GS test space) 
TCAP O15273 Telethonin HuRI (HI-III, unpublished 
GS test space) 
FANCL Q9NW38 E3 ubiquitin-protein ligase FANCL HuRI (HI-III, unpublished 
GS test space) 
CIAO1 O76071 Probable cytosolic iron-sulfur protein 
assembly protein CIAO1 
HuRI (HI-III, unpublished 
GS test space) 




YWHAQ P27348 14-3-3 protein theta BioGrid 
RPS3 P23396 40S ribosomal protein S3 STRING 
CNOT6L Q96LI5 CCR4-NOT transcription complex 
subunit 6-like 
STRING 
LRKK2 Q5S007 Leucine-rich repeat serine/threonine-
protein kinase 2 
STRING 
NNT Q13423 NAD(P) transhydrogenase, 
mitochondrial 
STRING 
ASH1L Q9NR48 Histone-lysine N-methyltransferase 
ASH1L 
STRING 
PHLPP1 O60346 PH domain leucine-rich repeat-
containing protein phosphatase 1 
STRING 
PHLPP2 Q6ZVD8 PH domain leucine-rich repeat-
containing protein phosphatase 2 
STRING 
LRGUK Q96M69 Leucine-rich repeat and guanylate 
kinase domain-containing protein 
STRING 
GART P22102 Trifunctional purine biosynthetic 
protein adenosine-3 
STRING 
ACLY P53396 ATP-citrate synthase STRING 








s           
Rps3 P62908 40S ribosomal protein S3 STRING 
Gart Q64737 Trifunctional purine biosynthetic 
protein adenosine-3 
STRING 
Phlpp2 Q8BXA7 PH domain leucine-rich repeat-
containing protein phosphatase 2 
STRING 
Nos Q9Z0J4 Nitric oxide synthase, brain STRING 
Hsp90aa1 P07901 Heat shock protein HSP 90-alpha STRING 
Hsp90ab1 P11499 Heat shock protein HSP 90-beta STRING 
Phlpp1 Q8CHE4 PH domain leucine-rich repeat-
containing protein phosphatase 1 
STRING 
Lrrk1 Q3UHC2 Leucine-rich repeat serine/threonine-
protein kinase 1 
STRING 
Lrrk2 Q5S006 Leucine-rich repeat serine/threonine-











Supplementary Table 8. In silico analysis for DNA, RNA and nucleotides binding prediction. The first column displays the ANKRD55 isoform 001 protein sequence, which is followed by the results of 
predictions for 7 ligand types:  DNA, RNA, ATP, ADP, AMP, GTP, and GDP. Predictions for each ligand type include two columns that provide annotation of predicted binding (each ligand is annotated 
as either binding (B or 1) or non-binding (N or 0)) and prediction scores which estimate probability of binding to a given ligand. Residues with the probability > 0.4727 for the prediction of DNA-































M 0 0.1894 0 0.0470 N 0.024 N 0.016 N 0.022 N 0.017 N 0.016 
M 0 0.1969 0 0.0485 N 0.028 N 0.019 N 0.020 N 0.020 N 0.019 
R 0 0.3463 0 0.0409 N 0.031 N 0.031 N 0.048 N 0.016 N 0.029 
Q 0 0.2369 0 0.0418 N 0.028 N 0.025 N 0.027 N 0.014 N 0.016 
A 0 0.1557 0 0.0399 N 0.043 N 0.033 N 0.033 N 0.060 N 0.016 
T 0 0.2356 0 0.0417 N 0.034 N 0.033 N 0.030 N 0.040 N 0.016 
M 0 0.1887 0 0.0406 N 0.032 N 0.024 N 0.031 N 0.022 N 0.016 
D 0 0.2516 0 0.0420 N 0.039 N 0.025 N 0.042 N 0.038 N 0.018 
F 0 0.3632 0 0.0414 N 0.026 N 0.015 N 0.027 N 0.015 N 0.015 
S 1 0.5018 0 0.0420 N 0.023 N 0.027 N 0.033 N 0.011 N 0.019 
T 0 0.4313 0 0.0416 N 0.031 N 0.034 N 0.030 N 0.030 N 0.017 
P 0 0.2912 0 0.0410 N 0.037 N 0.027 N 0.027 N 0.015 N 0.018 
S 0 0.3016 0 0.0405 N 0.025 N 0.023 N 0.045 N 0.029 N 0.013 
V 0 0.1961 0 0.0393 N 0.020 N 0.026 N 0.018 N 0.017 N 0.017 
F 0 0.2466 0 0.0395 N 0.032 N 0.020 N 0.021 N 0.012 N 0.015 
D 0 0.3975 0 0.0406 N 0.025 N 0.016 N 0.020 N 0.015 N 0.014 
Q 0 0.3233 0 0.0402 N 0.026 N 0.016 N 0.019 N 0.014 N 0.019 
Q 0 0.2170 0 0.0435 N 0.022 N 0.014 N 0.022 N 0.026 N 0.013 
R 0 0.4190 0 0.0450 N 0.023 N 0.026 N 0.030 N 0.025 N 0.017 
G 0 0.2052 0 0.0444 N 0.030 N 0.035 N 0.026 N 0.027 N 0.016 


































S 0 0.1915 0 0.0436 N 0.029 N 0.028 N 0.031 N 0.021 N 0.021 
S 0 0.1671 0 0.0431 N 0.026 N 0.024 N 0.034 N 0.019 N 0.019 
E 0 0.1322 0 0.0425 N 0.031 N 0.027 N 0.031 N 0.024 N 0.017 
E 0 0.1136 0 0.0424 N 0.036 N 0.032 N 0.028 N 0.023 N 0.020 
V 0 0.1281 0 0.0424 N 0.027 N 0.035 N 0.026 N 0.019 N 0.016 
D 0 0.1236 0 0.0579 N 0.029 N 0.020 N 0.031 N 0.049 N 0.021 
L 0 0.1023 0 0.0567 N 0.063 N 0.032 N 0.021 N 0.014 N 0.014 
T 0 0.1676 0 0.0583 N 0.035 N 0.024 N 0.034 B 0.077 N 0.021 
M 0 0.1131 0 0.0481 N 0.034 N 0.059 N 0.047 N 0.057 N 0.023 
V 0 0.0916 0 0.0473 N 0.036 N 0.039 N 0.038 N 0.033 N 0.026 
Y 0 0.2154 0 0.0501 N 0.056 N 0.046 N 0.044 N 0.060 N 0.029 
Q 0 0.1534 0 0.0493 N 0.050 N 0.037 N 0.030 N 0.021 N 0.022 
A 0 0.1287 0 0.0480 N 0.025 N 0.028 N 0.037 N 0.036 N 0.022 
A 0 0.1304 0 0.0487 N 0.027 N 0.022 N 0.035 N 0.031 N 0.020 
S 0 0.2208 0 0.0504 B 0.135 N 0.027 N 0.027 N 0.026 N 0.021 
N 0 0.3360 0 0.0507 B 0.129 N 0.027 N 0.023 N 0.028 N 0.018 
G 0 0.3106 0 0.0521 N 0.029 N 0.025 N 0.033 N 0.029 N 0.021 
D 0 0.2663 0 0.0515 N 0.027 N 0.026 N 0.028 N 0.028 N 0.017 
V 0 0.2056 0 0.0489 N 0.029 N 0.021 N 0.027 N 0.023 N 0.019 
N 0 0.2386 0 0.0500 N 0.025 N 0.020 N 0.028 N 0.023 N 0.016 
A 0 0.1345 0 0.0487 N 0.028 N 0.021 N 0.028 N 0.021 N 0.016 
L 0 0.0971 0 0.0481 N 0.029 N 0.029 N 0.034 N 0.022 N 0.016 
T 0 0.1451 0 0.0507 N 0.021 N 0.028 N 0.026 N 0.032 N 0.020 
A 0 0.1265 0 0.0519 N 0.023 N 0.022 N 0.027 N 0.017 N 0.016 


































I 0 0.0901 0 0.0551 N 0.025 N 0.019 N 0.014 N 0.020 N 0.010 
R 0 0.1825 0 0.0576 N 0.019 N 0.020 N 0.021 N 0.015 N 0.017 
E 0 0.1203 0 0.0636 N 0.029 N 0.021 N 0.026 N 0.026 N 0.015 
D 0 0.1098 0 0.0634 N 0.028 N 0.022 N 0.021 N 0.019 N 0.017 
P 0 0.1034 0 0.0626 N 0.029 N 0.021 N 0.024 N 0.027 N 0.018 
S 0 0.1117 0 0.0630 N 0.031 N 0.026 N 0.027 N 0.026 N 0.019 
I 0 0.0899 0 0.0615 N 0.033 N 0.027 N 0.029 N 0.020 N 0.020 
L 0 0.0876 0 0.0606 N 0.029 N 0.025 N 0.025 N 0.019 N 0.019 
E 0 0.1117 0 0.0630 N 0.031 N 0.032 N 0.030 N 0.026 N 0.020 
C 0 0.0987 0 0.0511 N 0.029 N 0.035 N 0.027 N 0.021 N 0.019 
C 0 0.1075 0 0.0513 N 0.041 N 0.023 N 0.033 N 0.018 N 0.018 
D 0 0.1339 0 0.0533 N 0.030 N 0.027 N 0.031 N 0.021 N 0.023 
S 0 0.1548 0 0.0527 N 0.035 N 0.027 N 0.025 N 0.022 N 0.016 
E 0 0.1739 0 0.0544 N 0.029 N 0.032 N 0.030 N 0.021 N 0.017 
G 0 0.1991 0 0.0538 N 0.027 N 0.034 N 0.033 N 0.068 N 0.026 
C 0 0.1813 0 0.0520 N 0.061 N 0.036 N 0.026 N 0.020 N 0.018 
T 0 0.2997 0 0.0544 N 0.033 N 0.038 N 0.036 N 0.050 N 0.030 
P 0 0.1264 0 0.0510 N 0.061 B 0.153 N 0.036 N 0.053 N 0.028 
L 0 0.0956 0 0.0370 N 0.031 N 0.062 N 0.036 N 0.034 N 0.031 
M 0 0.2082 0 0.0408 N 0.074 N 0.054 N 0.038 N 0.066 N 0.030 
H 0 0.2133 0 0.0387 N 0.046 N 0.038 N 0.032 N 0.028 N 0.023 
A 0 0.1353 0 0.0377 N 0.033 N 0.032 N 0.037 N 0.036 N 0.022 
V 0 0.1391 0 0.0380 N 0.028 N 0.020 N 0.035 N 0.028 N 0.020 
S 0 0.2713 0 0.0396 N 0.094 N 0.029 N 0.029 N 0.031 N 0.021 


































R 1 0.5380 0 0.0407 N 0.029 N 0.024 N 0.035 N 0.027 N 0.021 
Q 1 0.4985 0 0.0408 N 0.029 N 0.029 N 0.029 N 0.026 N 0.018 
A 0 0.3152 0 0.0389 N 0.030 N 0.024 N 0.027 N 0.023 N 0.019 
D 0 0.2738 0 0.0392 N 0.025 N 0.020 N 0.030 N 0.024 N 0.017 
T 0 0.1578 0 0.0384 N 0.029 N 0.035 N 0.031 N 0.025 N 0.018 
V 0 0.1156 0 0.0373 N 0.029 N 0.031 N 0.033 N 0.023 N 0.018 
K 0 0.2670 0 0.0394 N 0.023 N 0.029 N 0.031 N 0.032 N 0.023 
L 0 0.1247 0 0.0381 N 0.026 N 0.023 N 0.028 N 0.018 N 0.017 
L 0 0.0906 0 0.0389 N 0.029 N 0.026 N 0.027 N 0.027 N 0.014 
L 0 0.1002 0 0.0430 N 0.025 N 0.018 N 0.021 N 0.033 N 0.012 
K 0 0.2469 0 0.0457 N 0.025 N 0.029 N 0.028 N 0.019 N 0.018 
M 0 0.1848 0 0.0449 N 0.031 N 0.030 N 0.025 N 0.031 N 0.020 
G 0 0.2655 0 0.0461 N 0.030 N 0.023 N 0.022 N 0.037 N 0.018 
A 0 0.1703 0 0.0439 N 0.030 N 0.029 N 0.024 N 0.028 N 0.018 
N 0 0.3425 0 0.0396 N 0.024 N 0.024 N 0.031 N 0.038 N 0.024 
I 0 0.1781 0 0.0370 N 0.030 N 0.028 N 0.032 N 0.027 N 0.021 
N 0 0.4023 0 0.0394 N 0.032 N 0.034 N 0.036 N 0.031 N 0.019 
M 0 0.2137 0 0.0374 N 0.030 N 0.029 N 0.030 N 0.032 N 0.023 
Q 0 0.3082 0 0.0392 N 0.034 N 0.026 N 0.033 N 0.024 N 0.019 
D 0 0.3498 0 0.0398 N 0.031 N 0.020 N 0.030 N 0.025 N 0.019 
A 0 0.4037 0 0.0388 N 0.033 N 0.030 N 0.026 N 0.022 N 0.021 
Y 1 0.5458 0 0.0392 N 0.030 N 0.039 N 0.027 N 0.024 N 0.016 
G 0 0.3100 0 0.0390 N 0.030 N 0.059 N 0.033 N 0.060 N 0.023 
R 0 0.4123 0 0.0399 N 0.049 N 0.040 N 0.026 N 0.019 N 0.019 


































S 0 0.1567 0 0.0383 N 0.070 B 0.162 N 0.035 N 0.052 N 0.028 
L 0 0.1061 0 0.0364 N 0.031 N 0.063 N 0.035 N 0.034 N 0.029 
C 0 0.2287 0 0.0398 N 0.088 N 0.048 N 0.038 B 0.075 N 0.033 
L 0 0.1319 0 0.0372 N 0.046 N 0.033 N 0.031 N 0.028 N 0.023 
A 0 0.1190 0 0.0427 N 0.032 N 0.034 N 0.038 N 0.036 N 0.022 
T 0 0.1240 0 0.0444 N 0.030 N 0.025 N 0.034 N 0.029 N 0.019 
Y 0 0.2464 0 0.0449 B 0.100 N 0.028 N 0.027 N 0.027 N 0.020 
L 0 0.1622 0 0.0566 N 0.078 N 0.026 N 0.025 N 0.031 N 0.019 
G 0 0.2602 0 0.0583 N 0.027 N 0.027 N 0.045 N 0.030 N 0.020 
W 0 0.2341 0 0.0582 N 0.023 N 0.024 N 0.028 N 0.026 N 0.017 
L 0 0.1342 0 0.0553 N 0.027 N 0.020 N 0.025 N 0.025 N 0.019 
E 0 0.1658 0 0.0485 N 0.024 N 0.018 N 0.030 N 0.021 N 0.016 
G 0 0.1505 0 0.0475 N 0.027 N 0.031 N 0.029 N 0.023 N 0.016 
C 0 0.1127 0 0.0467 N 0.026 N 0.028 N 0.030 N 0.023 N 0.017 
V 0 0.1611 0 0.0475 N 0.023 N 0.028 N 0.030 N 0.029 N 0.022 
S 0 0.1750 0 0.0368 N 0.025 N 0.021 N 0.026 N 0.019 N 0.016 
L 0 0.1192 0 0.0350 N 0.026 N 0.020 N 0.025 N 0.025 N 0.014 
L 0 0.1231 0 0.0351 N 0.026 N 0.017 N 0.015 N 0.036 N 0.012 
R 0 0.3640 0 0.0372 N 0.024 N 0.024 N 0.029 N 0.019 N 0.017 
N 0 0.2973 0 0.0384 N 0.031 N 0.030 N 0.027 N 0.033 N 0.019 
G 0 0.2929 0 0.0389 N 0.032 N 0.024 N 0.019 N 0.033 N 0.017 
A 0 0.2073 0 0.0369 N 0.031 N 0.027 N 0.029 N 0.030 N 0.020 
K 1 0.5568 0 0.0428 N 0.026 N 0.023 N 0.030 N 0.032 N 0.021 
H 0 0.2382 0 0.0386 N 0.031 N 0.029 N 0.033 N 0.030 N 0.021 


































I 0 0.1944 0 0.0382 N 0.030 N 0.031 N 0.029 N 0.032 N 0.026 
P 0 0.2703 0 0.0403 N 0.037 N 0.029 N 0.031 N 0.021 N 0.018 
D 0 0.3733 0 0.0408 N 0.028 N 0.023 N 0.031 N 0.027 N 0.017 
K 0 0.4029 0 0.0403 N 0.031 N 0.028 N 0.027 N 0.021 N 0.020 
N 0 0.2414 0 0.0391 N 0.028 N 0.040 N 0.027 N 0.022 N 0.015 
G 0 0.2265 0 0.0486 N 0.029 N 0.038 N 0.033 N 0.059 N 0.024 
R 0 0.3035 0 0.0482 N 0.045 N 0.040 N 0.025 N 0.022 N 0.020 
L 0 0.2770 0 0.0478 N 0.032 N 0.038 N 0.036 N 0.058 N 0.029 
P 0 0.1219 0 0.0470 N 0.054 B 0.239 N 0.034 N 0.063 N 0.028 
L 0 0.0956 0 0.0444 N 0.038 N 0.061 N 0.032 N 0.037 N 0.028 
H 0 0.1990 0 0.0511 N 0.055 N 0.051 N 0.042 N 0.068 N 0.032 
A 0 0.1101 0 0.0537 N 0.044 N 0.040 N 0.035 N 0.035 N 0.023 
A 0 0.0985 0 0.0518 N 0.031 N 0.038 N 0.039 N 0.036 N 0.022 
T 0 0.0990 0 0.0523 N 0.031 N 0.019 N 0.034 N 0.027 N 0.020 
A 0 0.1375 0 0.0553 B 0.185 N 0.029 N 0.027 N 0.029 N 0.021 
E 0 0.1561 0 0.0624 B 0.189 N 0.027 N 0.023 N 0.031 N 0.019 
P 0 0.1352 0 0.0638 N 0.028 N 0.024 N 0.032 N 0.032 N 0.021 
D 0 0.1376 0 0.0628 N 0.025 N 0.025 N 0.027 N 0.028 N 0.016 
M 0 0.1072 0 0.0664 N 0.025 N 0.021 N 0.021 N 0.023 N 0.018 
R 0 0.1442 0 0.0678 N 0.026 N 0.020 N 0.028 N 0.022 N 0.015 
L 0 0.0960 0 0.0660 N 0.028 N 0.028 N 0.033 N 0.024 N 0.018 
L 0 0.0891 0 0.0653 N 0.030 N 0.032 N 0.032 N 0.023 N 0.017 
T 0 0.1114 0 0.0672 N 0.022 N 0.029 N 0.030 N 0.029 N 0.021 
V 0 0.0990 0 0.0673 N 0.022 N 0.017 N 0.023 N 0.018 N 0.014 


































L 0 0.0898 0 0.0648 N 0.025 N 0.019 N 0.017 N 0.018 N 0.011 
Q 0 0.1229 0 0.0680 N 0.026 N 0.027 N 0.020 N 0.020 N 0.018 
Q 0 0.1376 0 0.0641 N 0.035 N 0.028 N 0.027 N 0.021 N 0.019 
S 0 0.1297 0 0.0643 N 0.033 N 0.033 N 0.026 N 0.033 N 0.022 
N 0 0.1313 0 0.0634 N 0.029 N 0.029 N 0.023 N 0.021 N 0.018 
I 0 0.1386 0 0.0592 N 0.032 N 0.023 N 0.030 N 0.026 N 0.023 
S 0 0.1446 0 0.0561 N 0.035 N 0.016 N 0.037 N 0.042 N 0.023 
E 0 0.1565 0 0.0564 N 0.030 N 0.032 N 0.033 N 0.052 N 0.022 
I 0 0.1058 0 0.0546 N 0.034 N 0.047 N 0.029 N 0.027 N 0.021 
N 0 0.1839 0 0.0572 N 0.035 N 0.032 N 0.031 N 0.047 N 0.017 
H 0 0.1660 0 0.0564 N 0.029 N 0.030 N 0.027 N 0.021 N 0.019 
Q 0 0.1730 0 0.0576 N 0.041 N 0.035 N 0.033 N 0.026 N 0.019 
D 0 0.2142 0 0.0600 N 0.029 N 0.023 N 0.029 N 0.028 N 0.016 
N 0 0.2499 0 0.0597 N 0.029 N 0.029 N 0.028 N 0.021 N 0.021 
E 0 0.2075 0 0.0587 N 0.028 N 0.037 N 0.025 N 0.022 N 0.015 
G 0 0.1777 0 0.0574 N 0.029 N 0.040 N 0.033 N 0.071 N 0.020 
M 0 0.1794 0 0.0570 N 0.050 N 0.045 N 0.027 N 0.019 N 0.020 
T 0 0.2285 0 0.0577 N 0.031 N 0.038 N 0.036 N 0.051 N 0.030 
P 0 0.1058 0 0.0488 N 0.059 B 0.275 N 0.034 N 0.073 N 0.029 
L 0 0.0881 0 0.0473 N 0.041 N 0.069 N 0.033 N 0.038 N 0.030 
H 0 0.1554 0 0.0485 N 0.055 N 0.061 N 0.045 N 0.062 N 0.045 
W 0 0.1102 0 0.0469 N 0.037 N 0.035 N 0.037 N 0.040 N 0.023 
A 0 0.0988 0 0.0467 N 0.033 N 0.038 N 0.037 N 0.036 N 0.022 
A 0 0.1126 0 0.0475 N 0.030 N 0.022 N 0.036 N 0.029 N 0.020 


































H 0 0.3408 0 0.0518 B 0.127 N 0.027 N 0.025 N 0.030 N 0.018 
N 0 0.3168 0 0.0522 N 0.029 N 0.025 N 0.039 N 0.031 N 0.021 
Q 0 0.3642 0 0.0516 N 0.028 N 0.028 N 0.028 N 0.026 N 0.018 
P 0 0.2327 0 0.0492 N 0.028 N 0.021 N 0.025 N 0.024 N 0.019 
Q 0 0.2652 0 0.0486 N 0.025 N 0.019 N 0.030 N 0.022 N 0.017 
H 0 0.1839 0 0.0471 N 0.029 N 0.040 N 0.030 N 0.023 N 0.017 
T 0 0.1235 0 0.0467 N 0.031 N 0.030 N 0.031 N 0.023 N 0.017 
Q 0 0.1937 0 0.0485 N 0.023 N 0.028 N 0.030 N 0.032 N 0.022 
M 0 0.1194 0 0.0471 N 0.026 N 0.022 N 0.027 N 0.020 N 0.017 
L 0 0.0923 0 0.0458 N 0.027 N 0.023 N 0.025 N 0.027 N 0.015 
L 0 0.0962 0 0.0529 N 0.028 N 0.018 N 0.018 N 0.031 N 0.012 
K 0 0.1815 0 0.0557 N 0.022 N 0.025 N 0.025 N 0.021 N 0.017 
K 0 0.1902 0 0.0624 N 0.030 N 0.029 N 0.027 N 0.035 N 0.018 
G 0 0.1720 0 0.0628 N 0.032 N 0.023 N 0.020 N 0.032 N 0.018 
A 0 0.1163 0 0.0595 N 0.031 N 0.024 N 0.024 N 0.028 N 0.018 
D 0 0.2019 0 0.0621 N 0.027 N 0.025 N 0.031 N 0.033 N 0.022 
P 0 0.1282 0 0.0598 N 0.030 N 0.029 N 0.033 N 0.029 N 0.021 
T 0 0.1864 0 0.0609 N 0.030 N 0.032 N 0.035 N 0.031 N 0.018 
L 0 0.1221 0 0.0587 N 0.025 N 0.029 N 0.027 N 0.031 N 0.023 
V 0 0.1271 0 0.0596 N 0.039 N 0.032 N 0.031 N 0.019 N 0.018 
D 0 0.1463 0 0.0610 N 0.029 N 0.022 N 0.029 N 0.026 N 0.020 
K 0 0.2065 0 0.0566 N 0.031 N 0.031 N 0.028 N 0.018 N 0.025 
D 0 0.1394 0 0.0563 N 0.026 N 0.039 N 0.026 N 0.021 N 0.015 
F 0 0.1496 0 0.0558 N 0.029 N 0.034 N 0.032 N 0.058 N 0.027 


































T 0 0.2165 0 0.0553 N 0.033 N 0.033 N 0.036 N 0.055 N 0.032 
A 0 0.1158 0 0.0523 N 0.058 B 0.251 N 0.036 N 0.060 N 0.030 
L 0 0.0959 0 0.0506 N 0.037 N 0.060 N 0.034 N 0.040 N 0.030 
H 0 0.2455 0 0.0555 N 0.052 N 0.053 N 0.046 B 0.075 N 0.031 
W 0 0.1478 0 0.0518 N 0.038 N 0.041 N 0.033 N 0.033 N 0.023 
A 0 0.1241 0 0.0508 N 0.031 N 0.037 N 0.039 N 0.036 N 0.023 
V 0 0.1508 0 0.0515 N 0.033 N 0.025 N 0.035 N 0.029 N 0.020 
Q 0 0.2954 0 0.0557 B 0.162 N 0.029 N 0.027 N 0.028 N 0.021 
S 0 0.3059 0 0.0559 B 0.142 N 0.029 N 0.027 N 0.027 N 0.019 
G 0 0.2800 0 0.0557 N 0.028 N 0.026 N 0.038 N 0.029 N 0.020 
N 0 0.2753 0 0.0577 N 0.027 N 0.027 N 0.032 N 0.033 N 0.017 
R 0 0.3091 0 0.0548 N 0.028 N 0.023 N 0.026 N 0.028 N 0.020 
I 0 0.1900 0 0.0539 N 0.023 N 0.018 N 0.031 N 0.022 N 0.017 
L 0 0.1231 0 0.0523 N 0.028 N 0.031 N 0.031 N 0.023 N 0.016 
C 0 0.0994 0 0.0523 N 0.028 N 0.027 N 0.033 N 0.024 N 0.017 
S 0 0.1425 0 0.0540 N 0.023 N 0.028 N 0.028 N 0.030 N 0.020 
I 0 0.1061 0 0.0526 N 0.028 N 0.019 N 0.024 N 0.021 N 0.014 
I 0 0.0895 0 0.0514 N 0.020 N 0.016 N 0.026 N 0.016 N 0.012 
L 0 0.1014 0 0.0516 N 0.025 N 0.019 N 0.021 N 0.024 N 0.013 
S 0 0.2073 0 0.0613 N 0.021 N 0.019 N 0.026 N 0.015 N 0.019 
H 0 0.2351 0 0.0625 N 0.030 N 0.024 N 0.029 N 0.017 N 0.014 
H 0 0.2410 0 0.0613 N 0.023 N 0.021 N 0.025 N 0.009 N 0.015 
Q 0 0.1563 0 0.0591 N 0.026 N 0.026 N 0.016 N 0.020 N 0.017 
G 0 0.1902 0 0.0599 N 0.026 N 0.014 N 0.021 N 0.024 N 0.014 


































S 0 0.1621 0 0.0586 N 0.020 N 0.036 N 0.023 N 0.028 N 0.013 
I 0 0.1332 0 0.0564 N 0.016 N 0.020 N 0.022 N 0.015 N 0.014 
I 0 0.1214 0 0.0562 N 0.020 N 0.034 N 0.030 N 0.022 N 0.019 
N 0 0.1542 0 0.0504 N 0.023 N 0.031 N 0.036 N 0.049 N 0.015 
Y 0 0.1531 0 0.0487 N 0.029 N 0.020 N 0.028 N 0.024 N 0.017 
D 0 0.1525 0 0.0500 N 0.030 N 0.018 N 0.034 N 0.015 N 0.021 
D 0 0.1839 0 0.0507 N 0.028 N 0.021 N 0.026 N 0.033 N 0.015 
E 0 0.2100 0 0.0499 N 0.031 N 0.029 N 0.028 N 0.023 N 0.020 
S 0 0.2005 0 0.0498 N 0.027 N 0.032 N 0.026 N 0.023 N 0.015 
G 0 0.2168 0 0.0497 N 0.030 N 0.045 N 0.033 N 0.066 N 0.022 
K 0 0.3493 0 0.0503 N 0.072 N 0.040 N 0.027 N 0.021 N 0.022 
T 0 0.3346 0 0.0507 N 0.032 N 0.036 N 0.037 N 0.046 N 0.028 
C 0 0.1443 0 0.0486 N 0.047 B 0.266 N 0.036 N 0.072 N 0.029 
V 0 0.1014 0 0.0470 N 0.032 N 0.063 N 0.033 N 0.036 N 0.029 
H 0 0.2583 0 0.0519 N 0.048 N 0.055 N 0.039 N 0.059 N 0.041 
I 0 0.1254 0 0.0483 N 0.037 N 0.039 N 0.035 N 0.039 N 0.023 
A 0 0.1182 0 0.0479 N 0.032 N 0.035 N 0.038 N 0.035 N 0.022 
A 0 0.1240 0 0.0480 N 0.034 N 0.023 N 0.036 N 0.029 N 0.021 
A 0 0.2600 0 0.0507 B 0.202 N 0.031 N 0.028 N 0.027 N 0.021 
A 0 0.2557 0 0.0556 B 0.169 N 0.028 N 0.024 N 0.029 N 0.019 
G 0 0.2469 0 0.0564 N 0.026 N 0.027 N 0.038 N 0.032 N 0.020 
F 0 0.2060 0 0.0555 N 0.026 N 0.026 N 0.031 N 0.027 N 0.017 
S 0 0.1426 0 0.0560 N 0.026 N 0.019 N 0.023 N 0.022 N 0.018 
D 0 0.1317 0 0.0559 N 0.027 N 0.016 N 0.030 N 0.021 N 0.016 


































I 0 0.0978 0 0.0535 N 0.030 N 0.027 N 0.032 N 0.019 N 0.016 
H 0 0.1550 0 0.0572 N 0.020 N 0.023 N 0.022 N 0.026 N 0.016 
E 0 0.0969 0 0.0561 N 0.029 N 0.032 N 0.024 N 0.019 N 0.017 
L 0 0.0833 0 0.0588 N 0.023 N 0.018 N 0.034 N 0.022 N 0.014 
A 0 0.0906 0 0.0645 N 0.023 N 0.029 N 0.018 N 0.024 N 0.018 
R 0 0.1488 0 0.0682 N 0.034 N 0.022 N 0.021 N 0.018 N 0.019 
V 0 0.1137 0 0.0659 N 0.031 N 0.022 N 0.038 N 0.019 N 0.018 
P 0 0.1161 0 0.0672 N 0.028 N 0.024 N 0.028 N 0.018 N 0.019 
E 0 0.1193 0 0.0668 N 0.026 N 0.021 N 0.030 N 0.039 N 0.018 
C 0 0.1020 0 0.0663 N 0.030 N 0.031 N 0.028 N 0.037 N 0.019 
N 0 0.1178 0 0.0679 N 0.030 N 0.025 N 0.029 N 0.028 N 0.023 
L 0 0.0906 0 0.0654 N 0.030 N 0.033 N 0.034 N 0.020 N 0.021 
Q 0 0.1230 0 0.0585 N 0.031 N 0.032 N 0.034 N 0.043 N 0.018 
A 0 0.1057 0 0.0548 N 0.025 N 0.036 N 0.028 N 0.044 N 0.020 
L 0 0.1092 0 0.0546 N 0.037 N 0.033 N 0.033 N 0.021 N 0.018 
D 0 0.1319 0 0.0562 N 0.030 N 0.023 N 0.030 N 0.029 N 0.017 
V 0 0.1405 0 0.0553 N 0.028 N 0.028 N 0.026 N 0.021 N 0.021 
D 0 0.1398 0 0.0560 N 0.026 N 0.034 N 0.030 N 0.029 N 0.016 
D 0 0.1311 0 0.0564 N 0.029 N 0.034 N 0.033 N 0.057 N 0.028 
R 0 0.2238 0 0.0567 N 0.040 N 0.037 N 0.024 N 0.025 N 0.018 
T 0 0.2476 0 0.0575 N 0.035 N 0.037 N 0.036 N 0.062 N 0.030 
P 0 0.1162 0 0.0558 N 0.054 B 0.210 N 0.035 N 0.059 N 0.028 
L 0 0.0923 0 0.0539 N 0.051 N 0.062 N 0.038 N 0.042 N 0.034 
H 0 0.2316 0 0.0559 N 0.060 N 0.056 N 0.042 N 0.067 N 0.032 


































A 0 0.1055 0 0.0513 N 0.034 N 0.044 N 0.039 N 0.036 N 0.022 
A 0 0.1115 0 0.0524 N 0.031 N 0.022 N 0.036 N 0.027 N 0.020 
A 0 0.1587 0 0.0538 B 0.145 N 0.029 N 0.026 N 0.027 N 0.021 
A 0 0.1808 0 0.0541 B 0.147 N 0.025 N 0.025 N 0.032 N 0.018 
G 0 0.2303 0 0.0545 N 0.028 N 0.024 N 0.035 N 0.033 N 0.021 
K 0 0.2876 0 0.0552 N 0.028 N 0.028 N 0.029 N 0.028 N 0.017 
A 0 0.1524 0 0.0526 N 0.030 N 0.023 N 0.025 N 0.023 N 0.019 
E 0 0.1937 0 0.0532 N 0.026 N 0.020 N 0.031 N 0.023 N 0.016 
C 0 0.1254 0 0.0516 N 0.030 N 0.034 N 0.031 N 0.026 N 0.017 
V 0 0.1113 0 0.0513 N 0.031 N 0.032 N 0.031 N 0.026 N 0.018 
Q 0 0.1492 0 0.0524 N 0.024 N 0.030 N 0.031 N 0.031 N 0.022 
S 0 0.1033 0 0.0515 N 0.024 N 0.020 N 0.027 N 0.019 N 0.016 
L 0 0.0860 0 0.0503 N 0.031 N 0.021 N 0.026 N 0.027 N 0.014 
L 0 0.0934 0 0.0557 N 0.028 N 0.020 N 0.018 N 0.032 N 0.013 
E 0 0.1376 0 0.0577 N 0.026 N 0.026 N 0.026 N 0.022 N 0.019 
L 0 0.1432 0 0.0582 N 0.032 N 0.028 N 0.027 N 0.031 N 0.019 
G 0 0.1418 0 0.0581 N 0.035 N 0.028 N 0.024 N 0.038 N 0.019 
M 0 0.1081 0 0.0563 N 0.031 N 0.024 N 0.025 N 0.028 N 0.019 
D 0 0.1613 0 0.0592 N 0.026 N 0.025 N 0.030 N 0.034 N 0.023 
S 0 0.1207 0 0.0578 N 0.029 N 0.029 N 0.033 N 0.029 N 0.021 
N 0 0.2208 0 0.0598 N 0.031 N 0.030 N 0.033 N 0.030 N 0.019 
L 0 0.1228 0 0.0527 N 0.025 N 0.028 N 0.027 N 0.036 N 0.023 
R 0 0.2000 0 0.0540 N 0.037 N 0.026 N 0.033 N 0.023 N 0.019 
D 0 0.2152 0 0.0547 N 0.030 N 0.028 N 0.030 N 0.029 N 0.019 


































N 0 0.1906 0 0.0549 N 0.027 N 0.035 N 0.027 N 0.028 N 0.015 
E 0 0.1834 0 0.0543 N 0.034 N 0.037 N 0.035 N 0.060 N 0.024 
S 0 0.1688 0 0.0538 N 0.042 N 0.036 N 0.025 N 0.023 N 0.019 
T 0 0.2692 0 0.0480 N 0.036 N 0.032 N 0.037 N 0.054 N 0.028 
P 0 0.1340 0 0.0465 N 0.057 B 0.204 N 0.034 N 0.052 N 0.028 
L 0 0.0941 0 0.0451 N 0.040 N 0.068 N 0.036 N 0.036 N 0.028 
A 0 0.1777 0 0.0477 N 0.080 N 0.052 N 0.039 B 0.076 N 0.029 
Y 0 0.1390 0 0.0462 N 0.044 N 0.033 N 0.032 N 0.033 N 0.023 
A 0 0.1100 0 0.0456 N 0.040 N 0.034 N 0.039 N 0.035 N 0.022 
L 0 0.1281 0 0.0464 N 0.031 N 0.027 N 0.035 N 0.028 N 0.019 
Y 0 0.3624 0 0.0479 B 0.125 N 0.030 N 0.028 N 0.031 N 0.021 
C 0 0.2689 0 0.0485 B 0.123 N 0.027 N 0.027 N 0.030 N 0.019 
G 0 0.2845 0 0.0492 N 0.031 N 0.026 N 0.048 N 0.034 N 0.021 
H 0 0.3635 0 0.0495 N 0.027 N 0.026 N 0.031 N 0.037 N 0.017 
T 0 0.2049 0 0.0485 N 0.024 N 0.023 N 0.023 N 0.026 N 0.019 
A 0 0.1871 0 0.0482 N 0.025 N 0.020 N 0.030 N 0.022 N 0.016 
C 0 0.1248 0 0.0474 N 0.029 N 0.035 N 0.032 N 0.025 N 0.018 
V 0 0.1313 0 0.0467 N 0.028 N 0.030 N 0.033 N 0.024 N 0.018 
K 0 0.3383 0 0.0491 N 0.023 N 0.030 N 0.031 N 0.032 N 0.021 
L 0 0.1102 0 0.0467 N 0.027 N 0.021 N 0.023 N 0.019 N 0.016 
L 0 0.0901 0 0.0456 N 0.027 N 0.013 N 0.026 N 0.021 N 0.015 
S 0 0.1215 0 0.0474 N 0.020 N 0.013 N 0.014 N 0.014 N 0.013 
Q 0 0.1780 0 0.0514 N 0.022 N 0.017 N 0.030 N 0.010 N 0.019 
E 0 0.1434 0 0.0501 N 0.028 N 0.020 N 0.034 N 0.022 N 0.016 


































R 0 0.2187 0 0.0506 N 0.032 N 0.024 N 0.023 N 0.029 N 0.018 
T 0 0.1836 0 0.0600 N 0.020 N 0.017 N 0.027 N 0.021 N 0.017 
E 0 0.1469 0 0.0566 N 0.028 N 0.025 N 0.030 N 0.021 N 0.019 
P 0 0.1608 0 0.0610 N 0.022 N 0.025 N 0.026 N 0.022 N 0.019 
T 0 0.1483 0 0.0539 N 0.024 N 0.026 N 0.030 N 0.016 N 0.018 
R 0 0.2312 0 0.0558 N 0.029 N 0.024 N 0.029 N 0.014 N 0.020 
P 0 0.1726 0 0.0529 N 0.021 N 0.028 N 0.026 N 0.013 N 0.029 
P 0 0.1736 0 0.0513 N 0.037 N 0.030 N 0.029 N 0.016 N 0.020 
P 0 0.2472 0 0.0546 N 0.020 N 0.031 N 0.028 N 0.012 N 0.026 
S 0 0.2884 0 0.0577 N 0.040 N 0.027 N 0.032 N 0.030 N 0.020 
Q 0 0.2388 0 0.0560 N 0.024 N 0.026 N 0.034 N 0.030 N 0.014 
S 0 0.3872 0 0.0522 N 0.029 N 0.047 N 0.035 N 0.037 N 0.046 
S 0 0.2420 0 0.0495 N 0.042 N 0.033 N 0.035 N 0.037 N 0.071 
R 0 0.4087 0 0.0488 N 0.068 N 0.034 N 0.045 N 0.026 N 0.021 
P 0 0.1716 0 0.0474 N 0.030 N 0.037 N 0.031 N 0.021 N 0.020 
Q 0 0.1595 0 0.0471 N 0.036 N 0.032 N 0.033 N 0.054 N 0.020 
K 0 0.2281 0 0.0479 N 0.030 N 0.034 N 0.029 N 0.034 N 0.013 
K 0 0.2593 0 0.0497 N 0.029 N 0.024 N 0.029 N 0.024 N 0.011 
E 0 0.1661 0 0.0472 N 0.031 N 0.020 N 0.027 N 0.015 N 0.016 
R 0 0.3077 0 0.0451 N 0.032 N 0.025 N 0.028 N 0.017 N 0.015 
R 0 0.2532 0 0.0450 N 0.020 N 0.030 N 0.056 N 0.017 N 0.018 
F 0 0.1545 0 0.0508 N 0.021 N 0.014 N 0.020 N 0.014 N 0.014 
N 0 0.2557 0 0.0530 N 0.024 N 0.018 N 0.030 N 0.023 N 0.014 
V 0 0.1741 0 0.0511 N 0.027 N 0.024 N 0.036 N 0.016 N 0.015 


































N 0 0.1961 0 0.0514 N 0.019 N 0.023 N 0.019 N 0.028 N 0.017 
Q 0 0.2291 0 0.0520 N 0.023 N 0.017 N 0.021 N 0.016 N 0.014 
I 0 0.1312 0 0.0500 N 0.024 N 0.018 N 0.016 N 0.011 N 0.009 
F 0 0.1361 0 0.0506 N 0.030 N 0.022 N 0.018 N 0.012 N 0.013 
C 0 0.2191 0 0.0530 N 0.021 N 0.018 N 0.019 N 0.009 N 0.016 
K 0 0.3025 0 0.0533 N 0.023 N 0.021 N 0.019 N 0.018 N 0.015 
N 0 0.1774 0 0.0521 N 0.032 N 0.022 N 0.022 N 0.013 N 0.018 
K 0 0.2521 0 0.0522 N 0.028 N 0.021 N 0.023 N 0.013 N 0.010 
K 0 0.2899 0 0.0534 N 0.023 N 0.019 N 0.028 N 0.016 N 0.015 
E 0 0.1494 0 0.0492 N 0.036 N 0.041 N 0.029 N 0.022 N 0.015 
E 0 0.1313 0 0.0491 N 0.024 N 0.034 N 0.029 N 0.021 N 0.016 
Q 0 0.2065 0 0.0511 N 0.022 N 0.024 N 0.036 N 0.013 N 0.011 
R 0 0.2431 0 0.0509 N 0.026 N 0.026 N 0.027 N 0.008 N 0.008 
A 0 0.1296 0 0.0492 N 0.027 N 0.023 N 0.035 N 0.020 N 0.017 
H 0 0.2437 0 0.0532 N 0.032 N 0.033 N 0.027 N 0.014 N 0.012 
Q 0 0.1642 0 0.0549 N 0.029 N 0.017 N 0.019 N 0.011 N 0.013 
K 0 0.3189 0 0.0605 N 0.035 N 0.024 N 0.027 N 0.010 N 0.019 
D 0 0.1691 0 0.0554 N 0.023 N 0.020 N 0.023 N 0.023 N 0.015 
P 0 0.1718 0 0.0551 N 0.028 N 0.030 N 0.024 N 0.012 N 0.019 
S 0 0.1746 0 0.0544 N 0.024 N 0.013 N 0.019 N 0.014 N 0.037 
R 0 0.2080 0 0.0555 N 0.020 N 0.046 N 0.030 N 0.028 N 0.031 
D 0 0.1356 0 0.0558 N 0.026 N 0.039 N 0.026 N 0.032 N 0.050 
R 0 0.1598 0 0.0547 N 0.027 N 0.033 N 0.034 N 0.033 N 0.026 
Y 0 0.1434 0 0.0509 N 0.032 N 0.046 N 0.022 N 0.033 N 0.016 


































E 0 0.1095 0 0.0605 N 0.025 N 0.026 N 0.033 N 0.044 N 0.012 
E 0 0.0998 0 0.0601 N 0.043 N 0.026 N 0.022 N 0.031 N 0.009 
D 0 0.1019 0 0.0602 N 0.026 N 0.021 N 0.021 N 0.025 N 0.012 
T 0 0.1125 0 0.0672 N 0.027 N 0.018 N 0.026 N 0.011 N 0.013 
S 0 0.1077 0 0.0663 N 0.027 N 0.021 N 0.023 N 0.015 N 0.014 
E 0 0.1033 0 0.0687 N 0.018 N 0.020 N 0.020 N 0.015 N 0.014 
V 0 0.0935 0 0.0698 N 0.031 N 0.019 N 0.022 N 0.018 N 0.013 
N 0 0.1151 0 0.0643 N 0.029 N 0.011 N 0.018 N 0.015 N 0.013 
D 0 0.1292 0 0.0573 N 0.027 N 0.031 N 0.026 N 0.021 N 0.016 
I 0 0.0975 0 0.0555 N 0.017 N 0.030 N 0.032 N 0.024 N 0.018 
I 0 0.0945 0 0.0552 N 0.027 N 0.031 N 0.024 N 0.025 N 0.017 
T 0 0.1136 0 0.0562 N 0.025 N 0.019 N 0.026 N 0.017 N 0.012 
T 0 0.1017 0 0.0565 N 0.034 N 0.024 N 0.023 N 0.016 N 0.011 
F 0 0.1211 0 0.0529 N 0.022 N 0.013 N 0.025 N 0.018 N 0.012 
D 0 0.1783 0 0.0545 N 0.021 N 0.018 N 0.019 N 0.018 N 0.016 
S 0 0.2399 0 0.0535 N 0.028 N 0.021 N 0.028 N 0.018 N 0.016 
I 0 0.1987 0 0.0521 N 0.030 N 0.022 N 0.028 N 0.016 N 0.017 
V 0 0.1536 0 0.0523 N 0.031 N 0.029 N 0.030 N 0.022 N 0.019 
G 0 0.1979 0 0.0536 N 0.021 N 0.019 N 0.030 N 0.020 N 0.020 
T 0 0.1374 0 0.0527 N 0.031 N 0.027 N 0.032 N 0.026 N 0.021 
N 0 0.2619 0 0.0546 N 0.023 N 0.022 N 0.030 N 0.028 N 0.020 
C 0 0.1387 0 0.0475 N 0.027 N 0.025 N 0.029 N 0.017 N 0.019 
Q 0 0.2761 0 0.0490 N 0.035 N 0.023 N 0.030 N 0.024 N 0.015 
E 0 0.1731 0 0.0479 N 0.024 N 0.027 N 0.027 N 0.020 N 0.019 


































P 0 0.1745 0 0.0481 N 0.025 N 0.035 N 0.025 N 0.016 N 0.016 
G 0 0.2091 0 0.0487 N 0.032 N 0.041 N 0.034 N 0.050 N 0.015 
D 0 0.1907 0 0.0487 N 0.054 N 0.035 N 0.020 N 0.013 N 0.017 
Q 0 0.3463 0 0.0506 N 0.032 N 0.035 N 0.034 N 0.039 N 0.015 
V 0 0.1391 0 0.0458 N 0.028 N 0.060 N 0.030 N 0.036 N 0.021 
A 0 0.1060 0 0.0375 N 0.041 N 0.054 N 0.045 N 0.032 N 0.022 
M 0 0.1314 0 0.0394 N 0.071 N 0.062 N 0.036 N 0.072 N 0.023 
V 0 0.0940 0 0.0376 N 0.060 N 0.029 N 0.033 N 0.030 N 0.022 
E 0 0.1154 0 0.0390 N 0.031 N 0.027 N 0.036 N 0.032 N 0.021 
F 0 0.1175 0 0.0391 N 0.028 N 0.026 N 0.032 N 0.022 N 0.015 
K 0 0.2818 0 0.0405 N 0.034 N 0.029 N 0.025 N 0.024 N 0.016 
K 0 0.3919 0 0.0408 N 0.061 N 0.021 N 0.022 N 0.023 N 0.017 
K 1 0.5325 0 0.0423 N 0.032 N 0.023 N 0.049 N 0.025 N 0.020 
T 0 0.4565 0 0.0422 N 0.032 N 0.027 N 0.029 N 0.024 N 0.017 
S 0 0.3848 0 0.0431 N 0.027 N 0.021 N 0.027 N 0.021 N 0.018 
D 0 0.2867 0 0.0439 N 0.025 N 0.017 N 0.029 N 0.022 N 0.016 
N 0 0.2181 0 0.0445 N 0.030 N 0.034 N 0.033 N 0.024 N 0.017 
S 0 0.1632 0 0.0424 N 0.033 N 0.033 N 0.032 N 0.023 N 0.018 
K 0 0.2515 0 0.0467 N 0.025 N 0.029 N 0.032 N 0.031 N 0.022 
Y 0 0.1772 0 0.0467 N 0.029 N 0.023 N 0.025 N 0.017 N 0.017 
L 0 0.0849 0 0.0436 N 0.023 N 0.019 N 0.026 N 0.025 N 0.014 
L 0 0.0926 0 0.0491 N 0.026 N 0.020 N 0.020 N 0.024 N 0.014 
P 0 0.1498 0 0.0675 N 0.024 N 0.023 N 0.031 N 0.017 N 0.018 
E 0 0.1405 0 0.0706 N 0.029 N 0.026 N 0.027 N 0.029 N 0.020 


































K 0 0.1138 0 0.0544 N 0.032 N 0.019 N 0.024 N 0.030 N 0.017 
P 0 0.1240 0 0.0583 N 0.026 N 0.022 N 0.029 N 0.027 N 0.022 
L 0 0.1560 0 0.0612 N 0.032 N 0.032 N 0.031 N 0.020 N 0.019 
A 0 0.1606 0 0.0607 N 0.031 N 0.030 N 0.029 N 0.033 N 0.019 
R 0 0.2663 0 0.0506 N 0.028 N 0.024 N 0.025 N 0.014 N 0.020 
K 0 0.2565 0 0.0502 N 0.026 N 0.019 N 0.026 N 0.017 N 0.018 
G 0 0.2338 0 0.0506 N 0.015 N 0.029 N 0.020 N 0.012 N 0.032 
L 0 0.1304 0 0.0434 N 0.021 N 0.021 N 0.025 N 0.014 N 0.015 
P 0 0.2450 0 0.0499 N 0.023 N 0.018 N 0.016 N 0.009 N 0.010 
P 0 0.2042 0 0.0486 N 0.013 N 0.014 N 0.022 N 0.011 N 0.006 
I 0 0.1262 0 0.0414 N 0.013 N 0.016 N 0.017 N 0.015 N 0.007 
R 1 0.4811 0 0.0539 N 0.024 N 0.021 N 0.022 N 0.028 N 0.011 
T 0 0.3826 0 0.0494 N 0.049 N 0.037 N 0.030 N 0.021 N 0.020 
Q 0 0.2083 0 0.0437 N 0.030 N 0.027 N 0.026 N 0.069 N 0.014 
S 0 0.2132 0 0.0428 N 0.037 N 0.021 N 0.029 N 0.034 N 0.015 
L 0 0.0957 0 0.0358 N 0.020 N 0.024 N 0.028 N 0.032 N 0.009 
P 0 0.1670 0 0.0401 N 0.028 N 0.017 N 0.028 N 0.017 N 0.010 
P 0 0.1465 0 0.0396 N 0.028 N 0.024 N 0.024 N 0.027 N 0.010 
I 0 0.1101 0 0.0392 N 0.023 N 0.027 N 0.021 N 0.027 N 0.010 
T 0 0.4036 0 0.0392 N 0.030 N 0.018 N 0.028 N 0.019 N 0.009 
L 0 0.3820 0 0.0381 N 0.029 N 0.016 N 0.031 N 0.017 N 0.015 
G 0 0.3619 0 0.0334 N 0.025 N 0.023 N 0.035 N 0.023 N 0.020 
N 1 0.5579 0 0.0353 N 0.038 N 0.025 N 0.028 N 0.018 N 0.024 
N 0 0.3566 0 0.0314 N 0.026 N 0.041 N 0.029 N 0.015 N 0.011 


































L 0 0.1522 0 0.0290 N 0.056 N 0.051 N 0.038 N 0.013 N 0.016 
T 1 0.5703 0 0.0321 N 0.034 N 0.025 N 0.038 N 0.053 N 0.026 
A 0 0.3052 0 0.0289 N 0.055 B 0.161 N 0.040 N 0.042 N 0.026 
S 1 0.7072 0 0.0317 N 0.059 N 0.056 N 0.041 N 0.032 N 0.031 
H 1 0.7067 0 0.0325 B 0.112 N 0.088 N 0.037 N 0.066 N 0.038 
R 1 0.7105 0 0.0320 B 0.120 N 0.024 N 0.025 N 0.014 N 0.023 
A 0 0.2623 0 0.0291 N 0.027 N 0.028 N 0.034 N 0.033 N 0.020 
T 1 0.6075 0 0.0318 N 0.038 N 0.025 N 0.030 N 0.021 N 0.015 
S 1 0.5098 0 0.0329 N 0.065 N 0.029 N 0.026 N 0.023 N 0.017 
H 1 0.7260 0 0.0335 B 0.104 N 0.023 N 0.021 N 0.028 N 0.017 
A 0 0.3480 0 0.0298 N 0.035 N 0.022 N 0.035 N 0.026 N 0.016 
G 0 0.2524 0 0.0300 N 0.020 N 0.022 N 0.028 N 0.021 N 0.015 
L 0 0.2343 0 0.0295 N 0.026 N 0.013 N 0.018 N 0.017 N 0.015 
S 1 0.5036 0 0.0331 N 0.018 N 0.016 N 0.026 N 0.018 N 0.013 
S 1 0.4933 0 0.0334 N 0.026 N 0.024 N 0.035 N 0.018 N 0.014 
A 0 0.3340 0 0.0304 N 0.024 N 0.024 N 0.037 N 0.022 N 0.017 
P 0 0.2280 0 0.0308 N 0.023 N 0.025 N 0.027 N 0.032 N 0.019 
H 0 0.2769 0 0.0351 N 0.019 N 0.026 N 0.026 N 0.016 N 0.016 
H 1 0.6196 0 0.0420 N 0.021 N 0.020 N 0.024 N 0.022 N 0.012 
M 0 0.3242 0 0.0367 N 0.021 N 0.013 N 0.016 N 0.024 N 0.010 
A 0 0.1598 0 0.0313 N 0.027 N 0.020 N 0.024 N 0.016 N 0.016 
Q 0 0.3476 0 0.0358 N 0.025 N 0.020 N 0.025 N 0.019 N 0.015 
R 1 0.6162 0 0.0341 N 0.035 N 0.027 N 0.019 N 0.023 N 0.016 
S 1 0.5977 0 0.0345 N 0.031 N 0.017 N 0.025 N 0.025 N 0.015 


































K 1 0.6683 0 0.0360 N 0.025 N 0.028 N 0.030 N 0.021 N 0.019 
S 1 0.6649 0 0.0355 N 0.022 N 0.023 N 0.028 N 0.021 N 0.019 
R 1 0.6931 0 0.0349 N 0.025 N 0.028 N 0.031 N 0.014 N 0.020 
S 0 0.4642 0 0.0350 N 0.031 N 0.025 N 0.035 N 0.021 N 0.015 
E 0 0.1156 0 0.0309 N 0.032 N 0.026 N 0.029 N 0.032 N 0.025 
Q 0 0.2881 0 0.0362 N 0.046 N 0.039 N 0.036 N 0.045 N 0.020 
D 0 0.1759 0 0.0345 N 0.022 N 0.023 N 0.024 N 0.024 N 0.025 
L 0 0.0946 0 0.0305 N 0.036 N 0.026 N 0.033 N 0.012 N 0.018 
L 0 0.1260 0 0.0312 N 0.028 N 0.021 N 0.034 N 0.015 N 0.016 
N 0 0.3410 0 0.0336 N 0.023 N 0.031 N 0.025 N 0.013 N 0.015 
N 0 0.3818 0 0.0392 N 0.030 N 0.023 N 0.027 N 0.015 N 0.027 
R 1 0.5902 0 0.0399 N 0.026 N 0.015 N 0.045 N 0.012 N 0.011 
T 0 0.4725 0 0.0380 N 0.032 N 0.032 N 0.033 N 0.017 N 0.019 
G 0 0.4431 0 0.0381 N 0.026 N 0.021 N 0.034 N 0.016 N 0.024 
C 0 0.1291 0 0.0367 N 0.034 N 0.029 N 0.030 N 0.018 N 0.026 
Q 0 0.2728 0 0.0373 N 0.024 N 0.040 N 0.031 N 0.027 N 0.021 
M 0 0.1872 0 0.0330 N 0.025 N 0.024 N 0.020 N 0.021 N 0.015 
L 0 0.1004 0 0.0321 N 0.033 N 0.020 N 0.039 N 0.026 N 0.014 
L 0 0.0948 0 0.0320 N 0.022 N 0.012 N 0.018 N 0.016 N 0.010 
D 0 0.1645 0 0.0347 N 0.021 N 0.025 N 0.019 N 0.015 N 0.014 
N 0 0.2939 0 0.0353 N 0.024 N 0.023 N 0.021 N 0.013 N 0.019 
P 0 0.1565 0 0.0342 N 0.026 N 0.028 N 0.024 N 0.014 N 0.015 
W 0 0.4272 0 0.0335 N 0.026 N 0.025 N 0.020 N 0.017 N 0.016 
K 1 0.6468 0 0.0357 N 0.026 N 0.043 N 0.020 N 0.017 N 0.013 


































D 0 0.2152 0 0.0330 N 0.024 N 0.024 N 0.025 N 0.016 N 0.011 
S 0 0.4308 0 0.0332 N 0.043 N 0.019 N 0.037 N 0.024 N 0.013 
N 1 0.5911 0 0.0341 N 0.015 N 0.017 N 0.017 N 0.023 N 0.041 
Q 1 0.5134 0 0.0341 N 0.017 N 0.014 N 0.021 N 0.020 N 0.025 
V 0 0.1469 0 0.0317 N 0.037 N 0.019 N 0.030 N 0.011 N 0.014 
F 0 0.1616 0 0.0325 N 0.026 N 0.034 N 0.042 N 0.037 N 0.018 
S 0 0.4358 0 0.0373 N 0.026 N 0.024 N 0.036 N 0.017 N 0.014 
Y 0 0.2063 0 0.0372 N 0.021 N 0.029 N 0.026 N 0.024 N 0.024 
K 1 0.5171 0 0.0370 N 0.026 N 0.030 N 0.031 N 0.023 N 0.025 
V 0 0.1478 0 0.0345 N 0.016 N 0.029 N 0.042 N 0.029 N 0.028 
W 1 0.5383 0 0.0373 N 0.013 N 0.027 N 0.029 N 0.025 N 0.016 
T 1 0.5095 0 0.0384 N 0.025 N 0.022 N 0.034 N 0.017 N 0.016 
V 0 0.2221 0 0.0366 N 0.019 N 0.024 N 0.032 N 0.014 N 0.016 
S 0 0.4567 0 0.0390 N 0.020 N 0.024 N 0.025 N 0.017 N 0.020 
S 0 0.3740 0 0.0393 N 0.014 N 0.024 N 0.033 N 0.018 N 0.017 
S 0 0.3084 0 0.0386 N 0.019 N 0.022 N 0.027 N 0.009 N 0.013 
D 0 0.2038 0 0.0387 N 0.023 N 0.028 N 0.014 N 0.028 N 0.015 
K 1 0.4995 0 0.0413 N 0.025 N 0.027 N 0.031 N 0.016 N 0.012 
L 0 0.1054 0 0.0374 N 0.031 N 0.012 N 0.029 N 0.021 N 0.010 
L 0 0.0925 0 0.0377 N 0.016 N 0.047 N 0.022 N 0.026 N 0.009 
D 0 0.1322 0 0.0411 N 0.033 N 0.019 N 0.023 N 0.014 N 0.030 
R 0 0.2523 0 0.0409 N 0.017 N 0.022 N 0.018 N 0.017 N 0.040 
L 0 0.0898 0 0.0372 N 0.020 N 0.019 N 0.013 N 0.008 N 0.013 
L 0 0.1026 0 0.0384 N 0.012 N 0.013 N 0.016 N 0.016 N 0.007 


































V 0 0.1917 0 0.0409 N 0.027 N 0.031 N 0.024 N 0.019 N 0.013 
R 1 0.4825 0 0.0429 N 0.027 N 0.020 N 0.035 N 0.018 N 0.012 
P 0 0.2391 0 0.0426 N 0.032 N 0.026 N 0.028 N 0.017 N 0.010 
G 0 0.2914 0 0.0432 N 0.046 N 0.025 N 0.046 N 0.046 N 0.010 
H 0 0.3042 0 0.0451 N 0.041 N 0.046 N 0.029 N 0.034 N 0.014 
Q 0 0.1966 0 0.0421 N 0.027 N 0.031 N 0.024 N 0.014 N 0.009 
E 0 0.1216 0 0.0403 N 0.042 N 0.040 N 0.047 N 0.026 N 0.025 
V 0 0.1397 0 0.0412 N 0.027 N 0.026 N 0.061 N 0.038 N 0.011 
S 0 0.1235 0 0.0405 N 0.034 N 0.026 N 0.025 N 0.015 N 0.012 
V 0 0.1042 0 0.0486 N 0.029 N 0.031 N 0.035 N 0.023 N 0.014 
P 0 0.1331 0 0.0512 N 0.031 N 0.026 N 0.041 N 0.023 N 0.019 
P 0 0.1547 0 0.0421 N 0.026 N 0.029 N 0.025 N 0.017 N 0.018 
H 0 0.3235 0 0.0456 N 0.024 N 0.057 N 0.052 N 0.028 N 0.016 
L 0 0.1021 0 0.0366 N 0.037 N 0.037 N 0.049 N 0.008 N 0.025 
R 0 0.2018 0 0.0423 N 0.034 N 0.020 N 0.037 N 0.020 N 0.017 
H 0 0.3487 0 0.0455 N 0.038 N 0.042 N 0.024 N 0.010 N 0.007 
L 0 0.1078 0 0.0364 N 0.019 N 0.015 N 0.020 N 0.014 N 0.012 
H 0 0.3000 0 0.0412 N 0.016 N 0.035 N 0.034 N 0.010 N 0.011 
N 1 0.5610 0 0.0436 N 0.020 N 0.031 N 0.018 N 0.010 N 0.029 
P 0 0.3539 0 0.0399 N 0.018 N 0.023 N 0.020 N 0.024 N 0.010 
S 0 0.3991 0 0.0409 N 0.022 N 0.031 N 0.026 N 0.027 N 0.012 
S 0 0.4561 0 0.0391 N 0.011 N 0.014 N 0.021 N 0.027 N 0.011 
G 0 0.3985 0 0.0383 N 0.020 N 0.014 N 0.024 N 0.020 N 0.024 
Q 1 0.5160 0 0.0397 N 0.022 N 0.026 N 0.017 N 0.020 N 0.007 


































F 0 0.3264 0 0.0377 N 0.042 N 0.037 N 0.020 N 0.016 N 0.015 
Q 1 0.5873 0 0.0429 N 0.011 N 0.012 N 0.014 N 0.014 N 0.020 
H 0 0.4597 0 0.0395 N 0.033 N 0.017 N 0.020 N 0.017 N 0.024 
L 0 0.1411 0 0.0355 N 0.038 N 0.009 N 0.016 N 0.003 N 0.011 
S 0 0.3823 0 0.0417 N 0.023 N 0.036 N 0.023 N 0.019 N 0.011 
P 0 0.1553 0 0.0361 N 0.030 N 0.021 N 0.023 N 0.021 N 0.012 
N 0 0.2520 0 0.0379 N 0.009 N 0.015 N 0.015 N 0.009 N 0.009 
R 1 0.4948 0 0.0387 N 0.023 N 0.028 N 0.054 N 0.016 N 0.036 
H 0 0.2401 0 0.0387 N 0.027 N 0.023 N 0.023 N 0.009 N 0.013 
K 1 0.4759 0 0.0486 N 0.032 N 0.026 N 0.021 N 0.033 N 0.011 
I 0 0.1323 0 0.0372 N 0.070 N 0.014 N 0.019 N 0.010 N 0.005 
R 0 0.4028 0 0.0442 N 0.023 N 0.016 N 0.022 N 0.028 N 0.011 
D 0 0.1334 0 0.0393 N 0.012 N 0.012 N 0.017 N 0.015 N 0.021 
L 0 0.1179 0 0.0368 N 0.021 N 0.015 N 0.024 N 0.009 N 0.012 
P 0 0.1416 0 0.0399 N 0.034 N 0.011 N 0.033 N 0.028 N 0.008 
F 0 0.1399 0 0.0384 N 0.026 N 0.018 N 0.021 N 0.011 N 0.013 
T 0 0.2907 0 0.0394 N 0.019 N 0.009 N 0.022 N 0.012 N 0.005 
R 1 0.5806 0 0.0415 N 0.029 N 0.023 N 0.033 N 0.012 N 0.010 
N 1 0.5489 0 0.0413 N 0.036 N 0.054 N 0.020 N 0.020 N 0.019 
N 1 0.5078 0 0.0415 N 0.030 N 0.017 N 0.025 N 0.036 N 0.011 
L 0 0.0997 0 0.0351 N 0.019 N 0.020 N 0.026 N 0.011 N 0.008 
A 0 0.1319 0 0.0368 N 0.026 N 0.011 N 0.022 N 0.021 N 0.005 
P 0 0.1592 0 0.0410 N 0.010 N 0.007 N 0.055 B 0.098 N 0.017 
L 0 0.0981 0 0.0356 N 0.036 N 0.011 N 0.028 N 0.036 N 0.011 


































D 0 0.1566 0 0.0444 N 0.030 N 0.019 N 0.026 N 0.026 N 0.015 
Q 0 0.2330 0 0.0421 N 0.031 N 0.040 N 0.025 N 0.038 N 0.017 
K 0 0.4475 0 0.0453 N 0.023 N 0.029 N 0.021 N 0.009 N 0.011 
F 0 0.1354 0 0.0355 N 0.024 N 0.031 N 0.022 N 0.023 N 0.023 
L 0 0.0958 0 0.0332 N 0.025 N 0.032 N 0.021 N 0.017 N 0.017 
S 0 0.3820 0 0.0394 N 0.034 N 0.026 N 0.028 N 0.015 N 0.006 
G 0 0.1922 0 0.0371 N 0.028 N 0.028 N 0.027 N 0.013 N 0.013 
E 0 0.1178 0 0.0341 N 0.037 N 0.016 N 0.025 N 0.017 N 0.011 
P 0 0.1617 0 0.0367 N 0.012 N 0.013 N 0.033 N 0.011 N 0.008 
L 0 0.1073 0 0.0331 N 0.024 N 0.014 N 0.027 N 0.019 N 0.012 
R 1 0.5988 0 0.0377 N 0.053 N 0.028 N 0.028 N 0.012 N 0.015 
T 0 0.4553 0 0.0371 N 0.034 N 0.016 N 0.034 N 0.007 N 0.013 
N 0 0.4112 0 0.0372 N 0.028 N 0.028 N 0.021 N 0.013 N 0.010 
R 1 0.5750 0 0.0385 N 0.029 N 0.018 N 0.017 N 0.011 N 0.010 
V 0 0.1369 0 0.0348 N 0.021 N 0.009 N 0.019 N 0.007 N 0.017 
L 0 0.0883 0 0.0287 N 0.018 N 0.017 N 0.026 N 0.008 N 0.008 
P 0 0.1355 0 0.0332 N 0.026 N 0.023 N 0.033 N 0.019 N 0.015 
A 0 0.1042 0 0.0295 N 0.021 N 0.025 N 0.032 N 0.010 N 0.016 
I 0 0.1033 0 0.0292 N 0.025 N 0.018 N 0.021 N 0.009 N 0.016 
P 0 0.1575 0 0.0330 N 0.017 N 0.017 N 0.027 N 0.018 N 0.022 
S 1 0.4750 0 0.0342 N 0.030 N 0.033 N 0.023 N 0.017 N 0.017 
Q 1 0.5741 0 0.0340 N 0.036 N 0.048 N 0.027 N 0.020 N 0.021 
R 1 0.7255 0 0.0331 N 0.056 N 0.016 N 0.030 N 0.025 N 0.027 
R 1 0.6229 0 0.0331 N 0.021 N 0.025 N 0.017 N 0.021 N 0.015 


































S 0 0.3627 0 0.0324 N 0.031 N 0.014 N 0.026 N 0.022 N 0.009 
T 0  0.1686 0 0.0305 N 0.035 N 0.012 N 0.028 N 0.009 N 0.005 
A 0  0.2083 0 0.0313 N 0.032 N 0.020 N 0.027 N 0.020 N 0.006 
A 0  0.1250 0 0.0297 N 0.009 N 0.009 N 0.015 N 0.010 N 0.007 
E 0  0.1100 0 0.0296 N 0.008 N 0.015 N 0.015 N 0.012 N 0.009 
E 0  0.1347 0 0.0332 N 0.013 N 0.023 N 0.018 N 0.018 N 0.005 
S 0  0.1445 0 0.0336 N 0.022 N 0.017 N 0.028 N 0.012 N 0.010 
E 0  0.1020 0 0.0469 N 0.019 N 0.022 N 0.024 N 0.012 N 0.009 
H 0  0.2295 0 0.0567 N 0.013 N 0.020 N 0.021 N 0.011 N 0.004 
S 0  0.2174 0 0.0568 N 0.024 N 0.019 N 0.029 N 0.018 N 0.010 
A 0  0.1881 0 0.0568 N 0.017 N 0.017 N 0.022 N 0.017 N 0.010 
N 0  0.1734 0 0.0568 N 0.027 N 0.024 N 0.021 N 0.016 N 0.008 
P 0  0.1209 0 0.0544 N 0.024 N 0.017 N 0.017 N 0.011 N 0.011 
T 0  0.2552 0 0.0579 N 0.027 N 0.023 N 0.026 N 0.014 N 0.008 
S 0  0.1806 0 0.0582 N 0.032 N 0.020 N 0.022 N 0.014 N 0.015 
D 0  0.2091 0 0.0584 N 0.028 N 0.036 N 0.026 N 0.017 N 0.022 
E 0  0.1374 0 0.0551 N 0.026 N 0.034 N 0.028 N 0.026 N 0.019 






Supplementary Table 9. Interaction between MS/RA risk genes and ANKRD55 and/or ANKRD55-interacting partners. In 
bold the proximal risk gene involved in the interaction. Abbreviations: TPE, total protein extracts and NE, nuclear 
extracts. 















rs9843355 TIMMDC1 X (TPE 2/3)   
rs72928038 BACH2 X (HuRI)   
rs37749689 STAT3 
 
CDK5, NDUFA13 (TPE 2/3) 
















rs12373588 MIR4435-1HG-ANAPC1 X (TPE 2/3)   
rs7690934 LEF1 X (HuRI) RUVBL1, RUVBL2 
rs32954092 TRIM71-CCR4 
 
CNOT1, RQCD1 (TPE 2/3) 
rs10271373 ZC3HAV1 
 
DDX17, DHX30 (TPE-NE 
2/3) 
rs11023242 RRAS2-COPB1 X (TPE 2/3)   



























































Supplementary Figure 1. Intracellular localization of ANKRD55 in PMA/LPS-treated U937 cells. 
Inmunostaining for ANKRD55 (Aviva Systems Biology Ab; green) and nuclei (DAPI; grey) in PMA/LPS-treated U937 
analyzed by confocal microscopy. To confirm the specificity, immunostaining was performed either in the absence (-







Supplementary Figure 2. Optimization process in the immunoprecipitation elution step from ANKRD55 isoform 001. 
HEK293 cells were transfected with FLAG-tagged isoform 001 of ANKRD55. Cells were treated +/- DSP, as indicated, 
and IP was performed in total protein extracts (TPE) after 48h of transfection. Elution step was carried out with (A) pH 
2 or pH 10, each three consecutive times (B) pH 3.5 or FLAG peptide and (C) pH 2 + 0,5% SDS. The five distinct elution 
procedures were followed by a final elution step by means of Laemmli buffer. This removes all remaining protein of 
the gel matrix and facilitates to semi-quantitatively estimate the amount of protein not eluted by the specific condition.  
Recombinant ANKRD55 isoforms were detected in TPE, pass-through (PT), washing (W1, W2) and elution steps with 
specific Ab (Sigma-Aldrich) by WB. 
Supplementary Figure 3. Validation of ANKRD55-interacting partners from BioGrid database. HEK293 cells were 
transfected with FLAG-tagged isoform 001 of ANKRD55 and IPed from total protein extracts (TPE) after 48h of 
transfection. Endogenous HIF1AN and overexpressed ANKRD55 were detected in TPE, pass-through (PT), and elution 
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